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Important differences between human cancers and
experimental animal tumours limit the potential of the latter as
models for cancer therapy research. This thesis describes the
development of a clonogenic assay for human tumour cells,
allowing for the first time the radiosensitivity and chemosensitivity
of these to be measured in a way previously restricted to cells
from experimental animal tumours and established tumour cell
lines. The technique involves the use of agar in diffusion chambers
implanted into murine peritoneal cavities, the mice acting both as
"incubators" and as a source of nutrients for cell growth. Human
tumour xenografts have been used for most experiments, although
the use of the assay to clone cells from human tumours taken direct
from the patient without xenograft passage has also been investigated.
With this assay, the radiosensitivities of cells from several
human tumours were measured, both in vitro and in vivo, and the
dose survival curves so obtained provided information on the
mechanisms underlying the clinical response of different human
tumours to radiotherapy. The system was also used to demonstrate
the enhancing effect of the radiosensitising drug Ro-07-0582 on the
radiosensitivity of hypoxic tumour cells in vivo.
Studies on the sensitivity of human tumour cells to cytotoxic
drugs showed important differences compared with cells from
experimental animal tumours, and some correlation was shown
between cell survival in the assay and clinical response to
chemotherapy.
The advantages of this assay over those based on animal
tumours as a tool to complement clinical cancer therapy research
are discussed, and suggestions are proposed for its further use.
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This thesis is about the development of a laboratory technique
for studying the response to therapy of human tumour cells. It is
based on a simple premise: experimental animal tumours have a
therapeutic response which frequently differs from that of their
human counterparts and are therefore of limited value as research
tools in this field; laboratory systems derived directly from human
tumour material might prove to be more useful and valid models for
study, if such systems could be developed.
1. 1: THE USES AND LIMITATIONS OF EXPERIMENTAL
ANIMAL TUMOURS
Experimental animal tumours propagated in inbred host
animals [Gross, 1943] have long been a cornerstone of cancer
-research. Their development has allowed meaningful and repro¬
ducible quantitative measurements of tumour behaviour to be made,
the influence of genetic and extraneous factors on tumour develop¬
ment to be studied, and epidemiological influences to be assessed.
More recently these tumour systems have increasingly come to be
employed in therapeutic aspects of cancer research. Where this
research has devoted itself to general therapeutic principles, further
important contributions have been made. For example, it has
recently been demonstrated in the murine Lewis lung carcinoma that
cells within very small tumours of less than 0. 5mm diameter are
more radiosensitive and more chemosensitive than cells within
larger tumours of the same type [Steel and Adams, 1975; Shipley
et al, 1975]. This reinforces the clinical concept of early adjuvant
radiotherapy or chemotherapy for clinically undetectable micro-
metastases at the time of treatment of the primary tumour.
But experimental animal tumours have also been used in a
much more specific way to predict clinical response to individual
cytotoxic agents, and to plan the scheduling of combination therapy.
For example, a series of animal tumours are used in screening
programmes for new anti-cancer drugs throughout the world. And
it has been advocated that cell cycle kinetic data obtained from
murine leukaemias should be extrapolated to develop elaborate drug
scheduling regimes in clinical cancer chemotherapy [Bergsagel,
1969; Vietti et al, 1971; Price et al, 1975],
It is in these latter areas of research that the value of animal
tumour models becomes questionable. Important differences exist
between these and human tumours, both in their cell proliferation
kinetics [reviewed by de Vita, 1971; Steel, 1973; van Putten, 1974;
Tubiania and Malaise, 1976], the therapeutic significance of which
will be discussed in Chapter 10, and in their inate sensitivity to
specific cytotoxic agents.
Some examples of the latter can be quoted here. The nitro¬
soureas are a group of compounds first detected in the N.C.I.
(National Cancer Institute, Bethesda) drug screening programme
and developed for clinical use over the last 15 years. Some of these,
including BCNU (1,3,bis 2-chloroethyl-l-nitrosourea), CCNU
(1, 2-chloroethyl~3 cyclohexy1-1 -nitrosourea) and Methyl-CCNU
are amongst the most active agents ever studied against experimental
animal tumours, both quantitatively and in the range of their anti-
tumour activity. Yet their clinical activity in man has proved in
general modest and rather disappointing. In particular BCNU has
been shown to cure murine leukaemias and the C3H mammary cancer
[Schabel, 1976], whereas this drug has little activity in human
leukaemias and is relatively ineffective in human breast cancer
[Slavik, 1976], DTIC (Diamino-triazeno-imidazole~carboxami.de),
another N.C.I, -developed drug, has a wide range of experimental
tumour activity, with cures reported for L1210 leukaemia; it is
inactive, however, in the B-16 mouse melanoma [Venditti, 1976].
Conversely, in man this drug is of little value in leukaemia but is
one of the few agents to which human melanoma shows any significant
response rate [Comis, 1976]. Vincristine is a highly active agent in
the induction therapy of acute lymphoblastic leukaemia in children
and yet shows no activity against any of three commonly studied
murine lymphocytic leukaemias (L1210, AKR, L5178Y) [Dykes and
Nelson, 1977]. And finally, L-asparaginase, an enzyme with
specific clinical activity in acute lymphoblastic leukaemia, is inactive
against all five tumours used until recently in the N.C.I, programme,
and would therefore have been completely missed by their screen
[Connors and Jones, 1970].
1. 2: HUMAN TUMOUR XENOGRAFTS
These important differences which limit the use of experi¬
mental animal tumours as models for clinical cancer therapy
research have not, of course, gone unrecognised, and their use has
been defended largely on the grounds that no other more appropriate
model has been available for this type of work. In recent years,
however, techniques have been developed for the transplantation of
human tumours into immune-suppressed animals. These xenograft
tumours can be maintained and propagated by serial passage in the
laboratory and therefore present an opportunity to carry out on
human tumour material the type of therapeutic research previously
restricted to animal systems.
Details of the development of human tumour xenografts and
the grounds for believing that they may represent a more valid
model for clinical therapy will be described in the next Chapter.
Here it can be stated that while their long-term value as a research
tool has yet to be clearly established, there is nevertheless
promising circumstantial evidence to suggest that they may respond
to therapy in a similar way to the parent human tumour; indeed two
human tumour xenografts have recently been added to the standard
animal tumour series used in the N. C.I. drug screening programme.
At present there are at least two important aims in human
tumour xenograft research. The first is to establish more clearly
their validity as models for cancer therapy in the clinic; the second
is to investigate what techniques for measuring tumour response
might be most appropriately applied to this system.
This thesis concerns research directed mainly at the second
of these problems. So far the response to treatment of xenografts
has been measured mainly by tumour growth delay techniques in
which tumour growth in the treated animal is compared with that in
untreated controls (Chapter 3). In experimental animal tumours,
important additional information can also sometimes be obtained on
the specific effect of such treatment on individual tumour cells,
using clonogenic assay techniques (Chapter 3). At the start of this
research project no such reproducible assay system for studying
individual human tumour cells had been described (although my
colleague Mrs. Doreen Courtenay working at the Institute of Cancer
Research was developing an in vitro assay technique for this
purpose). However, a clonogenic cell assay system using agar in
diffusion chambers (Chapter 4) had recently been developed for
human bone marrow [Gordon, 1974]. My project therefore was
first to study whether this technique could be adapted for human
tumour cells, and second to use the assay to study the effects on
these cells of irradiation and of cytotoxic drugs.
Before the results of these studies are presented, the
development and use of both human tumour xenografts and clonogenic
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CHAPTER 2:
HUMAN TUMOUR XENOGRAFTS
The ethical and practical problems which restrict research
on human tumours in patients, and the limitations to experimental
animal tumours already discussed, have stimulated attempts for
many years to grow human tumour material in animals. The
fundamental problem thwarting such attempts is of course the
rapid and complete rejection of foreign tissue by the immune
defence mechanisms of the host animal.
2,1: THE DEVELOPMENT OF XENOGRAFT TECHNIQUES
2.1. a: Sites of "Immune Protection''
The earliest efforts to overcome this immune response
were aimed at trying to grow tumour tissue at certain sites in the
animal which appeared to be relatively protected from host immune
mechanisms. The anterior chamber of the eye with its absence of
direct blood supply was an obvious site for study, and human
tumour biopsy material has occasionally been grown in this site
[Greene, 1942]. However, the techniques involved are difficult, the
percentage of failures to take high, the growth rate of successfully
implanted tumours slow and transplantability poor.
The hamster cheek pouch has also been found to confer
some degree of immune protection on implanted human tumours
[Lemon et al, 1952; Handler et al,. 1956; Patterson et al, 1957],
particularly when the hamster is further immune-suppressed with
cortisone or irradiation [Handler et al, 1956; Patterson et al, 1957].
With this technique human tumours have been grown and transplanted
through repeated animal passage, the tumours in the cheek pouch
maintaining with serial passage the histological characteristics of
the parent human tumour. An attractive feature of this site is that
growth of the implanted tumour can be visualised using a perspex
observation chamber inserted into the hamster, and important obser¬
vations on the development of a blood supply necessary for success¬
ful growth have been made in this way [Smith, 1969a].
Another approach to overcome host immune response has been
based on the relative immune "tolerance" of new-born animals. This
has been exploited to grow pulmonary and subcutaneous tumours in
new-born rats less than 24 hours old from human cancer cell lines
[Kutner and Southam, 1960] and subsequently directly from human
cancers [Southam, 1966]. However, the take-rate for tumours was
low both in rat lungs and subcutaneously, and tumours rarely grew
to more than a few millimetres in diameter. This raised doubts
about whether viable tumours were in fact being grown or whether
in this system the host animals were merely serving as a nutrient
medium for short term tissue culture.
2. Lb: Immune Suppressed Hosts
A more rewarding approach to the problem of immune
rejection of implanted tumour material has been the development of
techniques for suppressing the immune response of the host
animal. This was first successfully achieved by Toolan [1951] who
managed to grow subcutaneous tumours from human cancer tissue
implanted into albino rats and hamsters previously treated with
whole body irradiation. Some of these tumour xenografts could be
transplanted through two or more passages, but in the initial
studies tumour masses proliferated usually for only an 8 to 10 day
period, and raised doubts about tumour viability. Later Toolan
[1953] achieved a greater tumour-take rate in irradiated animals
subsequently treated with cortisone; and these grew for a longer,
but still self-limiting period. Despite its shortcomings, this
technique was important in demonstrating that the propagation of
human tumour material in immune suppressed animals was a
practical possibility, and the method was in fact used in what
appears to have been the first study of an anti-cancer agent on a
human tumour grown in vivo in the laboratory: the oncolytic effect
of Egypt virus on a human epidermoid carcinoma [Toolan and
"Moore, 1952].
A considerable advance in techniques for host animal
suppression came with the appreciation that thymus-derived
lymphocytes (T-lymphocytes) play an important role in rejecting
xenografts [Davies et al, 1966], It was found that human tumour
xenografts could be grown in mice depleted of T-lymphocytes and
several techniques were devised to achieve this. These included
thymectomy at birth [Osoba and Auersperg, 1968], treatment of
mice with antilymphocyte or antithymocyte serum [Phillips and
Gazet, 1967, 1970; Arnstein et al, 1972; Stanbridge et al, 1975],
a combination of thymectomy and antilymphocyte serum [Davis and
Lewis, 1968; Cobb, 1972, 1973; Cobb and Mitchley, 1974;
Stanbridge et al, 1975], thymectomy and whole body irradiation,
usually followed by marrow reconstitution [Castro, 1972; Cobb and
Mitchley, 1974; Mitchell et al, 1974; Franks et al, 1975; Pickard
et al, 1975; Stanbridge et al, 1975], and thymectomy, antilymphocyte
serum and whole body irradiation [Berenbaum et al, 1974]. These
techniques represented a major breakthrough in xenograft research
and permitted the successful growth in the T-cell depleted mouse
of viable, vascularised human tumours which could be readily
propagated through serial animal passage.
Genetically athymic* 'nude' mice with severe or complete
T-lymphocyte depression have also been used to grow and
propagate a variety of human tumour xenografts [Rygaara and Povlsen,
1969; Giovanella et al, 1974; Kelson et al, 1975; Povlsen and
Jacobsen, 1975; Stanbridge et al, 1975]. These animals are
expensive and require elaborate laboratory facilities for their
breeding and maintenance. On the other hand they have the advantage
of not requiring time-consuming immune-suppressive procedures
before use. Their xenograft 'take' rate is also probably slightly
*It has been recently suggested that these mice may have a residual
thymus and an associated low level of circulating T -lymphocytes
[Raff, 1973].
better: Giovanella and Stehlin [1974] report a 'take' rate of over
80% for primary human tumours, whereas only 50-70% of tumours
take in artificially immune suppressed mice [Castro, 1972;
Berenbaum, 1974]. 'Takd rates are themselves dependent on tumour
type: in our experience at this laboratory, oat cell carcinomas,
melanomas and to a lesser extent colonic carcinomas have high
'take' rates, whereas only 10% of breast carcinomas can be
established as xenografts.
Basically, however, there is no doubt that both types of
mouse have the ability to propagate xenografts, and the decision
on which to select is principally dependent at present on the type
of laboratory facilities locally available.
2. 2: THE VALIDITY OF THE HUMAN TUMOUR XENOGRAFT
AS A MODEL FOR CLINICAL THERAPY
Compared with experimental animal tumours, human
tumour xenografts are expensive and time-consuming to produce,
capricious to maintain and often adapt with difficulty to standard
experimental procedures (e. g. the production of single cell
suspensions - see later). Their use can only be justified on the
assumption that they offer a more valid model than animal tumours
for studies relating to clinical cancer therapy. It is therefore of
fundamental importance in xenograft research to verify whether
this is indeed the case in practice, or whether they are merely
eccentric and irrelevant laboratory artefacts.
2. 2. a: Xenograft Histology and Karyotype
There are several approaches to this problem, of which the
first is the study of xenograft tumour morphology and histology.
Many human tumour xenografts developed in recent years have
been derived from carcinomas of the large bowel. The histology of
these xenografts, even after multiple passages, has usually shown
a close resemblance to that of the parent tumour: they maintain
cellular appearance and function (e.g. mucin-producing), cellular
arrangement (e. g. acinar), and the degree of differentiation of the
original [Castro, 1972; Cobb, 1973; Helson et al, 1975; Pickard
et al, 1975]. A similar close histological resemblance to the
original has also been described for other tumour xenografts
including an oat cell carcinoma of lung [Kopper and Steel, 1975],
a malignant melanoma [Povlsen and Jacobsen, 1975] and a neuro¬
blastoma grown from a cell line derived from the original tumour
[Helson et al, 1975]. Chromosomal analyses are described in
most published studies on human tumour xenografts and these
invariably demonstrate tumour cells to be of human origin.
There are two interesting histological differences
frequently observed between xenografts and originals, however.
Pickard et al [1975] point out.that the stroma in their xenografts,
inevitably of murine origin, had a fine reticular appearance with
few inflammatory cells, in contrast to the dense stromal and
inflammatory reaction exhibited by the original tumours. This
seems scarcely unexpected in view of the differing environments
of the growing xenograft and the original tumour, and it is
surprising that it has not been more frequently commented on in
other reports, The other, and less predictable difference, is that
xenograft tumours only rarely appear to metastasise in the host
animals, even when their histology shows a very poor degree of
differentiation and a high mitotic index. Occasional exceptions
have been reported, the most significant being 18 metastases
from 63 tumour implants, most of which were however from
HeLa cells rather than fresh tumour biopsies [Franks et al, 1975].
A single metastasis of a human colonic tumour in a hamster
brain has also been reported [Goldenberg, 1970], as have
metastases from 3 melanoma xenografts to lymph nodes and lung
[Giovanella et al, 1973]. But these reports are exceptional, and
in general macroscopic metastases from human tumour xenografts
are not usually seen. Indeed even the intravenous injection of up to
g
10 xenograft tumour cells into immune-suppressed mice failed to
grow pulmonary tumours [Mr. R. George, personal communication].
This curious phenomenon may be associated with the
observation that xenografts invade with the advancing tumour edge
continuous with the main tumour mass and without outlying separate
islands of tumour cells seen in original specimens [Pickard et al,
1975]. All this may indicate some residual host immune response to th
xenograft despite immune-suppression and inevitably must raise doubt
about the interpretation of studies on tumour response to therapy.
Further evidence suggesting a residual immune response is
discussed below.
2. 2,b: Xenograft Response to Therapy
The most direct test of the xenograft as a valid model for
clinical therapy studies is to see whether its response to therapy
resembles that of the parent tumour. This is less easy to
investigate than it might at first appear. The problem is primarily
a practical one: not all tumour biopsies can at present be success¬
fully grown as xenografts and therefore clinical tumours whose
response to therapy can be measured may fail to provide derived
xenografts; conversely not all patients from whom successful
tumour xenografts have been established are subsequently treated
in a way that allows comparison with xenograft response to therapy.
Much of what data has so far been assembled on the therapeutic
response of xenografts is therefore of a general nature, and lacks
a specific correlation between the human tumour and its own
xenograft.
Smith [1969a] studied the effects of nitrogen mustard and
methotrexate on a series of human tumour xenografts implanted
into the hamster cheek pouch and found a considerable variation in
the response of different tumours, which he felt might be analagous
to the variation in clinical response anticipated for these agents.
He subsequently demonstrated that the response to cytotoxic drugs
of the rat Walker 256 tumour was the same when grown as a
xenograft in the hamster cheek pouch as in situ in the rat, and
extrapolated that the same might reasonably be anticipated for
human tumours [Smith, 1969b].
Sheard et al [1971] also showed that the rank order of effectiveness
of 4 drugs for a rat tumour was the same in the species of origin as
when grown as a xenograft in immune-suppressed mice.
Cobb and Mitchley [1974] studied the effects of several
chemotherapeutic agents on 2 human colonic carcinoma xenografts
and found that of these drugs only 5-fluorouraci.l (5-FU) achieved
complete tumour control, supporting the clinical observation that
5-FU is relatively more effective than most other drugs in what is
usually a chemoresistant tumour [BMJ Editorial, 1976]. Povlsen
and Rygaard [1974] reported a good response of a Burkitt's
lymphoma xenograft to cyclophosphamide, which parallels the
response seen in patients. Similarly Povlsen and Jacobsen [1975]
treated a melanoma xenograft with various drugs of which DTIC
(dimethyl-triazeno-imidazole-4 -carboxamide) was the most
effective and of which 5-FU had no effect whatsoever. This again
correlates with clinical experience in the chemotherapy of
melanomas, DTIC being one of the few agents to achieve any
response in this notoriously chemoresistant tumour [Carter and
Friedman, 1972; Comis, 1976]. Unfortunately in neither of these
studies were the patients' original tumours treated with
chemotherapy.
This was also the limitation to a detailed study on the effects
of various agents on growth delay of 3 xenografts derived from 2
colonic carcinomas and one oat cell carcinoma of lung [Kopper and
Steel, 1975]. Despite the lack of direct clinical correlation to back
up this study, it was of interest that the colonic tumours responded
best to 5-FU whereas the oat cell xenograft showed most response
to cyclophosphamide, findings which again agree well with clinical
observations on the chernosensitivity of these tumours [Holland and
Frei, 1973]. An unexpected finding in this study was that some of
the oat cell xenografts showed permanent regressions after
cyclophosphamide at a calculated level of cell kill which would not
have been expected to achieve long term tumour control; and the
authors considered the possibility that a residual host immune
response was still operating in the thymectomised irradiated mice.
Obviously this would require careful consideration in interpreting
the results of tumour growth delay and tumour case studies with
cytotoxic drugs in the xenograft system.
Very few studies have so far attempted to compare directly
the response of a xenograft with the response of the original tumour
in the patient. Burt et al [1966] described a bladder carcinoma in
a patient which responded to radiotherapy and 5-FU but not to
vinblastine; this subsequently retained these sensitivities when
treated as a xenograft in an immune-suppressed hamster. At
present there is only one other study of which I am aware where
the attempt has been made to correlate xenograft response to
chemotherapy with clinical response in the patient. Novak, working
in the same laboratory as myself, has studied xenograft tumour
growth delay after cytotoxic drugs from patients being treated with
chemotherapy for advanced colo-rectal carcinoma, and has so far
found that the xenograft showing maximal response to therapy is
from one of the few patients in the study who obtained an objective
tumour response to chemotherapy [personal communication].
This important and painstaking work provides the most
direct indication so far that xenografts may indeed be the valid
models sought for laboratory studies on clinical chemotherapy.
With the important proviso that xenograft tumour response may be
influenced by some degree of residual host immune activity, the
evidence suggested that further studies into developing this new
technique, including an attempt to produce a clonogenic tumour
cell assay, would seem worthwhile.
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CHAPTER 3:
CLONOGENIC CELL SURVIVAL ASSAYS
3. 1: GROSS MEASUREMENTS OF TUMOUR RESPONSE TO
TREATMENT
The response of experimental tumours to cytotoxic agents
can be measured in several ways. First, the percentage increase
in life span [% ILS] of treated animals compared to untreated controls
can be calculated. This approach is particularly suitable for widely
disseminated tumours including leukaemias and is commonly used
in experiments where new agents or combinations of agents are
screened for cytotoxic activity. For localised tumours, measure¬
ment of growth delay after treatment is often more appropriate, and
most studies with human tumour xenografts have used this method.
In tumour growth delay experiments some parameter of gross tumour
growth, for example volume doubling time, is compared in the
treated tumour to that of untreated controls. This technique is
appealingly similar to the clinician's measurement of the extent and
duration of tumour regression in his patients after treatment, and
is therefore an attractive tool for the laboratory study of anti-cancer
agents.
However these gross studies of tumour response are clearly
limited in the type of information they can provide. What they
measure and what the clinician measures in his patient is merely
an effect; they can provide little insight into the elaborate interplay
of mechanisms whereby this effect is mediated.
Changes in the rate of tumour growth after treatment may
depend on a variety of factors. These include first the fraction of
tumour cells killed by the cytotoxic agent under study. Second, the
effect of cell kill on tumour size in turn depends on the balance between
the rate of dead cell removal on the one hand and the rate of cell
repopulation on the other. Third, a variety of host tissue response
factors may also affect the size of the tumour: these can include a
non-specific acute inflammatory response with cellular infiltrate,
vascular changes and tissue oedema; in addition, the possibility of
a specific host immune response, at least against some tumours,
has also been argued, and immunotherapeutic approaches to exploit
this are at present under intensive study [Southam and Friedman,
1976]. Evidence suggesting the possibility of a residual host immune
against hximan tumour xenografts has already been mentioned
(Chapter 2. 2. b).
If the actual mechanisms underlying the effect of cytotoxic
agents on tumour growth are to be understood, and hence if a more
rational basis for designing new techniques of therapy is to be
achieved, then it is first necessary to be able to study not merely the
end effect of therapy as in tumour growth delay experiments but also
these individual mechanisms which underlie that effect.
In particular it is important to be able to measure the
specific effects of cytotoxic agents directly on tumour cells, and
not merely on the gross tumour, in a quantitative way. For this
reason assays for cell survival after exposure to these agents have
been developed in recent years.
3.2: CELL SURVIVAL ASSAYS
Tissue growth, maintenance and repair are based on the
existence in both tumours and normal tissue of what are termed
stem cells. These are cells which have the capacity to proliferate
and give rise to generations of daughter cells which may themselves
in turn either further proliferate, or else differentiate, mature and
eventually die. The factors controlling these fundamental processes
and their inter-relationship are intricate and only partly understood;
they have recently been reviewed [Cairnie et al, 1976],
Cell survival assays are experimental techniques designed
to study and measure in an appropriate artificial environment cells
from tumours or normal tissues which have this capacity for
proliferation. The artificial environment employed in the assay is
either an in vitro culture system, or an in vivo organ of a living
animal e. g. spleen or lung. Details of these sytvems will be
described below.
If a single cell suspension is made from the tissue under
study and introduced into such a system, then the cells with
proliferative capacity in that suspension can undergo a series of
divisions to form colonies or clones of cells. Colonies thus formed
can eventually be counted after an appropriate time interval, and the
number of colonies grown represents the number of parent cells with
proliferative capacity in the original cell suspension. By dividing
the number of colonies grown from a cell suspension of treated tissue
with that from an untreated control, a quantitative measurement of
the fraction of cells with colony-forming ability surviving after the
treatment can be obtained. The technique thus devised is called a
colony-forming or clonogenic cell survival assay.
3. 3: THE DEVELOPMENT OF MAMMALIAN CLONOGENIC CELL
SURVIVAL ASSAYS
For many years it proved technically impossible to grow
cellular colonies from single mammalian cells in vitro in a manner
analogous to that employed for bacteria and viruses. In 1955,
however, Puck and Marcus in a now classic paper described an
in vitro method for growing colonies from single cell suspensions
of the so-called HeLa cell line originally derived from a human
cervical carcinoma. In their original experimental design, single
cells were plated out on glass slides supported in a Petri dish above
a layer of heavily irradiated and therefore non-dividing "feeder" cells.
These latter were believed to provide some unknown conditioning
factor to the suspension medium which enabled the single cells to
reproduce to the point where colonies of cells could become self-
sustaining. The supporting medium itself was supplemented with
horse and human serum and cultures were incubated in 5%
Later, it was found that gentle trypsinisation of the initial cell
suspension eliminated the need for a "feeder" layer. Agar was
added to the medium in some experiments both to decrease loss by
diffusion of any necessary metabolites escaping from the cells and
to limit the tendency of individual colonies to migrate [Puck et al,
Using these techniques, single cells grew visible colonies with
a diameter of about 1mm (800 - 2000 cells) in about 10 days after
plating, with a plating efficiency of 100% (i. e. all plated ceils grew
colonies). Thus it became possible to assay the effect of external
agents on the colony-forming ability of mammalian cells, and the
first study on cell survival after in vitro irradiation was published
within the year [Puck and Marcus, 1956]; (Chapter 7. 1).
Colonies from many other cell lines were subsequently grown
using this technique and initially the assays were mainly used to
study the effects of in vitro irradiation on different types of
mammalian cell (Chapter 7.1). However, the artificiality of these
laboratory propagated cell lines greatly limited their use in studying
the effects of therapy on normal tissues growing in vivo under
physiological conditions.
3.4: CLONOGENIC CELL ASSAYS FOR ANIMAL MARROW
The development of an elegant spleen colony assay for cells
from normal mouse marrow by Till and McCulloch [1961] was an
important advance. Their assay was based on the fact that the
intravenous injection of marrow cells into syngeneic mice previously
exposed to supralethal whole body irradiation leads to the formation
of colonies of proliferating erythroid and myeloid precursor cells
at various stages of differentiation in the spleens of these animals;
these colonies could be counted as discrete nodules 10 or 11 days
after injection. In this technique the plating efficiency was only
one hundredth that of Puck and Marcus, but the marrow cell count
included all nucleated cells, a large proportion of which were already
differentiated and had presumably lost the capacity to give rise to a
new generation of proliferating cells. Apart from this the two methods
had striking analogies: in both a small number of individual cells
could be inoculated from which colonies of cells grew and could be
counted, and in both the viability of the inoculated cells and hence the
effects of external agents could be assayed. The spleen colony assay
moreover has one practical advantage: maintenance of a constant
biochemical medium, pH, humidity and temperature control, of such
critical importance in the in vitro culture system, is provided for
"de gratis" by the mouse host. Although the histology of the spleen
colonies could be readily studied, the exact nature of the progenitor
cell giving rise to colonies was uncertain and was therefore
designated "colony forming unit-spleen" (CFU-S).
Other techniques for assaying marrow colony-forming cells
were later described. Pluznick and Sachs [19613] and Bradley and
Metcalf [1966] developed an in vitro plating technique similar to
that originally described by Puck and Marcus; here however, the
addition of agar to the culture medium overcame the tendency of
plated cells to "wander" in the medium and allowed colonies to be
grown at a higher density than in monolayer without the problems of
overlap or of "feeding" of small colonies from larger ones. For
these reasons the addition of agar to culture medium has become a
widespread practice in most in vitro colony assay techniques. This
in vitro assay had the great advantage over the earlier spleen colony
assay that it did not require the use of syngeneic rodent hosts and
therefore raised the possibility of similar studies in higher animals
and in humans.
The principal disadvantage of all in vitro assays for marrow
colony forming cells is that the addition to the culture medium of an
external factor is necessary to promote colony growth. This so-
called colony stimulating factor (CSF) is obtained from various
sources: these include feeder layers of white blood cells [Pike and
Robinson, 1970], feeder layers of kidney embryo cells [Brown and
Carbone, 1971], "conditioned" medium in which feeder cells have
been previously grown [Iscove et al, 1971; Bull et at, 1973] or human
urine [Harris and Freireich, 1970], The exact nature of CSF is the
subject of intensive biochemical research at present, but from the
practical point of view, both the standardisation of colony stimulating
factor and variations in the terminology associated with different
sources of factor complicate analysis and comparison of data from
the in vitro assay.
More fundamentally, the colony progenitor cell in the in vitro
assay does not appear to be the same as that in the spleen colony
assay. Stained histological preparations of marrow colonies indicate
that the in vitro soft agar assay selects out a less primitive progenitor
cell already committed to forming granulocytes and macrophages
but not capable of giving rise to the erythroid elements also
found in spleen colonies [Metcalf and Moore, 1971]. By convention,
therefore, the two types of marrow colony forming cell are described
as CFU-C (for in vitro soft agar culture) and CFU-S (for spleen
colony growth).
3, 5: CLONOGENIC CELL SURVIVAL ASSAYS FOR OTHER
NORMAL TISSUES
Cells from normal tissues other than bone marrow do not
readily form colonies in agar culture, but the development of elegant
alternative in vivo techniques has led in recent years to the study of
clonogenic cells from cartilage, skin and intestinal epithelium. The
recovery of growth cartilage in rats after irradiation is marked by
the appearance of clones of dividing cells, and this physiological
repair process was exploited as a colony cell survival assay for
growth cartilage in rats, colonies of about 250 cells being counted
microscopically 25 days after in vivo irradiation [Kember, 1967],
A similar technique for assaying surviving epithelial cells of mouse
skin after irradiation was described by Withers [1967]. Here small
numbers of epithelial cells surviving in areas of irradiated skin
proliferated to form visible nodules after 10-20 days; by counting
regenerating nodules per unit area after measured doses of irrad¬
iation the relationship of cell survival with dose could be calculated
on the assumption that nodules are formed by the proliferation of
single surviving cells. Cell survival in murine intestinal epithelium
has been measured by irradiating in vivo a strip of jejunum,
temporarily exteriorised; microscopic clones of regenerating mucosa
are counted 13 days later. Again in this technique it is assumed
that each clone arises from a single surviving colony-forming cell
[Withers and Elkind, 1968]. An obvious attraction of these techniques
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is the physiological basis of their experimental design, and recently
one has been used for sophisticated studies on the ratiosensitivity of
skin clonogenic cells in both a well-oxygenated and a hypoxic environ¬
ment [Denekamp et al, 1974],
Finally, in considering cell survival studies on normal animal
tissues, mention must be made of a curious technique for assaying
the viability of mouse oocytes after irradiation [Lin and Glass, 1962];
here the end-point was not colony formation but, logically enough,
embryo-development after post-irradiation implantation into mated
female mice. The radiosensitivity measured by this technique lay
well outside the range for all other mammalian tissues however
(Chapter 9. 1), and this inevitably raised doubts about the validity of
the assay method.
3. 6: TUMOUR CELL SURVIVAL ASSAYS
Although the original in vitro technique of Puck and Marcus
was satisfactory for growing colonies from cell lines, some of which
had been originally derived from tumours, the culture environment
provided by this relatively simple system initially proved inadequate
to support the more rigorous demand of cells from tumours growing
in the animal. The first cell survival assays therefore had to depend
on in vivo techniques.
The earliest tumour studied in this way was a spontaneously
arising lymphocytic leukaemia in CBA mice and the number of
viable leukaemic cells in suspension was assayed by limiting dilution
technique [Hewitt and Wilson, 1959]. In this method, several dilutions
of leukaemic cells were injected into syngeneic mice and the number
of cells required to induce leukaemia in 50% of the injected mice
after a 90-day observation period calculated (TD^).
Limiting dilution assays have subsequently been used to
study cell survival in many experimental animal tumours; these
include a round cell sarcoma [Hewitt and Wilson, 1961], the Ehrlich
ascites tumour [Silini and Hornsey, 1962], the AKR mouse lymphoma
[Bush and Bruce, 1964], the MTG-B adenocarcinoma [Clifton et al,
1966], a rat rhabdosarcoma [Reinhoid, 1966], the C3H mouse fibro¬
sarcoma [Frindel et al, 1967], a well differentiated murine squamous
carcinoma [Hewitt, 1967], an osteosarcoma [van Putten, 1968], the
KHT mouse sarcoma [Kailman et al, 1967] and the Lewis lung
carcinoma in mice [Steel and Adams, 1975].
Limiting dilution assays have the advantage of great sensitivity
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and are capable of measuring cell survival fractions down to 10 .
This however, must be balanced against the large animal numbers
demanded by the experimental design of the technique. A more
serious disadvantage is the possibility of tumour cell antigenicity
to the recipient animals, particularly when non-syngeneic recipients
must be used. Occasionally host immune reactions can be circum¬
vented by using new born animals [Silini and Hornsey, 1962], but
clearly the assay could not be used for cross-species tumours and
in particular for tumours from human patients (unless of course
effective immune-suppressive therapy were first given to recipient
mice); even where syngeneic animals are available however the
possibility of tumour cell-specific antigenicity must be investigated
and the experimental design appropriately modified and standardised
[Kallman et al, 1967; Steel and Adams, 1975].
Two other in vivo assay systems have also been employed to
measure tumour cell survival. The spleen colony assay used to
study haemopoetic colony forming cells has been adapted for
malignancies of the haemopoetic system including cells from the
AKR mouse lymphoma [Bush and Bruce, 1964; Bruce et al, 1966],
the L1210 leukaemia [Wodinsky et al, 1967], a mouse plasma cell
tumour [Bergsagel and Valeriote, 1968] and mouse myelomas
[Park et al, 1971]. A lung colony assay similar in principle to the
spleen colony assay but applicable to non-haematological malignant
cells was proposed by Williams and Till [1966] who found that
polyoma virus-transformed cells from rat embryo tissue injected
intravenously into rats grew large macroscopic lung nodules within
17 days. Subsequently this system has been used to grow lung-
colonies from the KHT sarcoma [Hill and Bush, 1969] and the Lewis
lung carcinoma [Shipley et al, 1975].
Both these assays have the attraction over limiting dilution
techniques of rapidity, the colony growth end-point being achieved
in 2-3 weeks compared with up to 12 weeks for the latter; further¬
more the experimental design requires far fewer animals. However
the lung colony assay is often less sensitive than limiting dilution
methods; Shipley et al [1975] found for example a cloning efficiency
for untreated tumour cells of only 0. 2 to 0. 3%, which for cell
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survival after high doses of irradiation required more cells than
could be recovered from the treated tumour. A more important
disadvantage which both these assays inevitably share with the
limiting dilution technique and indeed with any design of in vivo
assay is host immune response unless syngeneic animals are used
as recipients; they are therefore useless for assaying cell survival
of tumours from larger animals and humans.
This problem therefore emphasised the need for an in vitro
cloning assay for tumour cells and stimulated research despite the
recognised difficulties in artificially fulfilling the rigorous nutrit¬
ional and metabolic demand of such cells. One approach was the
selecting out of tumour cell lines which could be adapted to grow
both in culture and in the animal. Frindel et al [1967] developed an
in vitro assay for a C3H mouse fibrosarcoma grown originally from
an established cell line. Conversely Barendsen and Broerse [1969]
devised a similar assay for a tumour which initially arose in vivo
and was subsequently adapted for tissue culture. This was achieved
by culturing in vitro a suspension of tumour cells from a radiation -
induced rat rhabdosarcoma; once a cell line had been established
a clone of cells was isolated and reinoculated into a rat where it
developed a tumour; repeated alternate in vitro and in vivo passages
eventually produced a tumour adapted for growth both in animals and
in culture. In the same way the EMT6 tumour was developed from
a mouse mammary tumour and its ability to grow in culture used to
develop an in vitro colony forming assay [Rockwell and Kallman,
1973].
Although colonies from single cell suspensions of these
specially adapted tumours could be grown in culture conditions
similar to those employed originally by Puck and Marcus for their
HeLa cell lines, in vitro cloning of tumours not previously adapted
to culture conditions was eventually achieved only with a much more
rigorous experimental design. The first such tumour to be assayed
in this way was a mouse plasma cell tumour for which a spleen
colony assay had previously been developed; the growth of colonies
from single tumour cell suspensions was achieved only when several
critical requirements were met: these included the use of a kidney
tubule feeder layer, the daily addition of fresh culture medium and
the addition of human serum, unnecessary for the growth of haemo-
poetic cell colonies in the same system [Park et al, 1971]. Thomson
and Rauth [1974] grew colonies of cells in vitro from the widely
studied KHT mouse fibrosarcoma; here they found the addition of
10% foetal calf serum and Bacto agar were important for colony
growth; no growth was seen with Noble agar or methyl cellulose.
In vitro colony growth of cell suspensions from the Lewis lung tumour
and the B16 melanoma in mice was achieved by Courtenay [1976];
here an incubation atmosphere of only 5% oxygen and the addition of
rat red blood cells to the culture medium were important factors.
Recently an in vitro colony assay for a rat brain tumour has been
described, requiring 10% foetal calf serum and a layer of heavily
irradiated "feeder" cells [Rosenblum et al, 1975].
Complex though these criteria for culture have proven to be,
the development of in vitro colony forming cell assays for animal
tumour was an important advance. They are in general less
elaborate and easier to carry out than parallel in vivo assays, they
are often more rapid in that colonies can be counted microscopically
at an early stage, they are certainly more economical eliminating
the need for recipient animals, and they offer some opportunity for
studying specific requirements of individual growth factors. But
most important, they eliminate the problem of host immune factors
which .limit the scope of in vivo assays, and raise the possibility of
developing a similar assay for human tumour cells.
3. 7: CLONOGENIC ASSAYS FOR HUMAN MARROW CELLS
In the 1960s successful attempts to grow in vitro colonies
from animal hacmopoietic tissues inevitably stimulated contemporary
efforts to grow similar colonies from human bone marrow. In 1967,
Senn et al described the successful growth of colonies in agar from
human marrow cell suspensions, using a technique very similar to
that previously described for the in vitro growth of mouse marrow
colonies [Pluznick and Sachs, 1965; Bradley and Metcalf, 1966].
Colony stimulating factor was provided by the addition of a "feeder"
layer of mouse-kidney tubules to the agar-culture medium.
Subsequently Pike a,nd Robinson [1970] described a similar method
for colony growth of human marrow cells; here however a "feeder"
layer of human peripheral white blood cells was used. Both
techniques grew colonies that contained principally granulocytic
precursor cells, with a low plating efficiency of approximately 16 to
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50 colonies per 10 cells. These observations were rapidly confirmed
by other studies which demonstrated, as in animal marrow assays,
the necessity for some source of colony-stimulating factor. Incon¬
sistencies in the levels of CSF generated by these sources have
therefore proved a disadvantage in this in vitro system and repeated
careful standardisation of controls are necessary. For this reason
the development of a diffusion chamber technique for growing human
marrow colonies without requiring the addition of a source of colony
stimulating factor was of some importance [Gordon et al, 1975].
This technique will be described in more detail below (Chapter 4).
3. 8: COLONY FORMATION IN HUMAN ACUTE LEUKAEMIA
Analysis of colony-formation by the marrow of patients with
acute leukaemia is complex. Some experimenters have found that
the marrow of patients with acute myeloid leukaemia in relapse
grows no colonies [Senn et al, 1967; Iscove et al, 1971; Brown and
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Carbone, 1971]; others have reported occasional small abortive
cluster-colonies of less than fifty cells [Harris and Freireich, 1970;
Greenberg et al, 1971; Bull et al, 1973], and very rarely apparently
normal colonies [Bull et al, 1973]. Moore et al [1974] found that the
marrow of 17% of a series of patients with acute myeloid leukaemia
grew colonies in agar, and that most of the rest grew large or small
clusters. Moore claimed that the ability of leukaemia marrow to grow
colonies or clusters was of prognostic significance, patients with
small cluster formation being more likely to achieve remission. This
observation has yet to be confirmed by others, and in general it would
appear that acute myeloid leukaemia blasts do not often form colonies
though they may form small clusters. Recently it has been reported
that acute myeloid leukaemia blasts can be stimulated to form
colonies of more than 500 cells in soft agar by the addition of phyto-
haemagglutinin, electron-micrographs demonstrating nuclear
"pockets" in colony cells consistent with chromosome abnormalities
in the leukaemic cell opoulation [Dicke et al, 1976]. The significance
of these artificially-stimulated colonies is hard to assess at present.
Colony formation by marrow cells from patients with acute
lymphoblastic leukaemia has been less intensively studied, although
one report suggests that normal granulocytic colony formation in
methyl cellulose was depressed by leukaemic lymphoblasts in patients
in relapse, but recovered once remission was achieved [Duttera et al,
1973]. Leukaemic lymphoblasts do not themselves grow colonies, nor
usually do normal lymphocytes. Again however it has recently been
reported that normal human peripheral blood lymphocytes can be
stimulated to grow large lymphoblast colonies in agar by phytohaem-
agglutinin or pikeweed mitagen (PWM) [Fibach et al, 1976]. Histo¬
logical staining demonstrated that the colonies were composed of
lymphoblasts. Rosetting techniques and immunofluorescent staining
showed the PWM -induced colonies contained both T and B lympho¬
blasts whereas PHA-induced colonies contained only T iymphoblasts.
While this technique may prove of value as an immunological tool,
the artificiality of the system at present makes its significance
hard to assess.
3. 9: COLONY FORMATION FROM HUMAN TUMOURS
Chronic granulocytic leukaemia (CGL) is the only human
tumour which at present consistently grows colonies from single
tumour cells. Brown and Carbone [1971] showed that large granulo¬
cytic colonies could be grown in methyl cellulose from both bone
marrow and peripheral blood samples of patients with CGL. The
malignant nature of these colonies was implied by their growth
from peripheral blood cells, an occurrence not seen with normal
peripheral blood, and later verified by the demonstration of the so-
called Philadelphia marker chromosome, characteristic of chronic
granulocytic leukaemia, in some colonies [Chervenick et al, 1971].
- Colonies were not however grown from a patient in the blast-crisis
end stage of this disease (Ibid). Theoretically CGL would seem to
provide an excellent opportunity for developing a colony-forming
cell assay system to study therapy in this disease, particularly
when the cell sampling technique, namely venipuncture, is so simple.
Indeed my initial plans had been to include chronic granulocytic
leukaemia in my research project. In practice however, the rarity
of the disease, and the medical indications for treatment to reduce
the peripheral leukaemia cell blood count once diagnosis has been
made, greatly limits the scope and potential for this type of research
work except over an extended period of time.
Colony growth in agar of cells from human solid tumours
has occasionally been described. McAllister and Reed [1968] grew
agar colonies from trypsin-dispersed cell suspensions of 9 out of 17
paediatric tumours studied. The original specimens included 3
Wilm's tumours, 2 ependymomas, 2 sarcomas, 1 glioma and 1
embryonal carcinoma. Eagle's medium with 10% foetal calf serum
and agar was used for colony culture without the addition of "feeder"
cells or conditioned culture medium. Plating efficiency was very
g
low, ranging from one to 133 colonies per 10 cells plated out,
after a 20 day incubation period. The authors claimed that the histo¬
logical characteristics in the colonies reflected the features of cells
from the original tumours. No tumour induction was achieved by
colony implantation into adolescent hamsters, although this seems
scarcely surprising in view of the immunological affront of heter¬
ologous tissue to the recipient animal. Cell suspensions plated out
in this study from 5 normal foetal tissues all failed to grow colonies.
Subsequently, the same group [McAllister et al, 1969] grew agar
colonies from 2 cell lines originally derived from an embryonal
rhabdosarcoma; the pitfalls in assuming that a tumour derived cell
line maintains the characteristics of the original tumour cells are
notorious but the authors described cytological, histochemical,
electron micrographic and chromosomal evidence compatable with
both the cell line and the derived colonies resembling the original
tumour cells.
More recently, cells from a malignant pleural effusion in a
child with rhabdosarcoma grew irregularly shaped colonies of 50 to
200 cells after 7 days incubation in both agar and methyl cellulose
[Altman et al, 1975]. A problem inherent in the type of experiment
is that inflammatory and immune reactive cells might reasonably
be anticipated in such an effusion and might themselves give rise to
colonies. In this case however, the authors described electron -
micrograph features of the colony cells which they claimed were
characteristic of rhabdosarcoma cells in the original tumour.
Considering the general interest in developing colony-forming cell
assays in general over the last 20 years, there appears to be sur¬
prising few other reports in the literature on attempts to grow
colonies from human tumours. To some extent this reflects the
technical difficulties involved, but there is also a major practical
problem which has presumably suppressed interest in what would
otherwise be a most useful investigative tool. The development of
an assay for human tumour cells would require serial tumour
samples over an extended period of time, first to standardise the
method and then to run the assay for the agents under study. However,
ethical considerations would nearly always rule out the possibility
of repeated biopsies of an untreated tumour in a patient, over a
prolonged period.
For this reason the development of human tumours which
could be propagated as xenografts in immune-suppressed mice was
a most interesting step forward and provided the opportunity for the
repeated tumour sampling necessary to develop a colony cell
survival assay.
Work on the development of an in vitro agar assay for human
tumour xenografts similar to that described above for animal tumours
and for human haemopoetic cells is being carried out by my colleague
Mrs. V. D. Courtenay in the same laboratory as myself, and pre¬
liminary results on this technique have been published [Courtenay
and Mills, 1976]. This assay has proved effective, but requires
extremely stringent and rigorous culture requirements. Further¬
more it is difficult to study the effects of drugs on colony-forming
cells in vitro; problems arise in trying to reproduce the biochemical
milieu for in vivo metabolism in the artificial culture medium of the
assay system.
For these reasons the possibility was raised of developing
a second, parallel assay system based on a recently devised
technique for assaying haemopoetic precursor cells growing in vivo
in diffusion chambers implanted into murine peritoneal cavities.
CHAPTER FOUR
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CHAPTER 4:
THE AGAR IN DIFFUSION CHAMBER ASSAY
The modern diffusion chamber consists of a small disc-
shaped perspex container one or both sides of which have been
replaced by a millipore filter of a pore size designed to allow the
transport of large molecules but not cells (Plate 4.1). Implant¬
ation of a cell-filled chamber into the peritoneal cavity of a mouse
thus allows the continuous diffusion of vital nutrients and metabol¬
ites,but not host reactive cells, across the filter in a physiological
milieu maintained relatively constant by the mouse; thus the need
for external maintenance of temperature, humidity, pK and fresh
culture medium inherent in in vitro techniques is obviated. Details
of the design of the chambers used in my research are described in
the next chapter.
The diffusion chamber technique is not a new one however,
and appears to have been invented by Metschnikoff [1887] who needed
a method to separate the effects of phagocytes from those of humoral
factors. For this purpose he developed thin-walled tubes from the
marrow of the reed Phragmites communis as diffusion chambers.
Later Nocaul and Roux [1898] used the technique to grow microbes,
including mycoplasma, which failed to grow well in vitro; these
researchers introduced microbe-containing nutrient media into bags
made from porous colloiden which were then implanted into experi¬
mental animals. Using the same type of cclloiden bag, Bisceglie
[1934] was the first to study tumour growth by the diffusion chamber
PLATE 4.1
0. 22/im Millipore Filter Diffusion Chambers. Details of manufacture
described in Chapter 5.4.
technique and the method duly became recognised as being of value
in the culture of cells and tissues which otherwise grew poorly
in vitro.
The modern perspex and millipore-filter diffusion chamber
described above was developed by Algire et al [1954] to prove the
importance of cellular immunity in transplantation rejection
phenomena. More recently intraperitoneal diffusion chambers have
been used to study haemopoietic stem cell growth and differentiation
[Boyum and Borgstrum, 1970; Brievik et al, 1971; Rothstein et al,
1971]. However, these measurements could initially only be made
by comparing total and differential cell counts before and after
chanber implantation [Boyum et al, 1972; Tyler et al, 1972];
colony assays akin to those carried out with in vitro techniques were
not attempted. The proliferation kinetics of experimental animal
tumour cells have also been studied in diffusion chambers [Schumann
et al, 1975]. Here changes in kinetic parameters were measured
by pulse-cytophotometry, and again no attempt was made to develop
a colony assay system.
The development of the diffusion chamber technique for
studies on colony growth was achieved by Gordon [1974] who
conceived the elegantly simple idea of introducing agar into the cell
suspension culture medium before loading into chambers. Thus a
semi-soft agar colony-forming cell culture, previously incubated
in vitro in Petri dishes, could now be maintained under more
physiological conditions in a mouse peritoneal cavity. Murine
marrow cells were found to grow colonies in this system, and these
were morphologically identical with colonies produced in the in vitro
method but without the need for colony stimulating factor and the
standardisation problems so involved. Later the technique was also
shown to grow colonies from human marrow cells [Gordon etal,
1975]; here however, pre-treatment of chamber-bearing mice with
whole-body irradiation was required for colony growth, This rather
curious prerequisite subsequently proved necessary in my research,
and is discussed in detail in Chapter 5.
Using the agar in diffusion chamber technique, cell survival
assays for the effect of irradiation and cytotoxic drugs 011 murine and
human haemopoietic precursor cells have been carried out [Gordon,
1975; Gordon and Douglas, 1976], and give the same results as those
obtained from in vitro assay techniques [Gordon, 1975], Apart from
eliminating the need for colony stimulating facto] when studying
-marrow cells, the agar in diffusion chamber assay has one other
important technical advantage over in vitro assays already
mentioned: it is possible,by injecting the host mouse after chamber
implantation, to study the effect of cytotoxic drugs on individual
cells under physiological conditions which allow normal drug
metabolism to proceed. Similar in vitro studies are less satisfac¬
tory in that artificial manipulation of the biochemical milieu, for
example by the addition of liver microsomal extracts, is necessary
to mimic physiological condition for drug metabolism.
These encouraging results with colony-forming cells from
human bone marrow, and the inherent advantages of the system
over in vitro techniques, held out the hope that it might be possible
to develop the agar in diffusion chamber technique for growing
colony-forming cells from human tumour xenografts. This would
allow for the first time the effects of radiation and cytotoxic drugs
on clonogenic human tumour cells to be assayed directly and would
do away with the necessity to extrapolate from experimental animal
tumours or tumour cell lines. Subsequent chapters in this thesis
describe the development of such a technique and of the results so
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CHAPTER 5:
THE DEVELOPMENT OF A CLONOGENIC CELL ASSAY
FOR HUMAN TUMOUR XENOGRAFTS USING AGAR IN
DIFFUSION CHAMBERS
5. 1: THE ORIGIN OF THE HUMAN TUMOUR XENOGRAFTS
USED IN THESE STUDIES
Eleven human tumour xenografts were used in these studies,
and their origins are listed in Table 5. 1. They include an anaplas¬
tic pancreatic carcinoma (HX32); four colonic carcinomas, three
of which were poorly differentiated (IIX18, HXUR5, HXK9) and one
moderately differentiated (HXK1); two rectal carcinomas, one of
which was poorly differentiated (HXK4) and one well differentiated
(HX12); two oat cell carcinomas of lung (HX29 and HX33); one
jmelanoma (HX34) and one anaplastic carcinoma of the uterus (HX35).
Four of the biopsies from which the xenografts were estab¬
lished came from the primary tumour, and the other seven from
metastatic deposits, as described in the Table.
The original tumour types were clearly established on
clinical and histological grounds, with one important exception.
This was the anaplastic pancreatic carcinoma (HX32) widely used in
experiments to be described in this Thesis. This tumour was
obtained at laparatomy from a 34-year old man presenting with
widespread peritoneal metastases which in the opinion of the surgeon
originated from the pancreas. Histological specimens showed a




















Rectaladenocarcinoma,welldiff ren i ted7/
Trypsin
HXK4














^MetastasisBiop y**PBS-Phosphate-BufferedS lin**Aft ro tTermM n layer
Culture( hapter5.2)





compatible with a pancreatic origin but not diagnostic of this. The
patient died soon after the operation and unfortunately no post
mortem was performed to add to this information. Throughout this
thesis, therefore, the HX32 xenograft will be referred to as a
pancreatic carcinoma, but implicit in this is the reservation that
this was merely the most likely diagnosis.
5, 2: XENOGRAFT IMPLANTATION
These xenograft tumours were established during the last
3 years by Mr. R. Pickard, F.R.C.S., Mr. K. Novak, F.R.C.S.
and Mr. J. Gibb working in the same laboratory as myself, and
to them I express my gratitude for this painstaking work which
allowed my own studies to proceed. Details of their technique have
been described elsewhere [Pickard et al, 1975], but the method
used, including some subsequent modifications, can be summarised
as follows: tumour biopsy specimens obtained at operation were
finely chopped and washed in medium TCI99. In early experiments
3
small pieces of about 8-10mm were implanted subcutaneously into
the flanks of immune-suppressed syngeneic CBA/lac mice (see below) (Plate
5. Later, it was found that the injection of a "mush" of
tumour cells injected by 19 guage needle intramuscularly into the
thighs of the mice was an easier and more efficient way of
producing tumours.
Both male and female CBA/lac mice were used for growth
and propagation of the xenografts. They were immune suppressed
by thymectomy at 3 to 4 weeks of age and 2 to 4 weeks later treated
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PLATE 5.1
Bilateral Human Pancreatic Carcinoma (HX32) Xenografts Growing
Subcutaneously in the Flanks of Immune-Suppressed CBA/lac Mouse
with 900 radwhole body irradiation with "rescue" by intravenous
injection of syngeneic bone marrow cells within 6 hours of
irradiation. Tumour implantation was carried out approximately
3 weeks later.
One xenograft, melanoma HX34, was prepared in a slightly
different way. The original biopsy specimen was considered too
small for xenografting, and a cell suspension was therefore
initially grown in monolayer culture. Cell numbers were built up
by subculturing, and after a six week period cells were harvested
and implanted by injection into the thighs of host mice as
described for other xenografts. It would ideally have been better
not to have had to resort to culture techniques at all, as with the
other 10 xenografts. There was good evidence however to suggest
that melanoma cells had been maintained in this short term culture
and had not been overgrown by non-malignant or contaminant cells:
tumours grew and could be passaged in the mice after implantation;
these were characterised as melanomas by their dark pigmentation
and by the demonstration of melanosomes in electron micrograph
sections of tumour cells [Dr. K. Dawson, personal communication].
This and other evidence confirming the human origin of the xeno¬
grafts will be described in more detail in Chapter 6.
5. 3: CELL SUSPENSIONS OF TUMOUR XENOGRAFTS
Tumours excised from mice freshly killed by neck dislocation
were washed and finely chopped in phosphate-buffered saline (PBS)
under sterile conditions using a crossed-scalpel technique. Further
treatment to produce a viable single cell suspension was then deter¬
mined empirically for each tumour and details are shown in Table 5.1.
The preparation of single cell suspensions of 4 tumours used in
experiments to be discussed in subsequent chapters will be described
here. These illustrate the different types of treatment required.
5. 3. a: Pancreatic Carcinoma (HX32)
The finely chopped pieces of this tumour were incubated in
collagenase (Worthington) 2mg/ml in Ham's F12 medium with 15%
special Bobby calf serum (Gibco Biocult) at 37°C for 30 minutes in
Falcon tubes. The material was then rinsed twice in PBS and trypsin -
ised for 5 minutes at 37°C with 0. 05% trypsin (Bacto trypsin Difco).
The trypsin-in-PBS supernatant was then decanted off, the cellular
material incubated for a further 5 minutes at 37°C in Ham's F12
medium without trypsin and a cell suspension produced in the super¬
natant layer by three or four vigorous shakes of the tube. This
supernatant was then added to 15% special Bobby calf serum to
inactivate any residual trypsin activity, the cells were re-suspended
in fresh medium and serum after gentle centrifugation for 2 minutes,
and the suspension was finally filtered through a 30/im polyester mesh
(Henry Simon, Stockport) to remove clumps and debris. The single
cell suspension so obtained was kept at 4°C.
5. 3.b: Colonic Carcinoma (HX18)
For this tumour, incubation with collagenase was found to be
unnecessary, and the finely chopped tumour material was incubated
with trypsin 0. 05% in PBS for 5 minutes. The supernatant was then
decanted off, the cellular material incubated for a further 5 minutes
at 37°C in Ham's F12 medium without trypsin, and again a cell sus¬
pension produced in the supernatant layer by three or four vigorous
shakes of the tube. The final single cell suspension was then achieved
by the same steps as described for pancreatic carcinoma HX32.
5. 3. c: Oat Cell Carcinoma (HX33)
A single cell suspension of this tumour was obtained without
the need for either trypsin or collagenase. Finely chopped pieces of
tumour were incubated in PBS for 10 minutes at 37°C, and the tube
then vigorously shaken 3 or 4 times to produce a cell suspension in
the supernatant layer. Cells were then re-suspended in Ham's medium
and serum and filtered as described for the previous two xenografts.
5. 3. d: Melanoma (HX34)
The same technique was used to produce a single cell
susjmnsion of this tumour as for oat cell carcinoma HX33.
Viability for suspension of all tumours was assessed by dye
exclusion using lissamine green, and a viable cell count was made
using a haemocytometer. Viability of single cells in suspension main¬
tained at 4°C remained fairly constant for a period of at least 4 hours,
assessed both by dye exclusion and by the fraction of the original cell
count growing colonies in agar. Exceptions to this general observation
were the 2 oat cell carcinomas of lung, the small tumour cells of
which began to lose the ability to exclude dye after 45 minutes in
suspension. These tumours were therefore correspondingly more
difficult to study, and cells from these were always loaded into
chambers within less than an hour of preparing the initial suspension.
5.4: MANUFACTURE, FILLING AND IMPLANTATION OF
DIFFUSION CHAMBERS
Diffusion chambers were made by attaching a Millipore filter
(pore size 0. 22/im) to one side of an acrylic ring (inside diameter
12. 5mm; wall thickness 2. 5mm; depth 3. 5mm) by the solvent
action of acetone. A circular glass coverslip was glued to the other
side of the ring with MF cement (Millipore Corporation, Bedford,
*
Massachusetts; Catalogue No. XX. 70. 000. 00), completing a chamber
whose volume was approximately 0.4ml (Plate 4.1). Completed
chambers were sterilised before use in dry heat at 80°C for 18 hours.
Molten agar, held at 44°C in a water bath, was added to the
required number of cells for assay suspended in Ham's medium and
serum at 4°C to produce a final agar concentration of 0. 3%. (The
ratio of cell suspension at 4°C to agar at 44°C was 9:1 and therefore
there was no possibility of overheating of cells in the final mixture.)
0. 35ml of this mixture was injected into each chamber through a
small hole in the acrylic ring, and allowed to set at room temperature.
The holes were then sealed with paraffin wax and the chambers
implanted into the peritoneal cavity of 11-12 week old male C57B1
mice, under ether anaesthesis.






Agar in Diffusion Chamber Assay Technique for Clonogenic Human
Tumour Cells
5. 5: COLONY COUNTING AND DEFINITIONS OF "COLONIES"
AND "CLUSTERS"
Chamber-bearing mice were killed by cervical dislocation,
and the Millipore filter of each chamber removed with a scalpel
blade; colonies were then counted in the chamber under a binocular
microscope at a magnification of x50. Colonies were defined as
aggregates of at least 50 cells; clusters were defined as aggregates
of between 20 and 50 cells. The optimum incubation period for
colony formation was determined by colony counting at various
times after implantation until there was no further increase in
colony numbers (Chapter 5. 10).
5. 6: COLONY GROWTH FROM CELL SUSPENSIONS OF HUMAN
TUMOUR XENOGRAFTS
Using this technique, cell suspensions of all 11 tumours
studied reproducibly grew agar colonies in diffusion chambers.
However, an essential pre-requisite for successful colony growth
was pre-treatment of the chamber-bearing C57B1 mice; little or no
colony growth from any of the xenografts was achieved in untreated
mice. This point is of great importance and will be discussed in
detail in a later section of this chapter (Chapter 5. 12).
5. 7: COLONY MORPHOLOGY
Interestingly, there was considerable variation in colony
morphology between different tumours. Most produced colonies
composed of rather loosely clumped cells (Plate 5.2), while a few,
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PLATE 5.2





Agar Colony from Cells of Melanoma Xenograft HX34 (x 100)
i
PLATE 5.4
Agar Colony from Cells of Colonic Carcinoma Xenograft HX18 (x 100)
PLATE 5.5
Giemsa-Stained Preparation of Colonic Carcinoma Xenograft HX18
Colony Removed from Agar, Showing Mucinous Capsule "Leaking"
Cells at 2 Sites
including melanoma HX34 and uterine carcinoma HX35 produced
more densely packed colonies (Plate 5. 3). One tumour, colonic
carcinoma HX18, produced colonies in the form of tightly packed
encapsulated spheres (Plate 5.4). Giemsa staining of one such
colony removed from agar showed an extraordinary mucinous
capsule surrounding the tumour cells (Plate 5. 5). (The technique
used here is described in Chapter 6.) The morphology of colonies
from each individual tumour remained absolutely constant in different
experiments and with different passages.
5.8: LINEARITY
A few of these xenografts, and in particular pancreatic
carcinoma HX32 and colonic carcinoma HX18, were used in experi¬
ments to be described in later chapters where the effects of irradi¬
ation and cytotoxic d^ugs on colony cell survival were studied. To
establish the validity of the technique as an assay for this purpose,
the relationship between the number of tumour cells introduced into
the diffusion chambers and the subsequent yield of colonies was
investigated. A linear relationship was demonstrated for pancreatic
3 3
carcinoma HX32 over a range of 0. 1 x 10 to 1. 75 x 10 cells per
chamber (Fig. 5. 2) and for colonic tumour HX18 over a range of
3 3
0. 5 x 10 to 4. 5 x 10 cells per chamber (Fig. 5. 3). The diffusion
chamber technique could therefore be used as a valid assay for the
effects of irradiation and drugs on the survival of clonogenic human
tumour cells, at least over these ranges.
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FIGURE 5.2
The Relationship Between the Number of Cells Cultured in Agar in
Diffusion Chambers and the Number of Colonies Scored, for Human
Pancreatic Carcinoma Xenograft HX32 (Vertical Bars Represent
+ Standard Error of the Mean)
FIGURE5.3HumanColonicarcinomaXenograftHX18 TheRelationshipB tweentNumberofCellsulturediAgarD ffu ionChambersndh NumberofC loni sSc r d(Vert calBarRepr sent+Stan ardEr orofhMean)
• —j
5.9: INCUBATION PERIOD
Details of the incubation period for colony growth for each
xenograft are given in Table 5. 2. This ranged from only 12 days
for the melanoma HX34, and the anaplastic uterine carcinoma HX35
to 28 days for the well differentiated rectal carcinoma HX12 and a
moderately well differentiated colonic carcinoma HXK1. Most
tumours had an incubation period of about 21 days, with a tendency
for colonies from the less differentiated tumours to grow more
rapidly than those from well differentiated ones. Despite the range
of incubation times between different tumours, this remained
generally constant for each tumour type in different passages and
experiments.
5. 10: THE GROWTH OF CLUSTERS AND COLONIES
Clusters (20-50 cells) and colonies (greater than 50 cells)
from the pancreatic tumour xenograft HX32 were counted at various
times after chamber implantation (Fig. 5.4). Initially, many more
clusters than colonies were seen, but the cluster count decreased
as colony count increased showing that most clusters continued
growing to form colonies. A few colonies began to appear around
the ninth day, after which the number of colonies rapidly increased
until about the 18th day and then plateaued at about 130 colonies per
1000 cells plated. About 70 clusters per 1000 cells plated persisted
once the colony count had levelled out, giving a final colony to cluster






































TABLE5.2 IncubationPeriodsforColo yGrowthfHumanT urXen grafts
Days
FIGURE 5.4
The Development of Clusters (O) and Colonies (0 with Time for
Cells From Pancreatic Carcinoma Xenograft HX32 (Vertical Bars
Represent + Standard Error of the Mean)
become colonies; some plated cells appear to have potential for a
limited number of divisions but are incapable of forming colonies of
50 cells or more. This observation becomes important in later
chapters in which the effects of radiation and cytotoxic agents on
colony growth were studied.
5. 11: PLATING EFFICIENCY
The mean plating efficiency of each tumour was fairly
constant, although the range between different tumours varied from
0. 3% for one of the oat cell lung tumours (and 1. 5% for the other) to
16% for the melanoma. Details of the plating efficiency for each
xenograft are given in Table 5. 3. It was not possible to assess the
extent to which this wide range reflected differences in the fraction
of cells with proliferative capacity in different tumours in situ, or
instead represented a laboratory artefact based on varying suscep¬
tibilities of different tumours to the trauma involved in producing
cell suspensions. It was of interest that most, but not all, of the
poorly differentiated and clinically aggressive tumours had a
relatively high fraction of colony forming cells. On the other hand,
the two oat cell carcinomas of lung, also in general clinically
aggressive, had low plating efficiencies. These may have been
associated with the unusually rapid loss of viability in single cell
suspensions of these tumours (Chapter 5. 3), giving an artificially
















































































The Influence of Pretreatment Whole-Body Co y -Irradiation on
Plating Efficiency for Colonic Carcinoma HX18 (a) and Pancreatic
Carcinoma HX32 (b). The Results for Each Pretreatment are
Expressed as a Percentage of the Yield Achieved Using 900 rad-
Irradiated Mice. (Vertical Bars Represent + Standard Error of the
Mean)
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5.12: PRE-TREATMENT OF CHAMBER-BEARING MICE AS A
PRE-REQUISITE FOR COLONY GROWTH
The ability of this system to grow colonies of tumour cells,
and the plating efficiency for each tumour, was critically dependent
on pre-treatment of the chamber-bearing C57B1 mice, and little or
no colony growth was seen in untreated animals from any tumours.
This observation had previously been made for human bone marrow
cell colonies grown in agar in diffusion chambers [Gordon et al,
1975], and it is of interest that Schumann et al [1975] were unsucc¬
essful in growing human tumour cells for proliferation kinetic studies
in diffusion chambers implanted into untreated animals. The effect
of different types of pre-treatment was studied in detail for 2 xenografts,
the pancreatic carcinoma HX32 and colonic carcinoma HX18 and
results are shown in Figures 5. 5 to 5. 8.
5.13: WHOLE BODY IRRADIATION
The first type of pre-treatment investigated was whole body
irradiation. This was given to mice 3 hours before chamber implan-
60
tation from a Cobalt source at a rate of around 50 rad per minute.
For this purpose, the mice were restrained in position in perspex
chambers.
It will be seen from Figures 5.5a and 5.5bthat the plating
efficiency increased for both tumours as the dose of irradiation was
increased up to a lethal dose of 900 rads. Gordon et al [1975] had
previously observed the same effect using this technique for human
marrow. 900 rad whole body irradiation produces fatal bone marrow
toxicity in mice around the ninth day after its administration. This
is unimportant in human bone marrow experiments where colonies
grow in eight days (ibid), but it presented serious problems in human
tumour studies which required much longer incubation periods for
successful colony formation. Initially the only solution was to trans¬
plant chambers to fresh batches of newly irradiated mice every
ninth day, despite the drain on both mice and time this involved.
5. 14: CYTOSINE ARABINOSIDE AND WHOLE BODY IRRADIATION
However, it had been found by Dr. John Millar, working in
the same laboratory but on a different project, that death after 900
rad and even lOOOrad whole body irradiation to C57B1 mice could be
prevented by prior treatment with cytosine arabinoside in a dose of
200mg/kg injected intra-peritoneally 1 to 3 days before incubation
[Millar et al, 1976]. This in itself was an extraordinary
finding with possible long term therapeutic implications, and the
underlying mechanism is being investigated at present. Clearly
this is outside the scope of this thesis, but the observation itself
suggested a technique whereby chambers could be implanted into
mice pre-treated with cytosine arabinoside 24 to 48 hours before
1000 rad whole body irradiation and thus be maintained for the whole
incubation period without the need for further transplantation. The
question posed was whether colonies would grow with the same
placing efficiency in this system as in chambers transplanted every
ninth day into a new batch of 900 rad irradiated mice. The results
of these experiments are shown in Figure 5. 6 and demonstrate
that for both tumours the plating efficiency was the same within the
limits of experimental error whether the chambers remained in the
same mice for the entire duration of the incubation period or were
transplanted every ninth day into newly irradiated mice. The saving
in mice and labour thus achieved resulted in the cytosine arabinoside
pre-treatment technique being adopted as standard procedure for
most of the experiments subsequently described in this thesis.
5. 15: CYCLOPHQSPHAMID E
Smith and van Dierendonk demonstrated that 200mg/kg
cyclophosphamide given intraperitoneally was many times more
effective than other pre-treatment schedules for promoting lung
colony formation from C22LR mouse osteosarcoma [personal
—communication]. The simplicity of this regime suggested that it
might be worth studying the effect of cyclophosphamide pre-
treatment in the agar diffusion chamber system. However,
cyclophosphamide 200mg/kg given intraperitoneally to C57B1
mice 24 hours before chamber implantation was ineffective,
-achieving a mean plating efficiency of only 5. 5% (HX32) and 14%
(HX18) of that reached with high dose whole body irradiation
(Fig. 5. 7). Cyclophosphamide pre-treatment was therefore not



































Ara-C + 1000 rad
(b)
The Influence on Plating Efficiency of 900 rad Whole-Body Irradiation
(Transplanting Chambers Every 9th Day) Compared with Cytosine
Arabinosi.de (Ara-C) 200mg/kg i.p. 24 hours Before 1000 rad Whole-
Body Irradiation (No Chamber Transplantation) for Colonic Carcinoma
HX18 (a) and Pancreatic Carcinoma HX32 (b). Results Expressed as



































The Influence on Plating Efficiency of Pretreatment with 900 rad
Whole-Body Irradiation Compared with Cyclophosphamide 200mg/kg
for Colonic Carcinoma 11X18 (a) and Pancreatic Carcinoma HX32 (b).
Results Expressed as in Figure 5. 5.
have been achieved by varying the time interval of administration
before chamber implantation.
5. 16: IMMUNE-SUPPRESSED AND "NUDE" MICE
Although the time, labour and expense in producing CBA/lac
mice immune-suppressed by thymectomy, whole body irradiation
and marrow re-constitution as previously described (Chapter 5. 2)
ruled these out as routine chamber-bearing hosts, chambers con¬
taining cells from pancreatic carcinoma HX32 were implanted into
these animals without further pre-treatment in one study in an
attempt to elucidate the mechanism of action of the pre-treatment
phenomenon. In this environment, colonies grew almost as well as
in whole body irradiated animals, with a plating efficiency of 83 +
12% that of 900 rad-irradiated mice (Fig. 5. 8).
An opportunity also became available during the early stages
of my research to carry out a single experiment on the ability of
genetically athymic "nude" mice to sustain colony growth of cells
from pancreatic carcinoma xenograft HX32. Chambers were
implanted into the peritoneal cavities of 5 untreated "nude" mice
and incubated for 18 days as usual. Here, the plating efficiency
was 125 + 4% that achieved by the 900 rad pre-treatment
technique (Fig. 5. 8) and the range of colony counts from individual
chambers was less than that for irradiated animals. This perhaps
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FIGURE 5.3
A Comparison of the Influence on Plating Efficiency of Chambers
Implanted into 900 rad Whole-Body Irradiated Mice, Thymectomised
Whole-Body Irradiated Mice and Nude Mice for Pancreatic Carcinoma
HX32. Results Expressed as in Figure 5. 5.
between those artificially pre-treated in the laboratory. Clearly no
statistical significance can be placed on a single experiment, however,
and lack of further availability of "nude" mice at present has pre¬
vented the verificiation of these initial observations. In practice,
cost would probably rule out the standard use of these animals as
chamber-bearing hosts in any case, but the experiment was of
interest in trying to elucidate the mechanisms of action which underlie
the pre-treatment phenomenon.
5. 17: WHY IS PRE-TREATMENT NECESSAJRY?
The reason for pre-treatment of chamber-bearing animals
as an essential pre-requisite for colony growth is not at all clear.
At first sight, suppression of a host immune response against the
human tumour cells would seem to be operating, and there is some
circumstantial evidence to support this. First pre-treatment is not
required for syngeneic tissues: C57B1 Lewis lung tumour and marrow
cells will grow colonies in this system without pre-treatment of
chamber-bearing animals [Gordon, 1974; Personal observations].
Second, the observation that colony growth is promoted in animals
experimentally or genetically depleted of T-lymphocytes favours an
innumological basis for the phenomenon.
However, it is hard to reconcile this with the experimental
design of the system: both the "affector" and "effector" arms of
the T-lymphocyte specific immune response to foreign antigens are
believed to involve direct interaction of host cells with antigen
[Basten and Mitchell, 1976a],], and yet the 0. 22/im Millipore filter
forms a complete barrier to cellular movement in and out of the
diffusion chambers. Large molecules can of course diffuse across
the filter and it could be postulated that "shed" tumour cell antigens
diffuse out of the chamber and initiate a host response, but this
seems unlikely since such antigens are currently believed to provide
only a very weak antigenic stimulus [Alexander, 1974]. Likewise, the
affector arm of the immune response might be solely medicated by
immunoglobulins; again this would be unexpected in a system based
primarily on T-cell deprivation provided by thymectomised or "nude"
mice. If non-cellular immune mechanisms are operating here they
would therefore appear to lie outwith current concepts of immunology.
Indeed this diffusion chamber system might prove a useful technique
for their further investigation.
Alternatively, a completely non-immunological process may
be operating. It is theoretically possible that T-cell depletion,
achieved by whatever mechanism,is associated with the production
of some factor which is essential for colony growth of human tumour
cells. This possibility is not so implausible as it might at first
seem: it has already been established by Courtenay for example
that human tumour colony formation in vitro demands very exacting-
growth requirements (Chapter 3. 9) and the same may be true of the
diffusion chamber system.
Much work remains to be done in elucidating the mechanism
underlying the pre-treatment effect and this might provide important
new information on immune or other factors associated with tumour
cell growth. For the purposes of this thesis, however, my approach
has been merely to make the observation, without pursuing under¬
lying mechanisms, and instead to use the system to study radiation
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CHAPTER 6:
EVIDENCE THAT DIFFUSION CHAMBER COLONIES
ORIGINATE FROM HUMAN TUMOUR CELLS
The most critical point underlying the entire basis of the
diffusion chamber technique as a valid assay system is that the
colonies grown by this method are indeed derived from human
tumour cells and not from some other cell type. Several
techniques were used to demonstrate this.
6. 1: GENERAL CONSIDERATIONS
Circumstantial evidence is very much against non-
malignant stromal cells from these tumours giving rise to colonies.
Some normal tissues, and in particular fibroblasts, can of course
be grown in monolayer cultures but such cells do not produce
colonies in agar either in vitro [McAllister and Reed, 1.968] or in
diffusion chambers [personal observation with human foetal
fibroblasts]. Furthermore one might expect the same stromal
elements to be present for different xenograft tumours, albeit
perhaps in different proportions, and it would therefore be surprising
that these same stromal cells would produce colonies whose morph¬
ology differs so strikingly depending on the tumour under study
(Plates 5. 2, 5. 3, 5.4). On purely circumstantial grounds therefore
it seems unlikely that colonies in this system are derived from
stromal cells.
A more plausible alternative candidate for colony formation
from xenograft cell suspensions might be the macrophage. This
cell has been demonstrated in both animal and human tumours
[Evans, 1972; Currie, 1976] and may well play an
important role in tumour rejection [Alexander, 1976; Lancet
Editorial, 1976]. There appears to be no published data on the
existence of mouse macrophages in human tumour xenografts, and
it therefore seemed relevant to investigate this possibility and to
exclude the macrophage as the basic colony-forming cell in the
diffusion chamber system.
6. 2: MACROPHAGES IN THE HX32 PANCREATIC CARCINOMA
XENOGRAFT
Macrophages cannot always be confidently identified either
by histological staining techniques or by direct microscopic
observation in suspension. This therefore raised technical problems
in studying their existence and possible colony-forming potential in
xenograft cell suspensions. Fortuitously, however, cell suspensions
of one xenograft, pancreatic carcinoma HX32, consistently
demonstrated two distinct cell populations of different size, in
approximately equal proportions. The possibility that one of these
populations might consist of macrophages was investigated by two
separate techniques.
In the first, the xenograft cell suspension was incubated
at 37°C for 10 minutes in a haemocytometer and then examined for
macrophages which adhere to, and spread over, the haemocytometer
cover slip [Evans, 1S72]. In the second, the cell suspension was
centrifuged at 800 r.p. m. for 10 minutes with sheep red blood cells
(RBCs) coated with the IgG fraction of hyper-immune rabbit anti-
sheep RBC serum. These sheep RBCs rosette with Fc-receptor
sites on macrophages, and rosettes so formed can be recognised
and counted in a haemocytometer [Basten and Mitchell, 1976b].
Each of these techniques demonstrated that approximately 50% of
cells in the HX32 tumour were macrophages, and that furthermore
these corresponded with the smaller of the two cell types seen in
suspension under direct light microscopy. The larger of the cell
types did not take part in either of these reactions and were
therefore not macrophages. (I am grateful to Dr. Graham Currie
for technical advice and assistance with these macrophage
experiments.)
The next problem was to establish which of the two cell
populations was giving rise to colonies in agar. Crude cell
separation was achieved by allowing the original suspension
sediment under gravity in Ham's medium and serum for one hour,
after which a suspension containing approximately 80% of the
smaller cells could be recovered from the uppermost layers and a
similarly enriched suspension of larger cells could be obtained from
the bottom layers. The colony forming ability of each of these
suspensions was then separately measured in diffusion chambers
using the standard technique previously described.
The plating efficiency of these differential cell suspensions
always correlated with the original percentage of large cells,
demonstrating that these, and not the macrophages were forming
colonies.
6. 3: COLONY MORPHOLOGY
One of the problems involved in studying colony morphology
is that colonies are difficult to remove intact from agar; neverthe¬
less this is necessary to allow satisfactory uptake of dye by colony
cells in histological preparations. Eventually the following
technique was employed: colonies were removed from agar by
Pasteur pipette under a binocular microscope, placed on a clean
slide, squashed under a coverslip and immersed in a freezing
mixture of liquid nitrogen. The coverslip was then flicked off the
frozen slide and the cells adhering to the slide were stained with
Giemsa.
This technique proved particularly successful for studying
the closely packed, encapsulated colonies grown from colonic
carcinoma HX18. Giemsa-stained preparations of colonies grown
from this tumour showed undifferentiated neoplastic cells with
high-nuclear: cytoplasmic ratio, all basically of the same type
(Plate 5. 5). Comparison with histological sections of the original
tumour xenograft showed that the colony cells were entirely
compatible with an origin from that tumour and indeed from the
original biopsy removed from the patient at surgery (Dr. A. Mackay,
Consultant Pathologist, Royal Marsden Hospital).
Similar studies on the other xenografts were less successful
at producing intact colonies, but the cells obtained from colony
fragments again had the cytological features of tumour cells
resembling those found both in the xenograft tumours and the original
human cancers.
6.4: CHROMOSOMAL ANALYSIS
A direct chromosomal analysis was carried out on cell
suspensions of all 11 xenografts by my colleague Miss J. Mills. The
technique used was as follows: the tumour cell suspension was
incubated with colcemid 0.4jug/ml in Ham's medium for 2-3 hours
at 37°C, and then resuspendea three times in Clark's fixative (3
parts methanol : 1 part glacial acetic acid) at 4°C for 30 minutes
each time. Drops of the final cell suspension were heat dried on a
clean glass slide and stained with Giemsa. Analysis was repeated
from time to time for different passages of the same tumour.
All xenograft cell suspensions analysed in this way were of
human karyotype with typical acrocentric and metacentric chromo¬
somes which are lacking in mouse karyotypes. For example, cells
of pancreatic carcinoma HX32 had a range of 42 to 68 chromosomes
and a mode of 62, with extra chromosomes coming from groups C,
D and E. Only the larger of the 2 cell populations of this tumour
were of human karyotype; occasionally a mouse karyotype
could be demonstrated in the smaller, macrophage population
known not to form colonies (Chapter 6. 2). One tumour, colonic
carcinoma HX18, had an added large acrocentric marker chromo¬
some, persisting throughout repeated passage.
6.5: ELECTRON MICROGRAPH STUDIES: MELANOSOMES
Melanocytes and malignant melanoma cells can be further
characterised by distinctive sub-cellular cytoplasmic organelles
called melanosomes, demonstrated by electron microscopy. These
are elongated structures 0.7x0. 3ju, in size, and are associated with
the biosynthesis of melanin [Seigi et al, 1963]. Melanosomes were
demonstrated in colony-forming cells from xenograft HX34 by
electron microscopy, further confirming their melanoma origin;
the colonies grown from this tumour were correspondingly darkly
pigmented. (I am grateful to Dr. Kent Dawson for carrying out
these electron microscopy studies.)
In conclusion, evidence based on morphology, chromosomal
analysis, the exclusion of non-malignant cells as candidates for
colony formation, and in one case the demonstration of characteristic
sub-cellular organelles, all strongly support the assumption that the
colonies grown in this assay system are indeed derived from human
tumour cells and not from some other cell type.
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THE IN VITRO IRRADIATION RESPONSE OF FOUR
HUMAN TUMOUR XENOGRAFTS
7. 1: INTRODUCTION
Although the effect of ionising radiation on the reproductive
capacity of bacteria and viruses had been studied for many years by
plating and plaque-forming techniques [Lea, 1946], similar measure¬
ments on mammalian cells were not possible until Puck and Marcus
[1955] developed the technique described in Chapter 3. 3 for growing
colonies of plated HeLa cells in culture.
Using this technique they found that exposure of HeLa cells
to ionising irradiation before plating out in Petri dishes limited
colony growth: some cells disappeared completely, some remained
single, some formed bizarre "giant forms" suggesting continued
growth but with immediate loss of reproductive capacity, some
formed "abortive" colonies of less than 50 cells suggesting loss of
reproductive capacity after 3 or 4 divisions and some grew colonies
as before [Puck and Marcus, 1956].
As the dose of irradiation was increased the ability of single
cells to grow colonies progressively decreased, and the colony-
forming cell survival curve so produced was of "sigmoid" or "C"
type. This type of cell survival curve has subsequently been found
for almost all mammalian cells so far studied after irradiation, and
is pertinent to data arising from my own research; it will be
described in some detail and is shown schematically in Figure 7.1.
FIGURE 7. 1
Schematic Representation of Sigmoid-Type Radiation Cell Survival
Curve for Mammalian Cells
This type of curve has an initial "shoulder" or pseudo-
threshold region followed by a region of exponential decline [Puck
and Marcus, 1956; Alper et al, 1962], and can be characterised by
two parameters: the first measures the slope of the exponential
region on a semi-logarithmic plot and is conventionally expressed
as Dq, that being the dose required to reduce survival to e * (37%)
in the exponential portion; the second measures the width of the
shoulder region and is conventionally expressed either as n, the
value obtained by extrapolating the exponential portion of the
survival curve to zero on a semi-logarithmic plot, or as Dq, the
dose obtained by extrapolating the exponential portion of the survival
curve to the point where it crosses the 100% survival level (all
shown in Figure 7.1).
The radiobiological significance of this "C form" type of
curve is that it consistutes evidence for a single-hit multi-target
mechanism* for mammalian cell killf by irradiation. The shoulder
*The single-hit multi-target theory of cell kill by irradiation means
that several points in the cell must be hit each by a single quantum
of irradiation to cause loss of proliferative capacity; if some but
not all these points are hit then damage is sub-lethal and the cell
can recover.
tCell "kill" in clonogenic cell assays is by convention taken to mean
loss of unlimited proliferative capacity.
portion of the curve represents the ability of cells to accumulate a
certain amount of sub-lethal damage, presumably through "non-
hitting" of some targets, before loss of proliferative capacity
occurs [Elkind and Sutton, 1959]. This differs from the simple
exponential irradiation survival curve without an initial shoulder-
region found for many bacteria, which suggests a single-target
single-hit mechanism of killing [Lea, 1946].
The slope of the exponential tail of the curve, which is
inversely proportional to Dq, gives a measure of the inate radio-
sensitivity of cells in vitro under standard, fully oxygenated
conditions, and provides the basis for comparison of the inate
radiosensitivity of cells from different tissues and species. Puck
and Marcus [1956] found the Dq for HeLa cells to be 96 rad, which
suggested that the proliferative capacity of mammalian cells was
many times more sensitive to ionising irradiation than those of
micro organisms; equivalent values for E. coli bacteria are 4, 000
rad [Lea, 1946] and for viruses around 40, 000 rad [Watson, 1950],
Both the method of Puck and Marcus and other types of cell
assay described in Chapters 3 and 4 have subsequently been used to
measure the in vitro radiosensitivities of a whole range of mammalian
tissues. These include laboratory cell lines [reviewed by Whitmore
and Till, 1964; and Okada, 1970], experimental animal tumours
[Hewitt and Wilson, 1961; Silini and Hornsey, 1962; Bush and
Bruce, 1964; Reinhold, 1966; Hewitt, 1967; Brown and Berry, 1968;
Reinhold and Debree, 1968; Hill and Bush, 1969; Rockwell and
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Kallman, 1973; Thomson and Rauth, 1974; Shipley et al, 1975;
Courtenay, 1976], haemopoietic precursor cells from animal bone
marrow [Robinson et al, 1967; Chen and Schooley, 1970; Senn and
McCulloch, 1970; Gordon, 1975], human bone marrow precursors
[Senn and McCulloch, 1970; Gordon, 1975], cells from normal
tissues [Whithers, lOS'L; Withers and Elkind, 1968] and recently
human tumour cell lines [Barranco et al, 1971; Thomson et al, 1975;
Weichsenbaum et al, 1975].
From these data it has emerged that the in vitro radiosens-
itivities of mammalian cells under well oxygenated conditions
appear to lie within a fairly narrow range: nearly all mammalian
cells have a Dq between 70 and 200 rad, and the large majority a
considerably narrower range than this, wuth Dq between 90 and 150
rad. Exceptions to this general observation have been occasionally
reported: radiosensitive mutant strains of radiation-induced
L5178Y leukemic cells in DBA/2 mice were shown to have a Dq as
low as 35 rad, depending on the medium used [Beer et al, 1963]; at
the other extreme, Lin and Glass [1962] studied the effects of in vitro
irradiation on the survival of mouse oocytes and found a Dq of 300
rad; in this assay the end-point was not colony formation but embryo
development after post-irradiation implantation into mated female
mice (Chapter 3. 5). Such exceptions have so far been described
very rarely and do not invalidate the general observation that the
inate radiosensitivities of nearly all mammalian cells so far studied
in vitro lie within a fairly narrow range.
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In striking contrast to these in vitro studies is the wide
range of clinical radiotherapy response of human tumours, long recognised
by radiotherapists [Moss et al., 1973]. It has been assumed
that these observed clinical differences must be based on factors
other than inate differences in the cellular radiosensitivity of human
tumours; various explanations, including for example differences in
tissue hypoxia within tumours and differences in the kinetics of
tumour cell repopulation after irradiation, have been postulated to
explain this [Berry, 1974; Lamerton, 1974; Nias, 1974], While
mechanisms such as these may undoubtedly be relevant in influen¬
cing the clinical response of a tumour to radiotherapy, it is impor¬
tant to note that the argument dismissing the possibility of inate
differences in radiosensitivity at the cellular level as an explanation
of observed clinical differences is based purely on extrapolation of
in vitro studies from other mammalian tissues; impressive though
-the volume of these data may be, no direct studies on the in vitro
radiosensitivity of clonogenic human tumour cells appear to have
been published, through lack of a suitable assay technique.
It was therefore decided to study the response to in vitro
irradiation of four human tumour xenografts in the diffusion chamber
assay system. From the xenografts available, tumour types were
selected to some extent on the basis of recognised differences in
their clinical raaiosensitivities.
7. 2: METHODS EMPLOYED FOR IN VITRO IRRADIATION OF
XENOGRAFT TUMOUR CELLS
7. 2. a: Tumour Xenografts and Cell Suspensions
The 4 human tumour xenografts selected for these experi¬
ments were a pancreatic carcinoma (HX32), a colonic carcinoma
(HX18), an oat cell carcinoma of lung (HX33) and a melanoma (HX34).
Details of these have been described in Chapter 5 and Tables 5.1 - 5. 3,
as have the techniques used to produce single cell suspensions
(Chapter 5. 3. a, 5. 3.b, 5.3.c, 5. 3.d).
7.2.b: Irradiation
Tumour cell suspensions in Ham's F12 medium and 15%
special Bobby calf serum were irradiated in vitro in air at room
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temperature from a Co y source at a dose rate of 400 rad per
minute. During irradiation, the cell suspensions were held in
Falcon tubes, themselves suspended in water in larger tubes to
ensure adequate build-up of irradiation dose.
Measured aliquots of cells were then mixed with agar to a
final agar concentration of 0. 3% and loaded into diffusion chambers
for intraperitoneal implantation as described in Chapter 5.
7. 2. c: Colony Counting
The technique for colony counting, the criteria used for
defining colonies, and the incubation periods for each tumour have
already been described in Chapter 5.
7. 2. d: Calculation of Surviving Fraction of Clonogenic Cells
The surviving fraction of colony-forming cells after each
dose of irradiation was calculated as the plating efficiency (number
of colonies produced per 100 cells plated) of the irradiated cells
divided by the plating efficiency of unirradiated controls.
7. 3: RESULTS OF IN VITRO IRRADIATION
(For a description of the statistical methods used to analyse
the results of data presented in this and subsequent chapters, see
Appendix One.)
The in vitro irradiation of tumour cell suspensions from all
4 xenografts decreased the fraction of colony-forming cells in the
suspension compared with that of controls. Many more single cells
and small clusters (20-50 cells) were seen in the irradiated cell
chambers than in the controls, suggesting that irradiation of
clonogenic human tumour cells inhibits further cell division
immediately for some cells but allows a limited number of further
divisions before eventual loss of proliferative capacity in others.
Giant cells of the type reported for HeLa cells after irradiation by
Puck and Marcus [1956], and mentioned earlier (Chapter 7.1), were
not seen here.
The relationship between in vitro irradiation dose and
clonogenic cell survival for the 4 human tumour xenografts studied
is shown in the dose-survival curves of Figures 7. 2, 7. 3, 7.4 and 7.
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In Vitro Co y-Irradiation Response of Cells from Human Melanoma
Xenograft HX34 (Vertical Bars Represent + Standard Error of the
Mean)
Survival Curves of HX32 (-•——-), HX18 (— -—) and HX33 (——)
are Superimposed (Figs. 7. 2, 7. 3 and 7. 4)
Tumour Dq (rad) Range* Dq Range*
HX18 123 (105 - 147) -9 (-60 - (+)27)
HX32 100 ( 81 - 126) 59 ( 17 - 93)
HX33 135 (121 - 152) 12 (-29 - (+)45)
HX34 192 (175 - 212) 230 ( 83 - 331)
*+ Standard Error of the Mean
TABLE 7. 1
Dq and D„ Values icrln Vitro Radiation Cell Survival Curves for
Human Tumour Xenografts HX18, HX32, HX33 and HX34
The cell survival curves for three of these tumours,
pancreatic carcinoma HX32, colonic carcinoma HX18, and oat cell
carcinoma HX33, were very similar, with small initial "shoulder"
regions followed by a region of exponential decline. The Dq value
of the exponential region for each tumour, derived by linear
regression analysis (see Appendix One for details),was as follows:-
11X32 100 (+26-19) rad, HX18 123 (+24-18) rad and HX33 135 (+17-14)
rad. The D„ value was 59 (+34-42) rad for HX32, -9(+36-69) rad for
HX18 and 12 (+33-41) rad for HX33 (figures in brackets represent +
one standard error of the mean).
The in vitro irradiation cell-survival curve of melanoma
xenograft HX34 differed from that of the other three tumours in two
respects, as can be seen from Figure 7. 5 and Table 7.1. First, the
Dq value of 192 (+20-17) rad was higher than the Dq for the other
three tumours. This difference reached statistical significance
compared with pancreatic xenograft HX32 (p 0.05). Second,
the width of the initial "shoulder" for melanoma cells, with a D.~
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value of 230 (+101-127) rad, was greater than that of the other three
tumours. This difference reached statistical significance compared
with colonic carcinoma HX18 (p ^ 0. 05) and oat cell carcinoma
HX33 (p - 0.05).
Because of the unexpected nature of these findings, more
in vitro irradiation experiments were carried out on the melanoma
tumour than on the other tumours, with more resultant points on the
dose-survival curve to verify the data. It will nevertheless be seen
that only one point has been obtained at the very high dose of 1400
rad, and this point has a critical effect on the slope of the exponential
part of the curve. (If this point is excluded from the calculations
the estimate of Dq rises to 233 rad.) Unfortunately it has not been
possible to obtain further points at this dose with accuracy and
confidence, and this is due to technical reasons: to obtain surviving
fractions as low as 0. 001 it is necessary to load each diffusion
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chamber with 1 x 10 cells; these produce sufficient abortive
"clusters" of cells after incubation to form a dense, semi-
confluent background of cells against which accurate colony-counting
is extremely difficult. Nevertheless, my colleague Mrs. Courtenay
has also obtained a few points in this region for melanoma cells
using an in vitro agar assay (Chapter 3) and these corresponded well
with my own data and in particular with the one point I have been
confidently able to obtain at 1400 rad. For this reason I have felt
it justifiable to include this point in calculating for melanoma
cells.
7.4: DISCUSSION
The first and fundamental observation from these in vitro
studies is that the effect of irradiation on the proliferative capacity
of clonogenic human tumour cells can be quantified using this assay
system in a way similar to that employed for cells of other mammalian
tissues and that therefore human tumour cells are now for the first
time amenable to a wide range of radiobiological investigations
previously limited to cells from experimental animal tumours and
established tumour cell lines.
It is of interest that the in vitro radiosensitivities of cells
from pancreatic carcinoma HX32, colonic carcinoma HX18, and oat
cell carcinoma HX33 were similar to one another. Furthermore the
Dq values established here for these tumours lay within the same
fairly narrow range previously established for nearly all other
mammalian cells (Chapter 7. 1). This does not correlate well with
the clinical response to radiotherapy usually observed for these
tumour types: oat cell carcinomas of lung have a radiotherapy
response rate of over 80% [Carr et al, 1972] and a low incidence of
tumour recurrence within the locally irradiated field [Rissanen et al,
—1968]; in contrast, colonic and pancreatic carcinomas are in general
clinically more radioresistant and failure to achieve local control
with conventional radiotherapy is common [Moertel, 1973].
If these xenograft tumours can be considered typical of
tumours encountered in the clinic, then this discrepancy between
experimental and clinical observations implies that the intrinsic
radiosensitivity of tumour cells as established in vitro is not a major
factor in determining the therapeutic response in the patient, and
suggests that other extrinsic factors, including perhaps tumour cell
hypoxia in vivo, must be involved. To this extent, these findings
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therefore support the views of many radiobiologists, based on
previous experimental animal tumour data (Chapter 7. 1).
Studies on the in vitro radi.osensitivity of the fourth xeno¬
graft, melanoma HX34, would however appear to contradict this
general hypothesis. Here a clear difference was found between the
cell survival curve for this tumour compared with the other three.
First, the for melanoma tumour cells was higher than that for
the other tumours, reflecting a greater intrinsic radioresistance,
and indeed was very much at the upper limit of the range of Dq
values so far obtained for mammalian cells of whatever type
(Chapter 7. 1).
But the other important feature differentiating the melanoma
cell survival curve from that of the other tumours was its much
wider initial "shoulder". The implication of these data is there¬
fore that melanoma cells from this xenograft irradiated in vitro
have a greater capacity for repair of sub-lethal radiation damage
(Chapter 7. 1) than cells of the other tumours.
Conventional radiotherapy is usually given in fractionated
doses of around 300 rad. From Figure 7. 5 it can be seen that this
dose achieves about one decade kill of clonogenic pancreatic, colonic and
oat cell carcinoma cells; however, because of their larger "shoulder"
only 40% of melanoma cells would be lulled by this dose, with a surviving
fraction of 0. 8. To reduce the surviving fraction of melanoma cells
to the same as that of the other cells treated with 300 rad, a much
larger dose of about 700 rad would be required (Fig. 7. 5).
What makes this radiobiological observation of clinical
interest is that melanomas are notoriously resistant in the clinic to
conventional radiotherapy given in small fractionated doses [Rubin
et al, 1974], and it is tempting to speculate from the data found
here that larger fractionated doses might be more successful in
exceeding the capacity of melanoma cells for repair sub-lethal
damage and thus achieving greater cell kill with better tumour
control.
There are of course serious limitations to extrapolating
this type of data to the clinic. The first problem is that only one
melanoma has been studied in this assay system and this may not
be representative of the tumour type in general. Further studies
with a series of melanomas are indicated to clarify this point.
However it is of interest in this context that similar wide initial
"shoulders" have been reported for established human melanoma
cell lines irradiated in vitro [Barranco et al, 1971; Thomson et al,
1975]. Obviously further studies with a series of melanoma
xenografts are now indicated to clarify this point.
The second and more fundamental problem with the
extrapolation of in vitro data to clinical therapy is that many factors
may operate in vivo to modify the intrinsic radiosensitivity of tumour
cells. This point w7ill be developed in the next chapter, but it has
already been implied by these experiments with the demonstration
that a pancreatic and a colonic tumour have an in vitro radiosensitivity
no greater than that of an oat cell lung carcinoma. In vivo irradiation
studies are therefore of importance in adding to and modifying the
initial information provided by these in vitro experiments, and the
next step in this project was therefore to investigate the radiosens-
itivity of the human tumour xenograft model in vivo.
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CHAPTER 8:
THE IN VIVO IRRADIATION RESPONSE OF A HUMAN
PANCREATIC CARCINOMA XENOGRAFT. UNDER
AIR-BREATHING AND HYPOXIC CONDITIONS
8.1: INTRODUCTION
Although the response of human tumour cells to in vitro
irradiation can be measured using the techniques described in the
last chapter, important factors may modify this response when
cells are irradiated in vivo within the tumour. It is known, for
example, that many animal tumours contain a significant fraction
of hypoxic ceils whose resistance to irradiation is increased [Gray
et al, 1953; Suit and Maeda, 1967; Van Putten and Kallman, 1968;
Barendsen and Broerse, 1969; Thomlinson and Craddock, 1969;
Hewitt and Sakamoto, 1971; Rockwell and Kallman, 1973; Shipley
et al, 1975], and it has been reasonably postulated that the same may
be true of human cancers and may perhaps be a factor in preventing
local tumour control with radiotherapy [Thomlinson and Gray, 1955;
Duncan, 1973].
Techniques for studying tumour cell survival after in vivo
irradiation are therefore required to complement basic in vitro data
if clonogenic assays are to be of any value in studying the role of
hypoxia and other factors which underlie tumour response to
radiotherapy in the clinic. The principle behind such techniques is
of course a simple one: whereas a tumour is first excised and a cell
suspension prepared for irradiation to produce an in vitro survival
curve, an in vivo curve is produced by first irradiating the tumour
in situ within the animal and subsequently excising it to produce a
cell suspension for assay. The surviving fraction of cells irradiated
in vivo is obtained by dividing the plating efficiency of the irradiated
tumour by that of an unirradiated control.
While an entire in vitro dose survival curve can be obtained
using aliquots of cell suspension from a single tumour, the in vivo
assay requires a tumour-bearing animal for each irradiation dose.
The experimental technique is therefore more elaborate, time-
consuming and expensive, and it was therefore decided to concent¬
rate resources on studying only one xenograft, for the experiments
to be described.
8. 2: METHODS USED FOR IN VIVO IRRADIATION STUDIES
8. 2. a: Tumours
The pancreatic xenograft HX32 was selected for the in vivo
irradiation experiments to be described; this particular tumour was
chosen for two reasons. Firstly it has a relatively high plating
efficiency compared with most of the other xenografts (Table 5. 3)
and therefore lends itself to detailed study in this assay system.
Secondly, pancreatic carcinoma is of particular radiobiological
interest in that it is an example of a human tumour which is relativ¬
ely radioresistant and which frequently poses the radiotherapist
with the problem of failure of local control [Moertel, 1973].
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Tumours growing intramuscularly in the thigh muscles of
immune-suppressed C57B1 mice (Chapter 5.2) were used in these
experiments, and in vivo irradiation was carried out 3 to 4 weeks
after implantation, by which time tumours had grown to a diameter
of 0. 5 to 1cm.
8. 2,b: Irradiation Technique
Tumour-bearing mice were immobilised with nembutal
anaesthesia in a dose of 60mg/kg injected intra-peritoneally 5 to 10
minutes before irradiation was started. Irradiation was administered
locally to the tumour-bearing limb at a dose rate of 400 rad/minute,
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from a Co y source at a distance of 25cm and a 3mm perspex sheet
was placed in front of the tumours to allow adequate build-up of the
absorbed dose. The rest of the animal was protected during
irradiation by 13cm thick lead shielding (Figure 8. 1).
8. 2. c: Air-Breathing and Anoxic Assays
Tumours in air-breathing animals were assayed by killing
the animal, dissecting out the irradiated tumour under sterile
conditions and preparing a cell suspension as previously described
(Chapter 5). This was carried out either immediately after
irradiation (0 hour air-breathing assay) or 18 hours later (18 hour
air-breathing assay). This latter assay was carried out to see
whether cell survival after irradiation in vivo is influenced by the
length of time the irradiated cells remain in the tumour before












Experimental Set-Up for In Vivo Co y -Irradiation of Hind Limb
Xenograft Tumours in Nembutal-Anaesthetised Mice
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In vivo irradiation of hypoxic tumours was achieved by lulling
the animal and keeping it at 37°C for 15 minutes before irradiating
the tumour-bearing leg; this delay allowed tissue oxygen to be
metabolised and rendered the tumour hypoxic. The tumour was
immediately dissected out after irradiation and a cell suspension
prepared and plated out in the usual way.
8.3: RESULTS
The cell survival curves for pancreatic carcinoma HX32
tumour cells irradiated in vivo: (1) in air-breathing mice assaying
at 0 hours after irradiation; (2) in air-breathing mice assaying at
18 hours after irradiation; and (3) in hypoxic mice are shown in
Figure 8. 2, to which the in vitro irradiation cell survival curve
obtained for this tumour in experiments described in Chapter 7 has
also been added. The parameters with standard errors for each of
these curves, calculated by linear regression analysis, are given
in Table 8. 1.
The hypoxic in vivo dose survival curve had an initial
"shoulder" portion followed by a region of exponential decline. The
value of Dq for this curve was calculated as 351 (+26-23) rad, and
D~ was 222 (+50-58) rad.
The "air-breathing 18 hour" assay curve had a scarcely
discernible "shoulder" portion followed by a portion of exponential
decline parallel to that of the hypoxic curve within the limits of experi¬
mental error but displaced vertically downwards because of the smaller
"shoulder". For this curve Dq was calculated as 313 (+20-17) rad.
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FIGURE 8.2
The In Vivo and In Vitro Response of Pancreatic Carcinoma
Xenograft HX32 to Co y-Irradiation (Vertical Bars Represent +
Standard Error of the Mean)
O In Vitro © In Vivo Airbreathing Ohrs
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The "air-breathing 0 hour" assay curve was biphasic: it
had a small initial "shoulder" followed by a short portion of steep
exponential decline; at a dose of between 200 and 400 rad, the curve
then developed a second portion of exponential decline this time less
steep than the first part, with a Dq calculated as 325 (+26-22) rad. This
distal exponential portion extrapolated back to intercept the y axis
at 0.4 + 0. 1.
8.4: INTERPRETATION OF RESULTS AND DISCUSSION
These results are most easily discussed by considering
initially the relationship between the in vitro dose-survival curve,
the "air-breathing 0 hour" in vivo curve, and the anoxic in vivo
curve. The significance of the 18 hour air-breathing curve will be
discussed later (Chapter 8.4).
8. 4. a: Oxygen Enhancement Ratio
The shapes of these first 3 dose-survival curves for the
human pancreatic carcinoma xenograft HX32 resemble earlier
findings for experimental animal tumour systems similarly
irradiated [Powers and Tolmach, 1963; van Putten and Kallman,
1968; Barendsen and Broerse, 1969; Rockwell and Kallman, 1973;
Shipley et al, 1975], and the salient features have been interpreted
as follows: the Dq of the anoxic irradiation curve (351 rad) was
much greater than that of the in vitro irradiation curve under fully
oxygenated conditions (Dq = 100 rad) with a significance p<0. 001.
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This demonstrates the increased radioresi stance of human pancreatic
carcinoma cells from HX32 xenograft under hypoxic conditions.
Similar findings have been made for all other mammalian cells
previously studied. This enhancing effect of oxygen can be quantified
by what is referred to as the Oxygen Enhancement Ratio (O.E.R.).
This is obtained from the ratio of the slopes of the exponential regions
of the 2 curves (Dq anoxic : Dq oxygenated in vitro) providing these
originate from a common point; if this condition does not hold then
clearly the ratio of the surviving fraction of cells irradiated in the
presence or absence of oxygen will change over a range of doses
[van Putten and Kallman, 1968].
In these studies, this criterion is met for the anoxic and
oxygenated in vitro cell survival curves within the limits of
experimental error, and the O.E.R. for human pancreatic carcinoma
xenograft HX32 is calculated as 3. 5.
8. 4.b: Hypoxic Cells in Tumours of Air-Breathing Animals
It can be seen from Figure 8. 2 that the hypoxic cells have
not only a higher inate radioresistance than oxygenated cells but also
a greater capacity to repair sub-lethal damage, as evidenced by the
wider shoulder of their cell survival curve. Thus not only is a
greater dose of radiation required to kill a given fraction of hypoxic
cells compared with oxygenated cells in the exponential part of the
curve, but so also is a greater initial dose of radiation required to
overcome sublethal damage repair and allow cell kill to proceed
exponentially.
The biphasic nature of the survival curve for tumour cells
irradiated in the air-breathing animal and then immediately assayed
(air-breathing 0 hour assay) is interpreted as demonstrating a mixed
population of oxygenated and hypoxic cells in this tumour [van
Putten and Kallman, 1968; Rockwell and Kallman, 1973]. Initially,
at low doses of irradiation the more radiosensitive oxygenated cells
with less capacity for repair of sublethal damage will be preferentially
killed, producing a cell survival curve which approximates towards
that of oxygenated cells irradiated in vitro. As these oxygenated cells
are killed so the proportion of surviving cells that are hypoxic
increases until,beyond doses of 400 rad, this comes to represent
nearly all the remaining tumour cells in the air-breathing animals.
Thus beyond doses of 400 rad, the slope of the curve decreases, with
a higher Dq which reflects the greater radioresistance of residual
hypoxic cells.
"There is an important assumption in this argument, expounded
by Elkind [1970], and that is that the response to y-irradiation of
chronically hypoxic cells (in the tumour of the air-breathing animals)
is the same as that of acutely hypoxic cells (in the tumour of the
animal killed immediately prior to assaying). There is some
evidence that this may not always be the case with respect to repair
of sub-lethal damage, which may be less or slower in chronically
hypoxic cells [Suit and Urano, 1969; Shipley et al, 1975]. However,
my findings here that the Dq values for the exponential portions of
the two curves are the same within the limits of experimental error
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suggest that acute and chronically hypoxic cells probably do respond
in the same way to irradiation at least beyond the initial shoulder
portion.
8. 4. c: Calculation of the Hypoxic Fraction
On the basis of the foregoing argument the fraction of hypoxic
cells in the air-breathing tumour can be calculated from the ratio
of hypoxic: oxygenated + hypoxic cells, which is equivalent to the
air-breathing: hypoxic ratio in the terminal portions of the two
curves. Thus, from the data of Figure 8. 2, the hypoxic fraction
for human pancreatic carcinoma xenograft HX32 is 0.19.
8. 4. d: Clinical Implications of a Hypoxic Fraction in Pancreatic
Carcinoma Xenograft HX32
Any attempt to extrapolate the results of these studies to
human cancers in the clinic is limited by an important difference
between xenografts and their parent tumours: the basis of tumour
hypoxia is believed to be impaired vascularity within the tumour,
and whereas the actual tumour cells in our xenografts have been
shown to be of human origin, the supporting connective tissue stroma
and vascular supply must derive from the host mouse. Histological
differences in the connective tissue stroma of some xenografts
compared with that of their parent human tumour have been described
[Pickard et al, 1975] and it may not therefore be that the vascular
distribution of oxygen within the pancreatic tumour xenograft studied
here is an accurate replica of that in the patient's original tumour.
This is clearly a theoretical qualification to the use of any
xenografts for investigating the clinical problem of hypoxia, but
there exists comparative experimental evidence from animal tumour
studies that offers the basis for some encouragement. Using
similar experimental techniques to our own, the hypoxic fraction of
cells in several animal tumours have been measured: a hypoxic
fraction of 0.15 was found for a C3H mouse mammary carcinoma in
a tumour-bearing animal under normal aerobic conditions [Suit and
Maeda, 1967], 0.14 for a KHT mouse sarcoma [van Putten and
Kallrnan, 1968], 0.15 for a rat rhabdosarcoma [Barendsen and
Broerse, 1969], 0. 33 for the EMT 6 tumour [Rockwell and Kallman,
1973] and 0. 36 for the Lewis lung tumour [Shipley et al, 1975].
Thus the hypoxic fraction of 0.19 for the pancreatic
carcinoma xenograft lies well within the range found for these
experimental animal tumours with their own natural blood supply,
and perhaps therefore it may not be completely invalid to extrapolate
data on hypoxic cells in xenograft models despite the theoretical
objections implicit in their murine-derived stroma.
With this proviso, the demonstration in these experiments
that about 20% of clonogenic cells in this human tumour xenograft
are hypoxic is of considerable interest, in that it reinforces the
hypothesis that one of the factors which may clinically prevent local
tumour control with radiotherapy is the presence of radioresistant
hypoxic foci in human cancers. Furthermore, these studies suggest
that hypoxia may not merely be a problem in large tumours with
multiple necrotic areas commonly found in clinical practice, but
also in very much smaller nodules. The xenografts irradiated in
these studies were only of 0. 5 to 1cm diameter; this is equivalent
to a human tumour that in some circumstances might be hard to
detect clinically, and which, for example, would scarcely be
visible on a standard chest x-ray film [Rigler, 1966].
A further experimental approach to the problem of
xenograft hypoxia would therefore be to investigate whether extrem¬
ely small xenograft tumours also have a hypoxic fraction. Shipley
3
et al [1975] have recently shown that although 500mm Lewis lung
3
carcinoma tumour had a hypoxic fraction of 0. 36, minute 0. 5mm
pulmonary metastases nevertheless had a hypoxic fraction of less
than 0.005 with tumour cells correspondingly more sensitive to
3
irradiation. Similar findings have also been described for 0. 6mm
C3H mouse mammary tumours grown subdermaliy in the ear [Suit
and Maeda, 1967].
Were the HX32 xenograft also shown to exhibit this effect
when extremely small nodules were irradiated, this finding would be
important in supporting the use of "adjuvant" radiotherapy to regions
of the body, and in particular to the lungs, without clinical evidence
of tumour but where the probability of cryptic micrometastases
seemed high.
However, from a practical point of view, research along
these lines is thwarted by the lack of a suitable technique for growing
the necessary very small xenograft nodules at present.
A second line of research stemming from the demonstration
of hypoxia within xenograft HX32 concerns the use of therapeutic
techniques designed to overcome hypoxic cell radioresistance.
Recently for example, there has been considerable interest in
chemical radiosensitisers of hypoxic cells as a means of enhancing
tumour response to radiotherapy (Chapter 9). Therefore following
on from the experimental findings described in this chapter, it was
decided to investigate one such radiosensitiser in the diffusion
chamber assay system, and to see whether this might modify the
hypoxic exponential tail of the air-breathing dose survival curve of
Figure 8. 2. The results of this study will be described in the next
chapter. First, however, the implications of the 18 hour air-
breathing survival curve in Figure 8. 2 must be considered.
8.4. e: The MAir-Breathing 18 Hours" Dose Survival Curve
The "air-breathing 18 hours" dose survival curve differs
from the "air-breathing 0 hours" curve in that, although the slopes
of the exponential tails of both curves are approximately parallel,
the curves are nevertheless vertically displaced, with cell survival
increased in the 18 hour assay by a factor of 2.5. This is an
important observation: if cell survival in the assay system varies
depending on the time interval between irradiation and assay, then
it is obviously essential to know which of the two time intervals
gives a result that more accurately reflects the surviving fraction
of cells left undisturbed within the tumour after in vivo irradiation.
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There are at least two hypotheses which might explain this
discrepancy. The first is that during the 18 hour period betw7een
irradiation and tumour excision, "doomed" cells destined not to
form colonies as a result of irradiation are lysed or otherwise
removed from the tumour such that the fraction of surviving clono-
genic cells left within the tumour after 18 hours is raised, although
their absolute number remains unchanged. On the basis of this
explanation the true surviving fraction would be given by the "0
hour" assay, while that of the "18 hour" assay would be
artificially raised.
This explanation is unlikely however, First,, no histological
changes computable with cell lysis and removal are seen at so short
a time after assay in this xenograft. Second, cell suspensions made
from a tumour 18 hours after irradiation show no evidence of
irradiation damage, and it is not until 48 hours have elapsed that
features of irradiation death begin to appear in these cells observed
in monolayer culture [Mrs. V. D. Courtenay, personal communication].
Finally, in the agar colony assay system a large proportion of
irradiated cells form clusters of between 4 and 50 cells, which,
although too small to be scored as colonies, indicate that irradiation
has not immediately destroyed such cells but rather limited their
proliferative capacity to a few further divisions. This observation
also tends to argue against a significant number of cells being lysed
and removed within 18 hours of irradiation.
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8. 4. f: Repair of Potentially Lethal Damage
An alternative explanation to explain the differences in cell
survival obtained from the two assays is that removal of some cells
from their tumour "milieu" immediately after irradiation inter¬
feres in some way with their ability to repair irradiation damage and
survive, if left in situ for 18 hours. The existence of such a
phenomenon has been postulated recently by several authors and has
been referred to as "repair of potentially lethal damage" [Phillips
and Tolmach, 1966; Little et al, 1973; Hahn et al, 1974; Shipley
et al, 1975].
There is increasing evidence to suggest that the ability of
cells to repair damage caused by irradiation can be influenced by
their post-irradiation environment. For example, in vitro survival
is enhanced by a reduction in temperature after irradiation
[Whitmore and Gulyas, 1967], by a change in the nutritional state of
the medium [Belli and Shelton, 1969; Djordevic and Perez, 1970],
by inhibition of protein synthesis [Phillips and Tolmach, 1966] and
by maintenance of cells in crowded plateau-phase cultures [Little
et al, 1973]. Although these in vitro manipulations are of course
artificial, some at least might reasonably resemble environmental
differences between cells suspended in vitro and those growing
in situ within a tumour. Thus it is postulated that cell survival might
be increased by this so-called repair of potentially lethal damage if
cells were left in situ for some hours after tumour irradiation rather
than removed immediately for assay.
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Some experimental data exists to support this. Shipley et al
[1975] have recently observed a 3 to 6-fold increase in survival of
Lewis lung carcinoma cells after in vivo y-irradiation (but not fast
neutron therapy) if cells were left in situ for up to 24 hours post-
treatrnent. Similar observations have been made for a mouse
lymphoma grown as an ascites tumour [Belli et al, 1971], a mouse
fibrosarcoma [Little et al, 1973] and the EMT6 mammary sarcoma
[Hahn et al, 1974]. This repair effect appears to be time-dependent,
and for the EMT6 tumour the surviving fraction increases with time
up to 8 hours after irradiation and remains increased for at least
24 hours.
This phenomenon of repair of potentially lethal damage could
therefore explain the discrepancies found between the "0 hour" and
"18 hour" survival for pancreatic tumour cells found in these
experiments. Further studies are now indicated 'o establish the
—relationship between increase in survival and time after irradiation;
if the same phenomenon is demonstrated after a much shorter time
interval than 18 hours, then this would be completely incompatible
with the first hypothesis, lysis and disappearance of irradiation-
killed cells prior to assay, and would provide compelling further
evidence in favour of potentially lethal damage repair for pancreatic
xenograft HX32.
From the practical point of view, this is important, not
merely for further human tumour assay studies but for all clonogenic
assays, in that the removal of cells from a tumour immediately
after irradiation would not allow time for repair of potentially
lethal damage and would therefore markedly underestimate the
fraction of cells surviving a dose of irradiation. Most of the data
obtained in recent years on the effect of in vivo irradiation on
clonogenic cells has been based on assays performed immediately
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Very recently, the drug referred to in this Chapter
as Ro-07-0582 has been given the official generic
name Misonidazole.
CHAPTER 9:
THE EFFECT OF RADIOSENSITISER Ro-07-0582
ON THE IRRADIATION RESPONSE OF CELLS FROM
A HUMAN PANCREATIC TUMOUR XENOGRAFT
9.1: HYPOXIC CELLS AND RADIORESISTANCE
In the previous chapter evidence was presented demonstrating
that a human pancreatic carcinoma xenograft has a significant
proportion of radioresistant hypoxic cells. This is in keeping with
previous similar observations for experimental animal tumours.
Normal tissues do not usually contain hypoxic cells [Withers, 1965
and 1967b], and it has therefore been argued that this oxygen-
dependent difference in radiosensitivity may be an important factor
in limiting the chance of local tumour cure with radiotherapy
[Thomlinson and Gray, 1955; Duncan, 1973].
Various techniques for overcoming the radio-resistance of
hypoxic tumour cells have been studied: these include the use of
hyperbaric oxygen, densely ionising radiation including neutrons
and Tt-mesons, decreased oxygenation of normal tissues, and
fractionated radiotherapy dose schedules designed to take advantage
of tissue reoxygenation; the possibilities and limitations of these
approaches have been reviewed elsewhere [Duncan, 1973].
Recently, interest has also developed in the possible use of
chemical radiosensitisers to enhance the effect of radiotherapy on
hypoxic tumour cells.
9. 2: CHEMICAL RADIOSENSITISERS OF HYPOXIC CELLS
In the 1960's, various chemicals were shown to sensitise
bacteria to irradiation [Dewey, 1963; Adams and Cooke, 1969;
Barnes et ai, 1969]. Their mechanisms of action varied [Adams,
1973], but the large majority were specifically active on hypoxic
cells alone. These had in common a high electron affinity with an
oxygenmimicking action through which their radiosensitising effect
was understood to be mediated, and on which a rationale for further
research and development could be based [Adams and Dewey, 1963;
Adams and Cooke, 1969; Raleigh et al, 1972]. Many of the early
compounds studied failed to sensitise mammalian cells or were
cytotoxic, but radiosensitisation of hypoxic Chinese hamster cells
grown in monolayer culture was demonstrated with a substituted
acetophenone, p-nitroacetophenone (PNAP) [Chapman et al, 1971;
Adams et al, 1971]. Subsequently a variety of other compounds
proved to have a similar specific effect on hypoxic but not well-
oxygenated mammalian cells in vitro: these included nitrofurans
[Chapman et al, 1972], nitroimidazoles [Foster and Willson, 1973;
Asquith et al, 1974], nitropyrazoles [Asquith et al, 1974] and nitro-
benzenes [Adams et al, 1971; Raleigh et al, 1972].
Not all in vitro sensitisers proved effective in vivo, and
some were ruled out on the basis of poor water solubility, failure
to penetrate hypoxic tissue effectively because of rapid metabolism
or a high affinity for serum proteins, or unacceptable host toxicity
[Iwamoto et al, 1972; Denekamp et al, 1974; Rauth and Kaufman, 1975]
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But some of these chemical radiosensitisers clearly had
potential clinical advantages over most other hypoxic cell
sensitisation techniques: they were relatively inexpensive, easy to
administer, and one, metronidazole (Flagyl), was already in clinical
use for the treatment of trichomonas infections.
9. 3: IN VIVO USE OF METRONIDAZOLE (FLAGYL)
Using a skin cloning assay, Denekamp et al [1974] demonstrated
a specific radiosensitising effect on hypoxic epidermal cells in vivo
with metronidazole (Flagyl). Subsequently Rauth and Kaufman [1975]
showed a similar effect on the hypoxic cell population of solid tumours
in C3H mice, with an enhancement ratio of 1. 5 at a dose of 1. 5G/kg,
and tumour cure studies on mammary carcinomas in C3H mice showed
that large doses of metronidazole (3G/kg) increased the cure rate of
a dose of 3400 rad from 20% in control mice to 70% in drug treated
mice [Begg et al, 1974].
In these experiments, maximum radiosensitisation was only
achieved with high doses of metronidazole, peak murine serum
levels rising to more than 500qg/ml after intra-peritoneal injection.
Such serum levels cannot be achieved in humans without producing
unacceptable nausea, and therefore smaller doses must be used
clinically. Urtasun et al [1976] recently reported that patients with
glioblastoma treated with radiotherapy and metronidazole survived
longer than those treated with radiotherapy alone; a criticism of
this study however was that the radiotherapy dosage was lower than
that normally used in treating this tumour, and metronidazole-treated
patients fared no better than patients reported in other studies
treated with more conventional large dose radiotherapy alone.
Studies with metronidazole have been important in
demonstrating the feasibility of chemical radiosensitisation, and
have stimulated the search for better compounds that might be
more effective clinically.
9.4: Ro-07-0582*
Metronidazole is a 5-nitro-imidazole, and it therefore
seemed logical in the search for more effective clinical radiosens-
itisers to look at structurally related compounds. One such compound
already available was Ro-07-0582 (l-(2-nitro-I-imidazolyl) 3 methoxy-
2-propanol), a 2-nitro-imidazole whose structure is shown in Fig. 9.1.
This drug had also originally been developed as a possible agent
against trichomonas infection by Roche Products Ltd., and was
found to be readily absorbed after oral ingestion. Its highly electron
affinic structure suggested a possible role as a chemical radiosens-
itiser, and Asquith et al [1974] demonstrated a very marked radio-
sensitivity effect in vitro on hypoxic Chinese hamster cells grown
in monolayer culture. In this system the drug achieved an enhance¬
ment ratio of up to 2. 5 which was near the oxygen enhancement ratio
of 2. 8 for the system. Its effect was maintained in the presence of
high concentrations of serum proteins, and its known low toxicity
and slow rate of metabolism encouraged in vivo studies.
*Recently renamed Misonidazole.
Structure of Ro-07-0582
Several such studies confirmed tie effect of the drug in vivo
and demonstrated its superiority over metronidazole as a radio-
sensitiser. Denekamp et al [1974] found a specific effect of Ro-07-
0582 on hypoxic but not oxygenated murine epidermal cells using
the skin cloning assay mentioned above (Chapter 9. 3); it produced
a maximum enhancement ratio of 2. 2 compared with 1. 7 for
metronidazole. In tumour growth delay studies using mammary
tumours in CBA mice Ro-07-0582 gave an enhancement ratio of 2.1
compared with 1. 6 for metronidazole [Denekamp and Harris, 1975].
In a tumour cure study the drug was found to reduce the dose of
irradiation required to control 50% of C3H mouse mammary tumours
from 4380 to 2410, giving an enhancement ratio of 1. 8 [Sheldon et al,
1974], compared with 1.4 for metronidazole in a similar study
[Begg et al, 1974].
The maximum dosages used in these experiments were high,
as for metronidazole, but the therapeutic ratio in animals was
greater for Ro-07-0582, and a considerable radiosensitising effect
was still seen at much smaller dosages [Denekamp et al, 1974].
These observations encouraged studies into the use of Ro-07-0582
as a radiosensitiser in humans.
In a clinical toxicology study, single oral doses of up to
140mg/kg of Ro-07-0582 in suspension were tolerated before gastro¬
intestinal symptoms, including nausea, vomiting and occasional mild
diarrhoea, became unacceptable [Gray et al, 1976]. No neurological
or other clinical abnormalities were observed directly attributable
to the drug, despite a report that high doses led to a cerebellar
degeneration in dogs [Lennox-Smith, 1975]. At this dosage, peak
serum levels of around 200jUg/ml, within the range of radiosens-
itisation in animal tumours, were achieved between one and three
hours after oral ingestion, with a long half-life of 10 to 17 hours
[Gray etal, 1976].
Based on these data, clinical testing of Ro-07-0582 has
recently been started in patients with malignant disease. In one
study its ability to radiosensitise normal tissue rendered artificially
hypoxic was tested by observing skin reaction under hypoxic and
fully oxygenated conditions with and without Ro-07-0582 [Dische
et al, 1976]. Skin reactions to radiotherapy were enhanced under
hypoxic but not oxygenated conditions with an enhancement ratio of
up to 1. 68 at maximum tolerated dosage, calculated on the basis of
a skin pigmentation reaction scoring system [Dische and Zanelli,
1976]. The drug was approximately three times as effective at
radiosensitisation as metronidazole tested in the same system at
dosages comparable in terms of tolerance to side effects.
In some of these patients an attempt was made to measure
the enhancing effect of Ro-07-0582 on radiotherapy of metastatic
tumour deposits [Thomlinson et al, 1976]. Practical difficulties
limited the scope of this study, but an enhancement ratio of 1. 2 was
estimated in one patient with subcutaneous metastases from
carcinoma of the uterine cervix. In a second patient with pulmonary
metastases from breast carcinoma no enhancement was found.
Some patients died before measurements could be completed but a
qualitative assessment of three other patients suggested that two
of these also showed some evidence of enhancement.
Clinical studies of this type constitute the ultimate test of the
clinical value of radiosensitisers, but problems arise in their design
and interpretation. Estimates of hypoxic tumour cell kill can only
be made indirectly from the delay in tumour regrowth after radio¬
therapy with and without drugs. Recognised differences in the growth
rates of similar histological tumours between patients suggest that
these studies should therefore best be carried out on multiple
metastases in the same patient. Even here it is quite possible that
important differences in growth rate, vascularity and response to
therapy of such metastases may occur and invalidate interpretation
of tumour growth delay measurements. But quite apart from these
theoretical differences, practical difficulties exicc in finding suitable
patients with measurable multiple metastases of fairly uniform size.
Such patients, even when found, are often very ill from advanced
disease, and ethical considerations may limit optimal design of the
clinical experiment.
For these reasons adjuvant laboratory studies with an
appropriate experimental system might be of value in assessing the
effect of the drug on hypoxic human tumour cells. The agar in
diffusion chamber assay seemed to offer this opportunity in that the
survival of hypoxic and oxygenated clonogenic tumour cells after
irradiation in the presence and absence of the drug could be
measured directly in this system and an enhancement ratio calculated.
This latter point will be developed below (Chapter 9).
Human pancreatic xenograft HX32 which had already been
shown to have a hypoxic fraction of 0.19 (Chapter 8) was therefore
chosen to investigate the effects of Ro-07-0582 in vivo, using the
diffusion chamber assay technique.
9. 5: METHODS: DRUG ADMINISTRATION AND IRRADIATION
In these experiments on pancreatic carcinoma xenograft
HX32, some tumour-bearing mice were treated with single dose
irradiation alone and some with irradiation preceded by intra¬
peritoneal injection of Ro-07-0582 in a dose of Img/G (sic). The
drug was dissolved in warm* isotonic saline and then injected
intraperitoneally one hour before irradiation. Shorter time inter¬
vals have been previously employed in animal tumour studies
[Sheldon et al, 1974; Denekamp and Harris, 1975] but the serum
half-life of the drug in mice of about l\ hours encouraged us to
allow a longer gap between administration and irradiation to
increase the chance of adequate build up of drug concentration in
poorly vascularised areas of tumour.
*Ro-07-0582 is poorly soluble in saline, and to achieve the high
concentrations required to give the dose per mouse in a total volume
of about 0. 5ml, the drug was agitated in saline held at 37°C for
about 20 minutes.
The techniques for anaesthetising the mice, irradiating the
tumours and preparing cell suspensions for assay have been
described previously in Chapters 5, 7 and 8. Assays were carried
out in some experiments immediately after irradiation (0 hours)
and in others 18 hours later. Unirradiated tumours were again
used as controls to calculate surviving fractions.
Some unirradiated animals were treated with Ro-07-0582
alone in a dose of lmg/G i.p., and tumours were assayed 18 hours
later to study whether the drug had any specific cytotoxic effect of
its own in this system.
In one series of experiments, tumour cell suspensions were
incubated for 1 hour at 37°C with Ro-07-0582 in a dose of 0. 3mg/ml
and then irradiated in vitro under oxygenated conditions to measure
whether the drug had any radiosensitising effect on oxygenated
tumour cells.
9.6: RESULTS
In all cases, the administration of Ro-07-0582 in a dose of
Img/Gi.p. was well tolerated with no untoward effects noticed in
the mice.
The effects of pretreatment on clonogenic cell survival after
in vivo irradiation are shown in Figure 9. 2 for the 0 hour assay,
and in Figure 9. 3 for the 18 hour assay. Parameters and standard
errors for the cell survival curves are given in Table 9.1.
In both assays an increase in cell kill after single dose
irradiation was found in the Ro-07~0582 pretreated animals.
FIGURE 9.2
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The Effect of Radiosensitiser Ro-07-0582 on the Response to Co
y-Irradiation of Pancreatic Carcinoma Xenograft HX32 in the Air-
Breathing Mouse. Assay at 0 Hours (Vertical Bars Represent +
Standard Error of the Mean)






The Effect of Radiosensitiser Ro-07-0582 on the Response to Co
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TABLE 9. 2
Plating Efficiency of Cells from a Control Human Pancreatic
Carcinoma Xenograft HX32 Compared with Ceils from a
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The Dq for the 0 hour drug-treated curve was 159 (+36-25) rad
compared with 325 (+26-22) rad for the radiation alone control (p< 0. 02),
and the Dq for the 18 hour drug-treated curve was 182 (+71-40) rad
compared with 315 (+20-17) rad for the radiation alone control (p < 0. 05).
There was no significant difference between the DqS of the 2 drug-treated
curves. These data gave an enhancement ratio for Ro-07-0582 in this
system of 2.1 for the 0 hour assay and 1. 7 for the 18 hour assay, again
calculating the enhancement ratio from the ratio of Dq (irradiation
alone) : (irradiation + radiosensitiser) (Chapter 8. 4. a).
The plating efficiency of tumours from animals treated with
Ro-07-0582 alone, without irradiation is compared with that of
untreated controls in Table 9. 2. These show no statistically
significant difference, and indicate that Ro-07-0582 at a dose of
lmg/G had no specific cytotoxic effect of its own for xenograft HX32
in this system.
Figure 9.4 shows the in vitro irradiation survival curve for
cells previously incubated for 1 hour with Ro-07-0582, compared
with irradiated controls. Parameters and standard errors for these
curves are given in Table 9. 3. No significant difference was found
between these two curves, and tills demonstrates that the drug has no
radiosensitising effect on well oxygenated cells.
9.7: DISCUSSION
9. 7. a: Experimental Considerations
These experiments demonstrate that Ro-07-0582 enhances the
effect of single dose irradiation on clonogenic tumour cells from
pancreatic xenograft HX32. This enhancement is manifested in an
increase in sensitivity of the exponential tail of the air-breathing
curve, indicating that the enhancement effect is on hypoxic cells;
no enhancement is seen on oxygenated cells irradiated in vitro; and
no direct cell-killing effect is seen after treatment with the drug
alone. These experiments therefore demonstrate that Ro-07-0582
is indeed a specific hypoxic cell radiosensitiser of human tumour
cells, at least from a pancreatic carcinoma.
The degree of enhancement measured in the system is similar
whether the assay is carried out immediately after irradiation or
18 hours later. This finding is entirely in keeping with the drug's
action as a radiosensitiser, and argues against an alternative
explanation that it alters cell kill by some post-irradiation effect;
in other words this is not merely another manifestation or repair of
potentially lethal damage (Chapter 8).
Although a statistically significant difference in the of
the Ro-07-0582 curve compared with the oxygenated in vitro curve
could not be demonstrated for either the 0 hour or 18 hour assay,
the slope of the drug-treated curve was less steep in both cases
(Figure 9. 2 and 9. 3). This suggested that the degree of
irradiation enhancement achieved by the drug was not as great as
that achieved by oxygen. There are two likely explanations for this:
either all hypoxic cells are being sensitised by the drug but its
action at a molecular level, whatever that may be, is not as great as
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that of oxygen; alternatively it may be in theory just as affective as
oxygen, but in practice the drug is not achieving complete penetration
and not all hypoxic cells are being sensitised. This difference is
important, because it determines whether the timing and size of the
dose is adequate, or whether these need modification to achieve
greater tumour tissue penetration.
Rauth and Kaufman [1975] have suggested that these two
possible mechanisms can be differentiated from the shape of the
radiosensitiser curve and this is best illustrated with reference to
the two theoretical situations depicted in Figure 9. 5 (a) and (b). If
all cells are fully sensitised but the activity of the drug is not as
great as that of oxygen, then a straight line curve sloping less
steeply than the in vitro oxygenated curve would be anticipated,
indicating exponential kill of a single population of cells (Figure 9. 5 a).
If not all hypoxic cells are being sensitised on the other hand, then
a biphasic curve would be expected with an initial steep decline
indicating kill of sensitised cells, followed by a tail with the same
slope as the in vivo air-breathing curve tail, indicating kill of non-
sensitised hypoxic cells (Figure 9. 5 b). The argument in this latter
case is the same as that proposed to explain the biphasic air-
breathing curve in Chapter 8. 4.b.
The simplest fit by eye for cells irradiated after exposure to
Ro-07-0582 in the 0 hour assay, though not necessarily in the 18 hour
assay, is a straight line, which would favour the former explanation
that all cells are sensitised and that adequate tumour penetration has
(a) (b)
From Rauth and Kaufman [1975]
FIGURE 9. 5
Theoretical Diagram Showing Two Possible Effects of a Radiosensitiser
(solid lines) on Hypoxic Cell Survival from a Tumour Irradiated in vivo
in Air-Breathing Animals
In (a) All Hypoxic Cells are Sensitised
In (b) Only a Fraction of Hypoxic Cells are Sensitised
been achieved. This is in agreement with similar recent findings
for animal tumours using metronidazole (Rauth and Kaufman, 1975]
and Ro-07-0532 [Rauth et al, 1975]. However, the data are clearly
insufficient to exclude with complete confidence a biphasic curve
which would favour the latter hypothesis, and the problem could
satisfactorily be resolved only by obtaining many more data points.
9. 7. b: Clinical Considerations
The results of these experiments obviously justify current
clinical trials with Ro-07-0582 to try to enhance local tumour control
with radiotherapy. However, it is doubtful whether they are of value
in predicting the outcome of such trials.
First, significant enhancement in this system was only seen
with doses of irradiation higher than those currently used in most
fractionated radiotherapy regimes. It might perhaps be argued from
these data that fractions should be delivered in larger doses to
exploit more fully any radiosensitising effect.
Second, and more important, is the argument that even if
hypoxia is initially present within a tumour, fractionated treatment
regimes may allow sufficient re-oxygenation between each treatment
dose to render radiosensitisers superfluous. Indirect evidence for
this has been obtained from tumour control studies in experimental
animal tumours [Suit and Maeda, 1967; Field et al. 1968; Howes,
1969]. And Elkind [1970] has proposed that the hypothesis might be
investigated in a clonogenic assay system as follows: tumours are
first irradiated with a dose known to reduce the surviving fraction of
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cells to a value on the exponential tail of the biphasic air-breathing
curve which would imply survival only of hypoxic cells; at some later
time graded second doses of irradiation would be given to these
tumours to produce a second air-breathing survival curve. If all
cells remained hypoxic, this second curve should resemble the hypoxic
in vivo curve for 11X32 cells shown in Figure 8.2. If on the other
hand this curve showed any further biphasic displacement, as in the
0 hour air-breathing curve of Figure 8. 2, then this would indicate
that re-oxygenation of a fraction of previously hypoxic cells had
occurred between the two radiation treatments. This experiment
would be quite feasible in the xenograft system, but it would be large
and time-consuming, and has not so far been attempted.
In conclusion, therefore, it would seem unwarranted on
theoretical grounds to extrapolate at present these data from single
dose irradiation experiments to clinical treatment with fractionated
dose radiotherapy. The long term potential of this experimental
approach is more likely to emerge if current clinical trials first
demonstrate a correlation on purely empirical grounds, i. e. if
Ro-07-0582 proves to be as effective in improving tumour response
to radiotherapy in the patient as it is in the xenograft model. If a
predictive value for the diffusion chamber assay can be established
in this way, then the system may prove to be a very useful screening
assay for a wide range of potential new radiosensitising compounds
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CHAPTER 10:
THE RESPONSE TO CYTOTOXIC DRUGS OF
CLONOGENIC CELLS FROM HUMAN TUMOUR
XENOGRAFTS
10.1: INTRODUCTION
10.1, a: Chemosensitivity - Animal Tumours
So far in this thesis, clonogenic cell survival assays have
been discussed only in terms of the radiobiological data they can
provide. In recent years a large number of chemotherapeutic agents
have also been studied in this way using experimental murine
tumours. The effect of cytotoxic drugs on cell survival appears to
differ from that of radiation in two main ways: first, there is a much
greater variation in the steepness of the cell survival curve for a
given agent between different tumours; and second, the shape of the
curve may differ markedly for different drugs.
Some examples can be quoted. Cyclophosphamide produces an
exponential survival curve for most tumours tested, but the dose
required to achieve one log kill varies from about 2mg/kg for the
exquisitely sensitive PC-5 myeloma [Ogawa et al, 1973] to between
105 and 125mg/kg for the EMT6 tumour [Hahn et al, 1973] and the
B16 melanoma [Hill and Stanley, 1975], with the sensitivities of other
tumours including L1210 leukaemia, AKR lymphoma, C22RL osteo¬
sarcoma and Lewis lung tumour lying between these extremes
[Bruce et al, 1966; van Putten and Lelieveld, 1970; Razek et al,
1974; van Putten, 1974; Steel and Adams, 1975]. Other drugs for
which exponential survival curves with a wide range of sensitivities
for different tumours have been obtained include BCNU, CCNU and
vincristine [Bruce et al, 1969; Lin and Bruce, 1972; Razek et al,
1974; van Putten, 1974; Hill and Stanley, 1975; Steel and Stanley,
1976].
In contrast, some drugs give cell survival curves that are
not exponential but fall to a plateau; these include methotrexate and
vinblastine for the AKR lymphoma [Bruce et al, 1966] and cytosine
arabinoside for AKR lymphoma, L1210 leukaemia and B16 melanoma
[Bruce et al, 1969; Edelstein et al, 1974; Hill and Stanley, 1976].
5-fluorouracil gives a plateau for KHT and EMT6 tumours, though
with differing sensitivities of 40% and 5% respectively [Lin and
Bruce, 1972; Hahn et al, 1973]. On the other hand this drug gives
an exponential survival curve for AKR lymphoma whether given as
a single dose or in divided doses [Bruce et al, 1966; Vietti et al,
1971].
Tumour size, the time interval between treatment and
sampling, and for certain drugs the duration of exposure have all
been shown to influence chemosensitivity measured by cell survival
[Bruce et al, 1969; Steel and Stanley, 1976; Hahn et al, 1973] and
these must be standardised before comparisons of drug sensitivity
can be made. However, these alone cannot fully account for the
wide variation in both steepness of slope and shape of cell survival
curves after exposure to chemotherapeutic agents.
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Bruce, Meeker and Valeriote [1966] in a classic study
demonstrated three classes of response to anti-cancer agents for
the AKR lymphoma and for mouse marrow using a spleen colony
assay, and they interpreted these differences in response on the
basis of cell cycle kinetic parameters. In the first class (Type 1
response), obtained with nitrogen mustard and y-irradiation,
survival curves were approximately exponential and the sensitivities
of both marrow and lymphoma cells were similar. This is represented
schematically in Figure 10. la, and is explained on the basis that
all cells, both proliferating and non-proliferating, are equally
affected by these agents.
In the second class (Type 2 response) which included tritiated
thymidine, vinblastine and methotrexate, cell survival decreased
as a function of dose to constant values, i. e. the dose survival
curves above a certain dose plateaued out. These plateau levels
were similar for all drugs in this group but differed markedly
between normal and lymphoma cells. This is represented schem¬
atically in Figure 10. lb. This type of response is explained on the
basis that drugs in this group act only on proliferating cells during
a specific phase of the cell cycle and that cells not passing through
this vulnerable phase during the period of drug exposure will not be
killed however much dosage is increased. The differential plateau
effect with these agents is dependent on the fact that the proliferating
fraction of lymphoma cells during treatment is much greater than
that of bone marrow.
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In the third class of response (Type 3 response), obtained
with cyclophosphamide, actinomycin D and 5-fluorouracil, survival
curves were exponential as in the Type 1 response but with the
important difference that here the lymphoma cells were six to tenfold
more sensitive than marrow cells. This is represented schematically
in Figure 10. lc. This response was interpreted on the basis that
Type 3 agents act only on proliferating cells, but throughout all
phases of the cell cycle. Since all proliferating cells are at risk
cell kill is exponential, but since the fraction of proliferating cells
varies between the two types a differential effect is seen.
These observations of Bruce and his colleagues were of
importance in their demonstration that the activity of many cytotoxic
drugs was closely dependent on the proliferative state of the cell and
often on the specific phase of the cell cycle during drug exposure.
This has been of considerable clinical value, and has led for example
to the concept that high doses of phase-specific (Type 2 response)
drugs can be administered in cancer chemotherapy without intolerable
toxicity provided the duration of exposure to the drug is short
[Goldie et al, 1972].
However, in some instances Bruce's data have been extra¬
polated in a literal way to the design of clinical chemotherapy
regimes on the assumption that careful scheduling of drug administration
could exploit similar kinetic differences between human tumour and
normal tissues and thus increase tumour response [Price et al 1975;
Lampldn et al, 1976].
166
This assumption is questionable on two grounds. First,
others have suggested that differential chemosensitivity between
tumour and marrow cells is not always dependent on kinetic
differences. Van Putten and Lelieveld [1970] have demonstrated a
similar increased sensitivity to cyclophosphamide of C22LR osteo¬
sarcoma cells compared with marrow, but have argued that
differences in the kinetics of these two tissues are insufficient to
explain this differential response and that instead differences in
the inate chemosensitivity of the two cell types must be involved,
independent of their proliferative activity. And it seems increas¬
ingly likely that differential sensitivity must play an important part
in explaining many of the observed differences in drug effect for
different tumours, as more is learned of the characteristics of
their cell cycle kinetics.
The second objection is simply this: even if the interpretation
of his data on a kinetic basis is correct for the system Bruce studied,
important differences have been demonstrated between the kinetics
of human tissues and those of the AKR lymphoma and other experi¬
mental leukaemias. These include in particular the smaller fraction
of cells proliferating, the longer cell cycle time and the greater
heterogeneity of cell cycle times for human tumours so far studied
[Clarkson et al, 1965; de Vita, 1971; van Putten, 1974; Tubiana and
Malaise, 1976]. It is, sadly, not surprising therefore that no
convincing evidence for an increased therapeutic response based on
this type of kinetic scheduling appears so far to have been demonstrated


































Schematic Representation of Cell Survival for Mouse Marrow ( )
and AKR Lymphoma ( ) After Treatment with (a) Type 1 agents
(b) Type 2 agents (c) Type 3 agents. See Text for Details (Chapter i0. 1)
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Unfortunately, similar data on the chemosensitivity of human
tumour cells which might more validly be extrapolated to the clinic
have not so far been available.
10.1. b: Chemosensitivity - Human Tumours
The reason it has not been possible to repeat similar sophis¬
ticated cell survival studies for human tumours exposed to cytotoxic
chemotherapy has been the absence of an equivalent clonogenic assay
system. Other techniques have been employed in an attempt to
quantify the response of human tumour cells to cytotoxic drugs
in vitro and to correlate this with subsequent clinical response to
chemotherapy.
The earliest attempts were made almost 20 years ago [Wright
et al, 1957; 1962]; in these studies changes in the morphology of
cultured cells from human tumours were used as a measure of drug
sensitivity. And later, similar studies were attempted in which the
uptake of radioactive precursors of nucleic acid and protein
synthesis was used to measure chemosensitivity of human tumour
slices incubated in vitro [Yarnell et al, 1964; Bickis et al, 1966].
More recently Dendy and his co-workers have carried out pain¬
staking work in this field, and have described a technique for
growing cell suspensions of human tumours, and in particular ovarian
carcinomas, in short term monolayer cultures which are incubated
with a series of cytotoxic drugs to determine chemosensitivity
[Dendy, 1968; Dendy et al, 1970]. In early experiments, morpho¬
logical damage to cells in culture was used as a measure of drug
sensitivity. Later, the uptake of labelled precursors of DNA
synthesis was used as an end point to measure drug effect. Holmes
and Little [1974] used a tissue culture micro-test for predicting the
response of human tumours to chemotherapy. In this study single
cell suspensions of human tumours were incubated for 72 hours with
cytotoxic drugs, the end point for measurement of response being
the number of cells remaining as detected by Coulter counting. A
similar approach was used by Berry et al [1975] who described a
method for studying the chemosensitivity of fresh explants of human
tumours cultured in vitro for 7 days with different drugs added to
the culture medium; here increase in total cell number after 7 days
growth in culture was used as a biological end point.
Some, but not all of the studies, claimed a correlation
between the predicted in vitro chemosensitivity, and subsequent
clinical response to chemotherapy in the patient, but such data is so
far small and inconclusive. Furthermore detailed quantitative data
on cell survival is clearly not possible with the various end points
for measurement of drug response used. These in vitro systems
have several other important limitations. Certain drugs which first
require in vivo activation by the liver, including in particular •
cyclophosphamide, cannot be studied directly in this way. Toxic
derivatives of cyclophosphamide can be obtained in vitro by
incubating the drug with liver microsomes [Connors, 1970] but
attempts to standardise this procedure for in vitro assays have
proved unsuccessful in some hands [Denby et al, 1976] and usually
this important drug has been excluded from these studies. Secondly,
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it is becoming apparent that a good correlation between decreased
uptake of labelled precursors and cell kill does not always exist:
3
for example, H-thymidine incorporation initially increases after
methotrexate exposure in mammalian cells [TattersaLl and Harrap, 1973].
Finally, it is difficult to demonstrate in these short term culture
systems that the cells growing in monolayer are indeed all tumour
cells and not cells derived from stromal elements. Chromosomal
analysis was used in some of these studies to try to identify normal
from tumour cells, but this approach can only be applied to dividing
cells, and gives no information on non-dividing cells which may also
be affected by drugs in these systems.
More recently Berry's group has reported on the reproductive
survival of cells from their explant system after exposure to
vinblastine [Wells et al, 1976] or nitrogen mustard [Wells et al,
1977], using a cloning assay in which treated cells grow colonies
/
after plating on to irradiated foetal cell layers in Petri dishes.
This approach is of considerable potential interest in that it
permits more detailed quantitative data on the effects of different
cytotoxic agents on cell survival and allows cell survival curves to
be constructed. However, certain features of the assay suggest
that some artificial selecting out of unrepresentative cells may occur
during the initial monolayer culture and sub culture required for
this assay. First, the plating efficiencies of up to 75% for this
system are rather higher than that found for most animal tumour
systems in which cells are plated out directly from the tumour.
And second the data obtained does not always reflect clinical
experience: for example cells from a seminoma were less sensitive
to both vinblastine and nitrogen mustard than cells from most other
tumours studied including a melanoma; this certainly very much
contradicts the clinical response to chemotherapy usually observed
for these. Nevertheless this work represented an important attempt
to break away from the limitations of cell culture techniques in the
measurement of human tumour cell chemosensitivity, and encouraged
the hope that other techniques might be adapted to study the chemo¬
sensitivity of clonogenic human tumour cells.
10.2: METHODS
10. 2. a: Theoretical Approaches: In Vivo and In Mure
The diffusion chamber system can in theory be used to
measure the chemosensitivity of cells from human tumour xenografts
in two different ways. In the first method, the tumour-bearing mouse
is treated with the drug under study, and the tumour subsequently
dissected out after an appropriate time interval for assay (Fig. 10. 2a).
In the second method, a cell suspension of an untreated tumour can
be loaded into diffusion chambers for implantation; once this is done
the chamber-bearing mouse is treated with the drug and the chamber
then transplanted after an appropriate time interval (Fig 10. 2b).
The first is obviously an in vivo method whose main advantage
is that tumour cells in situ are exposed to drugs under physiological
conditions which hopefully might resemble those pertaining in the
clinic (with the inevitable proviso that drug metabolism is murine and
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(a)
Human Tumour Xenograft Cytotoxic Drug Assay Techniques
(a) In vivo by intra-peritoneal drug administration and assay 18hrs later
(b) In the mouse by tail vein injection of chamber-bearing mouse and
transplant 18 hours later
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not human). The second technique is highly unphysiologica.1: single
tumour cells in medium and agar are exposed to drugs under
conditions very different to those pertaining in vivo, and data
obtained with this technique must be interpreted with this important
limitation in mind. This point will be discussed in more detail
below (Chapter 10.4.b). But this second assay technique also has two
important advantages over the in vivo assay. First, since clono-
genic cells of both human tumours and human bone marrow can be
assayed in the diffusion chamber system, the relative sensitivities
of these to the same cytotoxic agent can be compared using this
latter technique. The low therapeutic index and high risk of marrow
toxicity associated with most current cancer chemotherapy regimes
suggest that such comparative data might be of value in understanding
and predicting differential therapeutic response between marrow
and tumour tissue. Second, this technique would provide the only
way of measuring the chemosensitivity of clonogenic human tumour
cells taken directly from the patient, rather than from a xenograft,
if the diffusion chamber assay could be adapted to grow colonies
directly in this way (Chapter 11).
The feasibility of both methods for assaying the chemosensitivity
of human tumour cells was therefore investigated in the experiments
to be described. The technique whereby cellular chemosensitivity
is assayed by treating chamber-bearing mice raises an interesting
question in semantics. The method is not strictly an in vivo one, but
neither can it be described as in vitro. A new term seems indicated
and since cells are treated after implantation into the mouse, I shall
use the term in mure to describe this system.
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10. 2. b: Experimental Design
Several groups of experiments were carried out. In the
first series the in vivo dose-survival characteristics for 2 tumours,
pancreatic xenograft HX32 and colonic carcinoma HX18, treated
with cyclophosphamide were studied. In the second series of
experiments similar studies were undertaken for cells from these
tumours treated with the same drug in mure. Once the feasibility
of the in mure technique had been established, this was used to
compare the sensitivity to cyclophosphamide of human tumour cells
with cells from the murine Lewis lung tumour.
In a final series of experiments the comparative chemo-
sensitivity of pancreatic carcinoma HX32 to a series of cytotoxic
drugs was measured, treatment being administered in vivo. Similar
comparative chemosensitivity studies were made on colonic carcinoma
xenograft HXK1 and a rectal carcinoma xenograft HXK4, treated
in mure. These latter experiments were designed to test whether
similar comparative chemosensitivity studies on human tumour cells
direct from the patient might be theoretically feasible.
10. 2. c: Xenograft Tumours
4 tumour xenografts were used in these experiments:
pancreatic carcinoma HX32, colonic carcinoma HX18, colonic
carcinoma HXK1 and colonic carcinoma HXK4. Relevant details of
these tumours have already been described (Chapter 5. 1 and Tables
5. 1 - 5. 3). The latter two xenografts were selected for study because
information was already available on the clinical behaviour of the
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original tumours from which they were derived. Furthermore
gross tumour growth delay studies (Chapter 3. 1) had also been
carried out on these xenografts by my colleague Mr. Novak. These
data will be described below (Chapter 10.4. e).
10. 2. d: Lewis Lung Tumour
The Lewis lung carcinoma is a transplantable tumour that
arose spontaneously in the lung of a C57B1 mouse [Sugiura and
Stock, 1955] and has subsequently been widely used in radiobiological
and chemotherapeutic aspects of experimental cancer research. It
is currently used as one of the standard animal tumours in the NCI
drug screening programme. For this reason it seemed an appropriate
choice of experimental tumour to compare with the human tumour
xenografts in chemosensitivity studies using the diffusion chamber
assay.
Single cell suspensions of this tumour were obtained for
these experiments by finely chopping the tumour with crossed
scalpels, washing the pieces in phosphate-buffered saline and then
trypsinising at 37°C for 15 minutes with 1:200 trypsin. Subsequent
steps to obtain the final single cell suspension were.identical to
those described for xenografts HX32 and HX 18 (Chapter 5. 3).
10. 2. e: Cyclophosphamide Administration - In Vivo Assays
Tumours growing intra-muscular ly in the thighs of immune-
suppressed mice (Chapter 5. 2) were used in these experiments, at
a time when the tumours had grown to a diameter of 0. 5 to 1cm.
Cyclophosphamide B. P. (W.B. Pharmaceuticals Ltd.) was dissolved
in saline and administered by intra-peritoneal injection 18 hours
prior to assay (Fig. 10. 2a).
10. 2, f: Cyclophosphamide Administration - In Mure Assays
Single tumour cell suspensions were loaded into diffusion
chambers and implanted into the peritoneal cavities of pre-treated
C57B1 mice under ether anaesthesia as previously described
(Chapter 5.4). At this time, cyclophosphamide was also administered
intra-venously by tail vein injection. This route was preferred to that
of intraperitoneal injection to prevent artificially high local concen¬
trations of drug developing initially around the implanted diffusion
chambers. Chambers were transplanted 18 hours later to a new
batch of pre-treated mice, because the combination of cyclophosphamide
and total-body irradiation in the same mouse was lethal after a few
days (Fig. 10. 2b).
10. 2. g: Comparative Chemosensitivity Experiments
In these experiments, the comparative chemosensitivity of
clonogenic cells from pancreatic carcinoma HX32 to adriamycin,
5-fluorouracil, vinblastine, methotrexate and methyl-CCNU was
studied in vivo, and the comparative chemosensitivities of clonogenic
cells from colonic carcinoma HXK1 and rectal carcinoma HXK4 to
5-fluorouracil, actinomycin D and methyl-CCNU ware studied in mure.
(For a note on all the cytotoxic agents used in these studies see
Appendix 2.)
It was decided to administer equitoxic, doses of each drug to
allow comparison of effects on tumour cell kill, and therefore the
LD^q dose of each drug for C57B1 mice (that dose which is lethal to
10% of this strain of mouse) was given in each of these comparative
chemosensitivity experiments. The LD^ doses for each drug, and
hence the dose used in these experiments, are given in Table 10.1.
All drugs were prepared by dissolving in saline immediately
prior to use, except for methyl-CCNU which posed special problems
because of its low solubility in aqueous solutions. Methyl-CCNU was
therefore obtained in solution by dissolving in dimethyl-sulphoxide
(DMSO) subsequently diluted 1:9 with a 5% solution of Tween 80 (BDH
Chemicals) in normal saline.
As before, drugs were administered intraperitoneal!}' 18
hours before assay for the in vivo studies and intravenously by tail
vein injection at the time of chamber implantation for the in mure
studies, chambers being transplanted 18 hours later.
10.3: RESULTS
10.3. a: In Vivo Cyclophosphamide Dose Survival
The dose survival curves for clonogenic cells from pancreatic
carcinoma HX32 and colonic carcinoma HX18 treated with single dose
cyclophosphamide in vivo are shown in Figure 10. 3 and their para¬
meters calculated by linear regression analysis given in Table 10. 2.
These curves appeared to be exponential but in both cases the range
of cell kill was small, with less than one log kill even at the maximum
tolerated dose to the mouse. The Dq convention has not been so
universally accepted for cell survival curves for cytotoxic drugs as
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Response to Cyclophosphamide of Cells from Pancreatic Carcinoma
HX32 (a) and Colonic Carcinoma HX18 (b) Treated In Vivo (Vertical
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achieve 1 log cell kill) is often used. This latter notation will be
used here. For HX32 the predicted was 456 (+52-41)mg/kg and
for HX18 404 (+116-73)mg/kg (Table 10.2) although in neither case
were doses as large as these actually tested. Pancreatic carcinoma
HX32 curve had a small initial shoulder with a Dq value of 53 (+15-20)
rad; colonic carcinoma HX18 curve had no definite shoulder within
the range of one standard error, the D„ value being 18 (+35-55)rad.
There was no significant difference between these cyclophosphamide
cell survival curve parameters for the two tumours.
10. 3. b: In Mure Cyclophosphamide Dose Survival
The dose survival curves for clonogenic cells from pancreatic
carcinoma HX32 and colonic carcinoma HX18 treated with single
dose cyclophosphamide in mure are shown in Figure 10.4 and their
parameters given in Table 10. 3.
Cell kill was exponential for both tumours over the range of
doses studied, and in both instances cells were significantly more
sensitive to cyclophosphamide treated, this way than when treated
in vivo. The value for HX32 cells was 169 (+7-7)mg/kg
compared with 456mg/kg treated in vivo (p 4^ 0. 01), and the D^q
value for HX18 cells was 105 (+17-12)mg/kg compared with 404mg/kg
treated in vivo (p < 0. 005). Although no difference in sensitivity to
cyclophosphamide between two tumours treated in vivo had been
demonstrated, a significant difference was found between the two
tumours treated with cyclophosphamide in mure (p 0. 05). No
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FIGURE 10.4
Response to Cyclophosphamide of Cells From Pancreatic Carcinoma
HX32 (A) and Colonic Carcinoma HX18 (£j) Treated In the Mouse
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10. 3. c: Lewis Lung In Mure Cyclophosphamide Dose Survival
The dose survival curve for clonogenic cells from Lewis
lung tumour treated with cyclophosphamide in mure is shown in
Figure 10. 5. Cell kill was again exponential, but Lewis lung tumour
cells with a D^q value of 48 (+3~2)mg/kg were significantly more
sensitive to cyclophosphamide than cells from either the colonic
carcinoma HX18 (p < 0.001) or from pancreatic carcinoma HX32
(p < 0. 001). No significant shoulder was found for this curve
(Table 10. 3).
10. 3. d: Human Bone Marrow In Mure Cyclophosphamide Dose
Survival
My colleague, Dr. M.Y. Gordon, working in the same
department, had previously established a cyclophosphamide cell
survival curve for clonogenic cells from human bone marrow also
using an agar in diffusion chamber technique, and details of her
experimental methods were identical to those used by me (Chapter
10. 2. f). She has kindly allowed me to quote her results here, and
the comparative cyclophosphamide cell survival data for human
marrow and human tumour xenografts (HX18 and HX32) treated in
mure are shown in Figure 10. 6. Cyclophosphamide cell kill was
again exponential for human marrow, but the sensitivity of bone
marrow cells was much greater than that of either tumour with a
D1q value of 37 (+3~3)mg/kg. This difference was statistically
significant compared with both colonic carcinoma HX18 (p < 0. 001)
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10. 3. e: Comparative Chemosensitivity In Vivo of Pancreatic
Carcinoma HX32
The surviving fractions (S. F) of cells from pancreatic
carcinoma HX32 after treatment in vivo with LD^q doses of 5 cyto¬
toxic drugs are shown in Figure 10. 7 and the results are as
follows: -
after adriamycin 15mg/kg i. p. the S. F was 0. 51 + 0. 06
after 5 -fluorouracil 250mg/kg i. p. the S. F was 0. 63 + 0. 07
after methotrexate 200mg/kg i. p. the S. F was 0. 40 + 0. 04
after methyl-CCNU 30mg/kg i. p. the S. F was 0. 08 + 0. 02
and after vinblastine 3mg/kg i. p. the S. F was 0. 49 + 0. 04
The increase in cell kill achieved with Methyl-CCNU compared with
the other 4 drugs was significant (p •< 0. 001). This experiment
however was only carried out once.
10. 3. f: Comparative Chemosensitivity In Mure of Colonic
Carcinoma HXK1 and Rectal Carcinoma I1XK4
The surviving fractions (S. F) of cells from colonic carcinoma
HXK1 and rectal carcinoma HXK4 after treatment in mure with
5-fluorouracil, methyl-CCNU and actinomycin D are shown in Figure
10. 8 and the results are as follows: - after 5-fluorouracil 250mg/kg
i. v. the S. F was 0.42 + 0. OS.for HXK1 and 0. 73 + 0.10 for HXK4
(this difference was significant at p < 0. 05); after actinomycin D
0. 5mg/kg i. v. the S. F was 0. 20 + 0. 03 for HXK1 and 0.46 + 0. 04
for HXK4 (this difference was significant at p < 0. 002); after
methyl-CCNU 30mg/kg i. v. the S. F was 0. 03 + 0. 01 for HXK1 and










































Response of Cells from Pancreatic Carcinoma Xenograft HX32 to
LD. „ Doses of Adriamycin, 5-FU, Vinblastine, Methotrexate and
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FIGURE 10.8
Response of Cells from Human Colonic Carcinoma Xenografts HXK1 (C)
and HXK4 (Q to Doses of 5-Fluorouracil, Methyl-CCNU and
Actinomycin D. Treatment In the Mouse (Vertical Bars Represent +
Standard Error of the Mean)
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10.4: DISCUSSION
The first point to be made about these studies is that they
demonstrate the feasibility of measuring the chemosensitivity of
clonogenic human tumour cells with the diffusion chamber assay,
and they show that it is now possible to provide quantitative
information on the effects of cytotoxic drugs previously limited to
work with experimental animal tumour models. Both the in vivo and
the in mure techniques can be used to assay chemosensitivity. The
latter therefore provides a means for comparing the sensitivity of
marrow and tumour cells to cytotoxic drugs, and perhaps for
measuring the chemosensitivity of tumour cells removed directly
from the patient. An important finding of these experiments, however,
is that the sensitivity at least to cyclophosphamide differs depending on
which assay is used; this will be discussed below.
10.4. a: In Vivo Cyclophosphamide
The in vivo cyclophosphamide experiments demonstrate that
cells from both the pancreatic and the colonic carcinoma xenografts
are very insensitive to this drug when treated in situ: the respective
doses of 456mg/kg and 404mg/kg to achieve 1 log cell kill are about
four times as great as that required for the EMT6 tumour, one of
the most cyclophosphamide-resistant experimental animal tumours
[Hahn et al, 1973], and more than 200 times as great as that
required for the PC-5 myeloma [Ogawa et al, 1973]. These
observations correlate well with clinical experience in the chemo¬
therapy of pancreatic and colonic carcinomas, which have a low
response rate of about 15% to cyclophosphamide [Livingstone and
Carter, 1970].
Such a correlation is encouraging and provides circumstantial
evidence that the assay may be a valid experimental model for
studying the cellular basis underlying clinical response to chemo¬
therapy. It has been calculated on the basis of comparative toxicity
data for cytotoxic drugs between mouse and man that the maximum
tolerated dose in man is about 1 /12 the in mice on a mg/kg
basis, and this appears to hold true for most drugs [Freireich et al,
1966], For cyclophosphamide 300mg/kg, the approximate LD^q
dose in C57B1 mice, would therefore be eqivalent to 25mg/kg in
man, and this is certainly around the maximum dose conventionally
used in clinical practice. Yet such a dose in this system produces
less than one log cell kill for both tumour xenografts, and if these
can be considered in any way representative of human pancreatic
and colonic carcinoma in general then the poor clinical response of
these tumours to cyclophosphamide can be readily understood. It
would obviously be of interest to carry out similar in vivo experi¬
ments in xenografts of human tumours known to be clinically
sensitive to cyclophosphamide, including for example lymphomas,
and attempts to establish such xenografts are under way.
10.4.b: In Mure Cyclophosphamide
It has already been noted that the sensitivity to cyclophos¬
phamide of these two tumours after treatment in mure was signific¬
antly greater than when treated in vivo; at the maximum dose of
drugs studied in mure, cell kill was increased by one decade for
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pancreatic carcinoma HX32 and by two decades for colonic carcinoma
HX18. Various factors might be proposed to explain this.
The first is that the trauma of cell suspension and chamber -
loading might stimulate some previously "resting" tumour cells
in situ into proliferative activity; in other words, "recruitment" of
cells from Gq into the cell-cycle might be occurring during the
experimental process. Since cyclophosphamide is a cycle-dependent
drug (Figure 10. lc), greater cell kill might therefore be achieved
by drug exposure in the diffusion chamber system than in situ. Many
factors have been shown to trigger resting cells into proliferative
activity in experimental systems [van Putten, 1974], and it is possible
that this phenomenon may be operating here. However, the magnitude
of the difference in cell kill between the two systems argues against
this being the only factor involved.
A more likely explanation is that not all cells in the tumours
treated in vivo are adequately perfused. Tumour blood supply is
maintained mainly by capillary proliferation with larger vessels
displaced peripherally; as tumours enlarge the ability of this
capillary network to maintain adequate tissue perfusion diminishes,
particularly in more central areas of the tumour [Thomlinson, 1973].
This is associated with tissue hypoxia, already discussed in
Chapters 8 and 9, and areas of poor perfusion can be demonstrated
by intra-arterial dye injection studies [Goldacre and Sylven, 1962].
Rowe-Jones [1968] has demonstrated that the penetration of cytotoxic
drugs to such areas is also impaired, and it is very possible that
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effective concentrations of active cyclophosphamide metabolites are
not uniformly achieved throughout xenograft tumours treated in vivo,
and that therefore cell kill in this situation is less than when
treatment is given in mure,
A third factor to be considered is the phenomenon of repair
of potentially lethal damage. This has already been discussed for
cell survival after radiation in the xenograft system (Chapter 8.4.f).
Hahn et al [1973] demonstrated that in the EMT6 tumour treated with
cyclophosphamide, 5-fluorouracil and bleomycin, cell survival was
increased in tumours assayed 24 hours after drug exposure compared
with those assayed after 2 hours, and it was postulated that some
potentially lethal cytotoxic drug damage might be repaired by factors
operating when cells were allowed to remain in situ for some time
after drug exposure. From their data a greater than 5-fold increase
in survival can be calculated for the tumours treated with cyclophos¬
phamide at maximum dosage. Were the interpretation of Hahn's
data correct, and were similar repair factors operating in the
xenograft tumours, then it is certainly possible that this might
explain differences in survival betv/een cells left in situ after treat¬
ment and in cells treated "in isolated" in diffusion chambers. At
present however little further is known of the phenomenon of
potentially lethal damage repair of tumour cells after cytotoxic
drugs and this explanation must therefore remain speculative. It is
possible that an in vivo cyclophosphamide experiment assayed 2 hours
later might be of value here: if cell survival after in vivo
cyclophosphamide were less assayed at 2 hours compared with
18 hours, this would argue in favour of repair of potentially lethal
damage rather than inadequate perfusion as a basis for the differ¬
ences in cyclophosphamide sensitivity observed between the in mure
and in vivo techniques.
Whatever the underlying explanation, it seems reasonable to
argue by analogy with in vitro radiation studies that the in mure
technique may measure the intrinsic chemosensitivity of elonogenic
tumour cells, whereas the in vivo technique may reflect chemosens¬
itivity under physiological conditions, where this intrinsic chemo¬
sensitivity is modified by extrinsic factors; these latter may include
many processes, of which inadequate tumour perfusion, the ability
to repair potentially lethal drug damage in situ, and a significant
fraction of "resting" Gq cells have been discussed here. The role
and influence of these extrinsic factors are at present perhaps even
less well understood for drugs than for radiation (Chapter 8), and
their significance may vary for different tumours, thus masking
differences in intrinsic chemosensitivity for different tumours.
This would explain the finding in these experiments that the in mure
sensitivity to cyclophosphamide for pancreatic carcinoma cells and
colonic carcinoma cells differed significantly, whereas no such
difference was detected with the drug administered in vivo.
10.4. c: Lewis Lung Tumour Studies
Previous studies on the murine Lewis lung carcinoma treated
with cyclophosphamide in vivo [Steel and Adams, 1975] have shown
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that this, like other animal tumours, is very much more sensitive
to cyclophosphamide than the pancreatic and colonic carcinoma
xenografts treated in vivo here. This marked difference in sensitivity
is maintained in the in mure studies and confirms that differences in
the intrinsic sensitivity to cyclophosphamide between cells from the
Lewis lung tumour and from the human tumour xenografts must
exist, independent of other extrinsic factors operating in vivo. It is
also of interest that the value of 48mg/kg obtained here for the
Lewis lung tumour is less than the D^q value of around 75mg/kg
which I have extrapolated from data on this tumour treated in vivo
[Steel and Adams, 1975]. Although a statistical comparison is not
possible here, this finding is consistent with the difference in xeno¬
graft cyclophosphamide sensitivity obtained in vivo and in mure.
10. 4. d: Comparative Human Bone Marrow and Human Tumour
Cell Studies
The relative sensitivity to cytotoxic drugs of tumour and
bone marrow cells is an important factor in determining the success
or failure of a cancer chemotherapy regime. Comparative data from
experimental animal systems has already been described and the
theoretical limitations to their clinical application discussed (Chapter
10.1. a). These limitations are further emphasised in the comparative
cyclophosphamide chemosensitivity data for cells from human marrow
and human tumours obtained here. Whereas both Bruce and his
colleagues [1966] and van Putten and Lelieveld [1970] found their
experimental animal tumour cells to be many times more sensitive
to cyclophosphamide than murine marrow, these present studies on
human material provide fundamentally different results in that human
pancreatic and colonic carcinoma cells are respectively four-fold
and two-fold less sensitive than human marrow to this drug.
Obviously this interpretation of these data requires important
qualifications. First, both these human tumour types are known to
be clinically chemoresistant and it would be of interest to carry out
similar comparative studies with chemosensitive tumours, including
lymphomas were these available as xenografts. Second, both the
data of Bruce and van Putten were obtained from studies in which
treatment was given in vivo. But it has already been postulated that
the in mure technique measures intrinsic chemosensitivity which may
be modified under in vivo conditions by outside factors. Direct
comparison of the data is therefore invalid. However, it has
been shown here that the sensitivity to cyclophosphamide of these
tumour xenografts is even less in vivo than in mure, whereas for
marrow sensitivity may not change. (This has been demonstrated
at least for murine marrow - Dr. M.Y. Gordon, personal
communication.) The conclusion is therefore that the difference in
cyclophosphamide sensitivity between human marrow and the two
human tumours studied here is probably even greater in vivo than
has been measured in mure, and the contrast between this and animal
tumour data is therefore emphasised rather than diminished.
Factors other than cell kill are also involved in predicting
differential clinical toxicity between marrow and tumours: in particular
the rate of cell repopulation and hence the rate of tissue recovery
is probably of importance and information on this would also be
necessary in predicting with greater accuracy overall differential
response. Nevertheless the findings described here support the
clinical observation already referred to above that the response
rate of pancreatic and colonic carcinomas to chemotherapy is low,
even in doses which produce considerable marrow toxicity [B.M.J.
Editorial, 1976]. And it seems reasonable to hope that this kind of
assay may be of more value in understanding and predicting clinical
chemotherapy response than experimental animal systems in the
future.
10.4. e: Comparative Chemosensitivity Studies
These last group of studies were carried out to examine the
feasibility of a cytotoxic drug sensitivity test for tumours, analogous
to antibiotic sensitivities provided by bacteriology laboratories.
They were of a preliminary nature and can be interpreted only in a
very limited way; but several observations can be made here.
First, in both the in vivo study and in the in vitro studies
differences in drug sensitivity were detected, the dose of
methyl-CCNU achieving up to one log greater cell lull than the other
drugs studied. This is of some interest in that recently it has been
claimed that this drug is more effective than others previously used
in the clinical chemotherapy of colonic and pancreatic cancers
[Moertel et al, 1976]. Although this might argue in favour of the
validity of the assay, it must be pointed out that the clinical
data on methyl-CCNU is controversial and is at present being
reassessed.
The second observation was that with the exception of
methyl-CCNU none of the agents achieved even one log kill
despite being administered in LD-^q doses equivalent to maximum
tolerated doses in man. This, though depressing clinically, again
is compatible with the poor clinical response of these tumours
generally observed with all current clinical chemotherapy. It is
perhaps surprising however that in none of the 3 tumours studied
was 5-fluorouracil more effective than any of the other agents
tested, since this drug, like methyl-CCNU, has been reported as
having greater single agent activity in intestinal cancers than most
other drugs studied. Three points must be made in the interpretation
of these data: first only three tumours were tested and these may
therefore be unrepresentative of their general types; second the
assay measures only single dose effects whereas frequency of drug
administration may be important clinically, particularly with 5-FU;
third metabolism of some of these agents may vary significantly
between mouse ana man.
The final observation from the studies in which cells from
colonic carcinoma. HXK1 and rectal carcinoma HXK4 were treated
in mure is the correlation with clinical data and with data obtained
from tumour growth delay studies.
The patient from whom HXK1 xenograft was obtained was
treated for multiple liver metastases with a chemotherapy regime
which included methyl-CCNU and 5»fluorouracil, and was one of the
few patients with metastatic colonic carcinoma treated in this way at
the Royal Marsden Hospital to make a good objective response. This
was assessed by general improvement in clinical condition, improve¬
ment in isotopic liver scan and a full to normal level of previously
raised serum carcino-embryonic -antigen (CEA) level. On the other
hand, the patient from whom HXK4 xenograft was obtained developed
clinical evidence of liver metastases soon after surgical removal of
the primary tumour and deteriorated very rapidly before chemo¬
therapy could be initiated.
Both these patients' xenografts were treated with 5-fluoro-
uracil and methyl-CCNU in tumour growth delay studies by my
colleague Mr. K. Novak who has kindly allowed me to describe his
results here. Tumour growth delay was calculated from the ratio
(TD treated - TD control) : (TD control), where TD was the median
time for the tumour to double in volume. This ratio may be regarded
as the number of tumour-doubling times saved by the treatment
[Kopper and Steel, 1975].
HXK1 was more sensitive than HXK4 to methyl-CCNU with a
growth delay ratio of 5. 2 compared with 0.4. HXK1 was also slightly
more sensitive than HXK4 to 5~fluorouracil with a growth delay of
1. 5 compared with 1.0.
Although increased cell ldLl measured by the clonogenic assay
for HXK1 therefore correlated with a better xenograft response to the
same drugs and with a clinical response to chemotherapy seen
infrequently for this tumour type, no detailed conclusions can be
drawn from this preliminary study. Indeed it might have been
anticipated that the difference in tumour growth delay between the
two xenografts would have been associated with a difference in cell
kill greater than the two-fold actually measured. The main value of
this study is that it at least demonstrates that such experiments
are now technically feasible and that further comparative data can
therefore be obtained to establish whether a real correlation between
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COLONY GROWTH WITH CELLS TAKEN DIRECT
FROM HUMAN TUMOUR BIOPSIES, USING THE
AGAR IN DIFFUSION CHAMBER TECHNIQUE
11. 1: INTRODUCTION
The reasons for assaying clonogenic ceils from xenografts,
rather than directly from biopsy specimens of human tumours,
were described in Chapter 3. Ethical and practical problems in
obtaining repeated samples of the same untreated tumour
severely restrict the potential of the latter source. Nevertheless,
the growth in agar of colonies of human tumour cells have
occasionally been reported [McAllister and Reed, 1968; Altman
et al, 1975] (details in Chapter 3. 9), and opportunities arose from
time to time during the course of my research to see whether
colony growth direct from tumour biopsy material could be
achieved with the diffusion chamber technique.
11.2: METHODS
11. 2. a: Tumours
Seven tumour biopsy specimens in Ham's F12 medium,
15% foetal calf serum, penicillin 200units/ml and streptomycin
100/ig/ml were obtained for study and details of these are given in
Table 11.1. Five of the seven were biopsies of the primary tumour
and included, a rectal adenocarcinoma, a pancreatic adenocarcinoma,
two colonic adenocarcinomas and a lymphoma; the other two were
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from metastases of an oat cell carcinoma of lung and an anaplastic
teratoma of testis.
Because of the difficulty in obtaining single cell suspensions
from these biopsies (see below), short term monolayer cultures of
cells from 6 melanomas and 3 hypernephromas were also studied in
the assay system (Table 11.1); these cultures had been grown in
primary tumour cell suspensions in medium 199 in Falcon flasks
for a period of between 7 and 14 days. Single cell cell suspensions
could be obtained with ease from these cultures by gently trypsin-
isation with a 0.1% solution in medium 199 for 3 or 4 minutes.
11. 2.b: Single Cell Suspensions
The optimum technique for obtaining single cell suspensions
from tumour biopsies was established empirically for each tumour
in the same way as previously described for xenografts (Chapter
5. 3); this is summarised in Table 11. 1. In general, it was more
difficult to obtain single cell suspensions from these tumour specimens
taken direct from the patient than from xenografts: more prolonged
periods of trypsinisation were usually required, and frequently only
a small yield of single cells was obtained. In most instances the
fraction of viable cells in suspension assessed by lissamine green
dye exclusion was much smaller than with xenografts.
The technique for obtaining single cell suspensions from
monolayer cell cultures is described above.
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11. 2. c: Assay Technique
Other aspects of the assay technique, including chamber
loading, implantation, mouse pre-treatment, colony counting, and
the determination of plating efficiency and optimum incubation period
were identical to that described for xenografts in Chapter 5. Mouse
pre-treatment in these experiments was always with 900 rad whole
body irradiation, chambers being transplanted every ninth day.
11.3: RESULTS
Colonies in agar were grown from only 3 out of 7 of the
tumour biopsy specimens (from the oat cell carcinoma of lung, the
pancreatic carcinoma and one of the colonic carcinomas) as shown
in Table 11.1. The plating efficiencies were low: these were 0.1%
for the oat cell carcinoma, 1% for the pancreatic carcinoma and 0. 25%
for the colonic tumour. The corresponding incubation periods were
4 weeks, 5 weeks and 3 weeks. Colonies were as large as from
xenograft clonogenic cells for the pancreatic carcinoma with some
containing several hundred cells, but were small for the other two
tumours and were defined in these as having 30 cells or more with
most colonies containing between 30 and 50 cells. No colonies or
clusters were grown from the other 4 tumours although in some
instances single cells remained structurally intact in the agar for up
to six weeks.
In contrast, 7 of the 9 cell suspensions obtained from mono¬
layer culture grew colonies in agar; these included 5 of the 6
melanomas and 2 of the 3 hypernephromas, as shown in Table 11.1.
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from 12 days to 4 weeks. Colonies were defined as containing 30
cells or more, and were usually small, rarely containing more
than 100 cells. A few clusters of less than 30 cells were seen in
both the monolayer samples which failed to grow colonies.
Some cells from one melanoma culture (No. 12, Table 11. 1)
were cryopreserved in liquid nitrogen, for 2 months and then
reconstituted for assay. These cells also grew colonies with the
same plating efficiency as the original.
11.4: DISCUSSION
These studies show that colony growth can sometimes be
achieved from cells taken directly from human tumours with the
diffusion chamber technique, but the system is less consistent
than with xenografts, success occurring in only 3 of the 7 tumours
so far studied.
It is possible that technical factors may to some extent
explain this. In particular, the trauma involved in obtaining good
single cell suspensions was in general considerably greater than
for xenografts. Dye exclusion studies demonstrated a low fraction
of viable cells and even these may have lost clonogenic potential in
the suspension process. To support this hypothesis was the fact
that the oat cell carcinoma of lung, which alone went into single
cell suspension easily, grew colonies; and more strikingly, all but
two of the monolayer culture samples from which via.ble single cell
suspensions were easily prepared achieved colony growth.
At present there appears to be no simple solution to this
technical problem, although various methods for improving single
cell suspensions from human tumours are being investigated. It
might for example be possible to extend the technique of preparing
initial short term monolayer cultures prior to making a single cell
suspension to other tumour types but this process carries with it
the risk of the rapid selecting out of unrepresentative tumour clones
or even of clones of non-tumour cells adapted for in vitro growth
[Sheard et al, 1971; Editorial, Lancet, 1972]. An alternative
approach is to study the clonogenic potential of malignant effusions
where virtual single cell suspensions already exist. The source of
human tumour cells previously reported to grow colonies in agar
was malignant pleural fluid in one instance [Altman et al, 1975] and
the possibility of growing colonies in diffusion chambers from
malignant pleural effusions and malignant ascites is now being
studied.
Finally, the single successful attempt so far to grow colonies
from reconstituted melanoma cells after cryopreservation in liquid
nitrogen is of considerable long term importance. This technique
might allow the storage of sufficient cells from a single biopsy
sample (or aspiration of a malignant effusion) to enable repeated
experiments on the same tumour to be carried out. In this way,
detailed radiosensitivity and chemosensitivity studies at present
restricted to xenograft tumour cells might become feasible with
tumour cells taken direct from the patient.
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CONCLUSIONS AND PROPOSALS FOR FUTURE STUDIES
12. 1: GENERAL CONSIDERATIONS: CLONOGENIC CELL
KILL - TUMOUR RESPONSE
The main contribution of the research described in this thesis
has been to demonstrate that the radiosensitivity and ehemosensitivity
of clonogenic human tumour cells can now be measured in a way
previously restricted to experimental animal tumours and to
established cell lines (Chapter 1.1 and Chapter 10.1). In this final
chapter the areas for further research of possible clinical relevance
will be discussed.
A fundamental problem in this and indeed any other clonogenic
cell assay is to establish the quantitative relationship, if any,
between clonogenic tumour cell survival and gross tumour response
after treatment. Only a few studies have so far attempted to examine
this. Tumour cure and cell survival for a rat rhabdosarcoma were
studied by Reinhold and de Bree [1968] who demonstrated a good
correlation and found that the tumour cure rate after a single dose
of X-irradiation could be correctly predicted by extrapolation of
cell survival data. Steel and Adams [1975] found that the curability
of small implants of Lewis lung carcinoma with cyclophosphamide
correlated with cell survival data, if allowance were made for the
increased clonogenic cell sensitivity to cyclophosphamide of these
small implants compared with larger tumours of the same type.
Others, however, have found less simple relationships.
Tumour growth delay and cell survival have been compared, for the
same rat rhabdosarcoma treated with X-irradiation [Hermens and
Barendsen, 1969] and a Lewis lung murine carcinoma treated with
cyclophosphamide [Steel and Adams, 1975]. In each of these studies
the actual clonogenic cell kill measured by assay was much greater
than that predicted by backward extrapolation of regrowth data.
Likewise, it has been shown for the RIB5 tumour that the induced
growth delay for a given level of cell survival varies depending on
whether radiation is given under air-breathing or hypoxic conditions
[McNally, 1973], and whether radiation is given as X-rays or as
fast neutrons [McNally, 1975],
Various explanations might be postulated to explain these
discrepancies. Nearly all clonogenic cell assays involve removal
of cells from their no mal "milieu"* and the artificial environment
provided by the assay might alter cell growth characteristics in
general and response to cytotoxic agents in particular. Furthermore,
the trauma involved in the preparation of single cell suspensions
*Techniques for studying clonogenic cells in situ have occasionally
been possible for some normal tissues including growth cartilage
[Kember, 1967], skin [Withers, 1967] and intestinal epithelium
[Withers and Elkind, 1968] as described in Chapter 3. 5
might result in the selecting out of an unrepresentative sub-
population of cells for assay.
Occasionally tumour antigenicity might induce a residual
host immune response such that tumour cure is obtained with doses
of radiation or drug too low to kill all clonogenic tumour cells.
This has been established for the EMT6 tumour treated with single
dose irradiation [Rockwell and Kallman, 1973], and probably also
explains occasional cures observed in a human oat cell carcinoma
xenograft with doses of cyclophosphamide predicted by the authors
as being too small to kill all clonogenic cells [Kopper and Steel,
1975].
In summary, these studies suggest that some kind of
relationship between clonogenic cell survival and tumour response
does appear to exist despite the artificial nature of the assays used,
but that this is often complex and may vary for different tumours,
depending on antigenicity or other factors.
For this reason correlative studies of the type described
above are indicated to elucidate further the quantitative relationship
between xenograft tumour response and cell survival; such studies
might investigate not merely the fraction of clonogenic cells killed
but their rate of recovery, as Hermens and Barendsen [1969] have
done for the rat rhabdosarcoma. This experimental approach,
though important, is elaborate and painstaking, and will inevitably
generate data fairly slowly.
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A second line of research is therefore also indicated in
which relationships between cell survival and tumour response are
sought on an empirical basis in the hope that such information may
be of qualitative, if not of quantitative, clinical significance. This
approach is best illustrated by considering some of the findings
described in this thesis, and by using these to indicate further areas
of research of clinical relevance.
12.2: RADIATION RESPONSE: FUTURE STUDIES
The general conclusion to be drawn from the experiments
reported in Chapters 7, 8 and 9 is that the radiation response of
cells from human tumour xenografts so far studied is often similar
to that previously obtained for cell lines and for experimental
animal tumours. For example, the in vitro radiosensitivities of all
but the melanoma xenograft HX34 lie within the same relatively
narrow range found for nearly all other mammalian cells (Chapter 7),
and the pancreatic carcinoma HX32 studied in vivo has a fraction of
radioresistant hypoxic cells of the same order as that previously
established for most experimental animal tumours (Chapter 8). It
may therefore prove in the long term that human tumour xenografts
have no great advantage over animal tumours for many areas of
radiobiological investigation. But further human tumour cell data
are first required to confirm or refute this hypothesis.
The first unresolved question is the underlying radiobiological
basis for variations in the clinical responsiveness to radiotherapy
of different tumour types. It has already been discussed in Chapter
7 that, as for experimental animal tumours, these variations are
independent of in vitro radiosensitivity differences and must be
based on other extrinsic factors; Chapter 8 indicates that hypoxia
may be one such factor. But the data from melanoma HX34 suggests
that this generalisation may not always hold true: here it is possible
that the wide initial shoulder and decreased slope of the in vitro
survival curve may in part explain the poor clinical response to
radiotherapy of this tumour type.
Further studies are therefore indicated on xenografts of
tumours in which the chance of clinical control with radiotherapy is
either very poor, e. g. melanomas, gliomas, some types of sarcoma,
or very good, e. g. lymphomas, seminomas. These would investigate
the extent to which clinical response correlates with intrinsic radio-
sensitivity characteristics similar to those of melanoma HX34, or
with extrinsic factors, including tumour cell hypoxia, l't is probable
that for some tumour types, both intrinsic and extrinsic factors are
involved, and the hypoxic fraction of melanoma HX 34 in vivo in air-
breathing animals is currently being studied with this in mind.
Such studies would not necessarily merely be of theoretical
interest but could be of clinical relevance. For example, the
identification of tumours with a large fraction of hypoxic cells would
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predict where hypoxic cell radiosensitiser drugs might prove most
effective clinically. And the possible use of the assay as a simple
screen for new radiosensitisers prior to clinical trial has already
been discussed (Chapter 9).
Likewise, tumours whose in vitro survival curves showed
wide initial shoulders might be amenable to different types of
radiation. It has been shown for animal tumours and tumour cell
lines that the ability to accumulate sub-lethal damage is less with
high linear-energy-transfer radiation including fast neutrons, than
with X- or y-irradiation [Hornsey and Silini, 1961; Shipley et al,
1975; Thomson et al, 1975]. The assay system should be used to
study whether a similar reduction in shoulder width with high LET
radiation can be obtained for melanomas and other tumours
proving to have similar radiobiological characteristics. Such a
finding might have important therapeutic implications, and in this
context it is of interest that preliminary clinical observations have
suggested that melanomas may be more responsive to neutron
therapy than to conventional y-irradiation [Dr. M. Catterall,
personal communication],
12._3: RESPONSE TO CYTOTOXIC DRUGS: FUTURE STUDIES
In Chapter 1, important differences in the response to
cytotoxic drugs of human and experimental animal tumours were
described, and the studies reported in Chapter 10 show that such
differences are based in large part on differences in intrinsic
cellular chemosensitivity. It is therefore my belief that the major
long term advantage of this assay over equivalent animal tumour
assays will be less in radiobiology than in chemosensitivity studies.
The first step is therefore to confirm the validity of the
assay as a reflection of clinical chemotherapy response. The cyto¬
toxic drug data presented in Chapter 10 provides some circumstantial
evidence towards this, first in the marked resistance to various
cytotoxic drugs of pancreatic and colonic carcinoma cells, and
second in the tentative correlation of cell kill with clinical tumour
behaviour in two patients. However, further data are required to
substantiate these preliminary observations, and in particular
correlative studies in which chemosensitivity in the assay can be
compared with the patient's response to chemotherapy need to be
carried out. These could be done either via the xenograft system
or perhaps directly from the patient treating the cells in mure, if
the technique described in Chapter 11 for cloning human tumour
cells directly can first be improved.
Second, it is possible that in the long term the in mure
assay system might be adapted in this way as a measure of tumour
sensitivity to different cytotoxic drugs for individual patients, in a
manner analogous to current bacteriological sensitivity testing in
the treatment of infection. Such information might be only of
qualitative value in view of the differences in sensitivity between the
in vivo and in mure assay described in Chapter 10; even this
however would be a considerable improvement on current combination
chemotherapy regimes designed on a "probability of response" basis.
At best, this would allow the selection of drugs to which the tumour
was maximally sensitive, with the possibility of increased clinical
response; at least, the system would allow the exclusion from
treatment of drugs to which the tumour cells were resistant, thus
minimising toxicity to the patient.
Third, a more immediate, and more important, role for the
assay is in determining the shape and steepness of dose response
curves for cytotoxic drugs against human tumours, in a manner
similar to that achieved by Bruce and his colleagues [1966] for the
AKR lymphoma (Chapter 10.1). This would provide information on
how best to administer drugs clinically, both in terms of dosage and
scheduling, and thereby might establish a more rational basis for
cancer chemotherapy.
Some examples can illustrate this further. There is a
current tendency to administer increasingly large doses of cytotoxic
drugs in cancer chemotherapy, based on the argument that the
inevitable increa.se in host toxicity will be outweighed by increased
tumour cell kill and hence a better clinical tumour response. At
present this strategy is mainly empirical, and depends on the
assumption that a steep log linear dose response curve exists for
drugs against tumour cell (Figure 10. la). However, a plateau-type
dose response curve (Figure 10. lb) or a shallow curve, as for
cyclophosphamide against pancreatic and colonic carcinoma cells
(Figure 10. 3) would suggest that such a treatment strategy were
illogical; I have already suggested that these latter curves may
explain the clinical observation that such tumours usually respond
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poorly to cyclophosphamide even in doses large enough to produce
significant toxicity to normal tissues (Chapter 10. 4. a).
A steep log linear dose response curve has recently been
demonstrated with the diffusion chamber assay for melphalan against
melanoma HX34 cells, and preliminary clinical studies at the Royal
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Marsden Hospital with high dose melphalan (up to 200mg/m )
undertaken on the basis of this dose survival curve in patients with
melanoma have shown several good clinical responses not previously
achieved with this drug in conventional dosage [Dr. P. Selby and
Dr. T.J. McElwain, personal communication]. This simple study
is a good example of how the validity of the chamber assay
technique as a model for studying clinical response may be established
on an empirical "try-it-and-see" basis. Further dose response curve
data of this type may help identify those clinical situations where
very high dose therapy is rational.
Clinical combination chemotherapy is commonly used in the
treatment of cancer, but again largely on an empirical basis. Here
the assay can be used to provide dose-response data for drugs used
alone and in combination. Synergistic, additive and antagonistic
effects can thus be determined, and a rational basis established for
clinical drug combinations of increased therapeutic effectiveness.
An added refinement to experiments of the type described
above would be the inclusion of similar data for human bone marrow
cells using the diffusion chamber assay, as shown in Figure 10. 6.
Predictions not merely of tumour response but of associated host
toxicity and hence of therapeutic effectiveness of specific chemo¬
therapy regimes could then be made.
Fourth, the diffusion chamber system could be used to study
new agents for cytotoxic activity; however the assay is too elaborate
to be used as a general screening system, and its role here would
need to be carefully defined. Its best use would probably be in
verifying cytotoxic activity against human tumour cells of agents
already suspected of having clinical potential, and in defining dose
survival curve characteristics following the principles established
by Bruce (above and Chapter 10. l.a). Again a specific example can
be quoted: vindesine (Eli Lilly) is a new vinca alkaloid similar to
vinblastine but with anecdotal reports of a broader therapeutic
range including activity against melanomas. The dose survival
curve for this agent against malenoma HX34 is about to be
studied with the diffusion chamber assay, first to verify its activity
compared with other cytotoxic agents and second to establish
whether response remains log-linear or develops a plateua, as
Bruce found for vinblastine in the AKR lymphoma (Figure 10. 2).
Such information may be of value in planning the optimal dose and
scheduling of this drug in clinical trials.
Finally, and in the long term perhaps most important of all,
the assay provides a means of isolating clones of human tumour
cells for further biological study. The areas for such study
include the fields of biochemistry, pharmacology, and perhaps
immunology and genetics. At present the major problem in clinical
cancer chemotherapy is the inadequacy of currently available
cytotoxic drugs to treat many tumours effectively. The ability to
isolate drug-sensitive and drug-resistant clones of human tumour
cells and to investigate in these the biological parameters underlying
drug action and the development of resistance might eventually
provide a basis for the design of a generation of more effective
anti-cancer drugs.
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APPENDIX ONE
A NOTE ON STATISTICAL METHODS USED
IN CHAPTERS 7-10
The original formula defining the radiation cell survival
curve for mammalian cells described in Chapter 7.1 was derived
by Lea [1946] and is given by: -
S.F. = 1 - (1 - e"D/D0)n ifD^D0
where S. F. is surviving fraction, D is dose to give this survival,
Dq is negative reciprocal of slope on the exponential part of the
curve on a semi -log plot, and n is the extrapolation number.
To simplify calculations, this approximates to: -
loggS. F. = logen - D/DQ
and this latter formula was used here to calculate the values of
slope, intercept and the errors on these by linear regression
analysis as formulated in Geigy [1970].
COMPARISON OF SLOPES FOR STATISTICAL SIGNIFICANCE
An F test (variance - ratio test) was done to see if the
variances about both regression lines were similar. If so, a Mt"
value was calculated and the probability "p" obtained from tables
[Bailey, 1959]. If the variances were significantly different a "d"
value was calculated as suggested by Bailey [1959] and again "p"
obtained from tables.
CALCULATION OF Dn
This was obtained from Dq and n according to the formula: -
°Q = logen x D0
=
^siope^'' (since D0 = "Vslope,
and log^n = intercept)
Fieller's theorem as laid out in Finney [1952] allowed the
Standard Error of this ratio to be estimated and the probability "p"
of significant differences to be calculated.
A CDC 6400 computer was used for all calculations and the
computer programs were kindly supplied by Dr. J. Millar of this
department.
APPENDIX TWO
A NOTE ON THE DRUGS USED IN
CHAPTER 10 OF THIS THESIS
ACTINOMYCES! D
An anti-tumour antibiotic derived from soil Streptomyces
and developed clinically in the 1950s for the treatment of Wilm's
tumour. It acts by binding to helical DNA and also by intercalation
between base pairs adjacent to guanine. DNA and protein synthesis
are inhibited at higher concentrations. Its main clinical uses are in
the treatment of paediatric malignancies including Wilm's tumour,
and malignant teratoma and chorion-carcinoma in adults.
ADRIAMYCIN
_A recently developed anthracycline antibiotic derived from
Streptomyces peuceuus, and very similar in structure to dauno-
rubicin. It acts by both binding and intercalation to form complexes
with DNA. It has a broad spectrum of clinical activity, particularly
in the treatment of breast carcinoma, lymphomas, acute leukaemias,
sarcomas ana paediatric malignancies, but cardiotoxicity is a
cumulative dose-limiting factor.
CYCLOPHOSPHAMIDE
An oxazaphosphorine alkylating agent, which is relatively
inactive in vitro and requires metabolic activation by the cytochrome
P450 system in the liver microsomes. It is the most extensively
used cytotoxic drug in cancer chemotherapy and has activity against
lymphomas, acute lymphoblastic leukaemia, carcinomas of the
breast, lung, ovary and testis, and in paediatric malignancies. Its
powerful immunosuppressive activity has also led to its occasional
use in auto-immune disorders.
5-FLUOROURACIL
A pyrimidine analogue anti-metabolite which acts mainly
by the inhibition of thymidylate synthetase and hence of DNA
synthesis. Its main clinical use has been in the treatment of gastro¬
intestinal carcinomas where its response rate, though low, is
probably better than that of most other agents. Also effective in
combination against breast carcinoma.
METHYL-CCNU
One of the nitroso-ureas, a group of compounds whose
anti-tumour activity was first detected in the National Cancer
Institute drug-screening programme. These compounds, which
include BCNU and CCNU, act as alkylating agents. They are highly
active against many animal tumours but have proved disappointing
in clinical use. They are lipophilic and are therefore used in the
treatment of tumours of the CNS with some success, and also as
second-line therapy against lymphomas and myeloma. Methyl-
CCNU has been reported to be active against gastro-intestinal
carcinomas, but response rates vary widely in different studies,
and toxicity is considerable.
METHOTREXATE
An anti-folate anti-metabolite whose effects are mediated by
the inhibition of dihydrofolate reductase. It has wide clinical
activity, and is used in particular against breast and lung carcinoma,
and in some paediatric malignancies including osteogenic sarcoma
where it is given in high dosage with folinic acid "rescue".
VINBLASTINE
A vinca alkaloid derived, like vincristine, from the
periwinkle plant. Its action is to arrest proliferating cells in
metaphase, probably by interfering with microtubular function. Both
compounds have broad clinical activity, although myelosuppression
is the major toxicity with vinblastine compared with neurotoxicity
for vincristine, and the latter is therefore more commonly used in
combination chemotherapy. Vinblastine is principally used in the
treatment of lymphomas, malignant teratoma, chorion-earcinoma
and in some paediatric malignancies including neuroblastoma.
APPENDIX THREE
PUBLISHED PAPERS ARISING FROM RESEARCH
DESCRIBED IN THIS THESIS
Studies on the Radiosensitivity of Human Bone Marrow and Human
Tumour Xenografts Using an Agar Diffusion Chamber Technique.
Smith I.E. and Gordon M.J. Br. J. Radiol. 49 : 558 (1976)
(Abstract).
/
In Vitro and In Vivo Radiosensitivity of Human Tumour Cells
Obtained from a Pancreatic Carcinoma Xenograft. Courtenay V.D.,
Smith I.E., Peckham M.J. and Steel G.G. Nature 263 : 771 (1976)
(Enclosed).
A Colony Forming Assay for Human Tumour Xenografts Using Agar
In Diffusion Chambers. Smith I. E., Courtenay V.D. and Gordon
M.Y. Br. J. Cancer 34 : 476 (1976) (Enclosed).
The Comparative Sensitivity to Cyclophosphamide of Cells from
\
Human Tumour Xenografts and Human Bone Marrow. Smith I. E,
and Gordon M.Y. Antibiotics and Chemotherapy (In Press).
(Reprinted from Nature, Vol. 263, No.
In vitro and in vivo radiosensitivity
of human tumour cells obtained from
a pancreatic carcinoma xenograft
Human tumours show a wide range of clinical response to
radiotherapy, but the extent to which this reflects differences
in intrinsic cellular radiosensitivity, extent of tumour cell
hypoxia, or host reaction against the tumour is unknown.
For tumours in laboratory animals, various assays for clono-
genic cells are available. These have shown that the range
of radiosensitivity of aerobic cells is quite narrow1,2 and
that the hypoxic fraction of clonogenic cells within tumours
of palpable dimensions is often in the range 10-35%. Until
now the lack of satisfactory assay for clonogenic cells has
prevented similar studies on human solid tumours treated
in vivo. We have developed two assays for clonogenic cells
from a human metastatic pancreatic carcinoma propagated
as a xenograft in immune-suppressed CBA/lac mice. This
xenograft was one of a series established by Pickard et al.3.
In the first assay, tumour-cell suspensions were incubated
in Ham's medium with the addition of 15% calf serum,
0.3% agar and rat red blood cells in 17-mm diameter test
tubes using a double layer technique. Colonies of 50 cells
or more were counted at 28 d and the plating efficiency was
20-40%. In the second assay, tumour-cell suspensions in
medium, serum and agar were grown in diffusion chambers
implanted into the peritoneal cavity of C57BL mice,
previously treated with whole-body radiation. Colonies,
growing slightly more quickly than in the first assay, were
counted at about 18 d and the plating efficiency was
10-20%. Detailed descriptions of the experimental methods
are being prepared for publication. Chromosomal analysis
of the cells after 16 d growth in culture verified a human
karyotype, with aneuploidy ranging from 42 to 68 chromo¬
somes and a mode of 62.
Tumours measuring 5-8 mm in diameter were grown in the
leg muscles of immune-suppressed mice and were irradiated
in vivo using 60Co y rays. The animals were killed and the
tumours removed either immediately after irradiation or
18 h later, and cell suspensions were prepared for assay.
Acute hypoxia was induced by killing mice by nitrogen
asphyxiation 15min before the start of irradiation. In vitro
aerobic irradiation was carried out on freshly prepared
tumour-cell suspensions.
The results of in vitro irradiation and in vivo irradiation
in air-breathing and hypoxic conditions are shown in Fig. 1.
The two assays agree well and we are unable to detect any
systematic differences between them. The in vitro cell
survival curve has a D„ of 96 ±9 rad. (Da is the dose that
reduces survival by 63% on the exponential part of the
curve.) The in vivo air-breathing survival curve for animals
killed immediately after irradiation shows an initial sensitive
component and a radioresistant component, the Z>,, of which
is 305±16 rad. The D« values for the terminal parts of the
other tv/o curves are not significantly different from this
and we have therefore drawn the three curves parallel.
From the vertical displacement of the hypoxic curve from
the lowest air-breathing curve we calculate an hypoxic
fraction of 0.25. The oxygen enhancement ratio is 3.1+0.4.
The data obtained on tumours that were taken 18 h after
irradiation, are displaced vertically from the other air-
breathing curve by a factor of 2.2. This displacement shows
that the fractional survival of tumour cells obtained at 18 h
after irradiation was greater than when the cells were
removed immediately. Two mechanisms may be involved :
the repair of potentially lethal damage or the selective
death or disappearance during the 18-h period of lethally
damaged cells. Repair of potentially lethal damage has been
reported in cell populations irradiated in vitro and in vivo
5580, pp. 771 — 772, October 28, 1976)
Fig. 1 Survival curves for the^ccnografted tumour cells treated
with single doses of y radiatiojigfe, Cells irradiated as a single-cell
suspension in aerobic conditions in vitro and assayed using the
in vitro colony assay. The other data are for tumours irradiated
in situ: O •, assay immediate* after irradiation in air-breathing
mice; A A. assay 18 h after irradiation in air-breathing mice;
□ ■, assay immediately after irradiation in nitrogen-asphyxiated
mice. Open symbols indicate the results of the diffusion chamber
assay; closed symbols the results of the in vitro assay.
The present data suggest that the 18-h curve is parallel to
the other two curves dovyj^ to radiation doses as low as
200 rad, but more data areirequired to confirm this.
Limited clinical experiend!| with irradiation in pancreatic
carcinoma suggests that this is not usually a radioresponsive
tumour6. It is therefore of interest that the D„ values which
we have obtained are withirLthe range of values determined
using tumours of laboratorCanimals. The hypoxic fraction
is also no less than has beenTound in experimental tumours,
but the significance of this must be interpreted with caution
because of the possible influence on this parameter of
vascular stroma derived from the mouse. One interpretation
of these data, however, is that the response of pancreatic
carcinoma to radiotherapy is limited by the high proportion
of hypoxic cells. This provides support for current efforts to
improve clinical therapeutic response by the use of chemical






Divisions of Radiotherapy and Biophysics,
Institute of Cancer Research,
Sutton, Surrey, UK
Received June 14; accepted September 16, 1976.
1 Brown, J. M., and Berry, R. J., in Symposium on the Effects of Radiation on
Cellular Proliferation and Differentiation (IAEA, Vienna, 1968).
2 Nias, A. H. W., in The Biological and Clinical Basis of Radiosensitivity (edit, by
Friedman, M.), (Thomas, Springfield, Illinois, 1974).
3 Pickard, R. G. Cobb, L. M., and Steel, G. G.. Br. J. Cancer, 31, 36-45 (1975).
4 Little, J. B., Hahn, G. M\, Frindel, E., andTubiana, M*., Radioloqv, 45, 116-120
(1973).
5 Shipley, W. U., Stanley, J. A., Courtenay, V. D., and Field, S. B., Cancer Res.,
35, 932-938 (1975).
6 Moertel, C. G., in Cancer Medicine (edit, by Holland, J. F., and Frei, E.), (Lea
and Febiger, Philadelphia, 1973).
Printed in Great Britain by Henry Ling Ltd., at the Dorset Press, Dorchester, Dorset
TUMOUR CELL COLONIES IN AGAR DIFFUSION CHAMBERS 477
buffered saline (PBS) using a crossed-scalpel
technique. Further treatment to produce
a viable single-cell suspension was then
determined empirically for each tumour and
details are shown in the Table. Some xeno¬
grafts required only incubation in PBS at
37°C for 15 min; some required incubation
with trypsin 1 : 100 in PBS for between 5 and
10 min; one (pancreatic carcinoma xenograft
HX32) required incubation in collagenase
2 mg/ml in Ham's medium with 15% foetal
calf serum for 30 min, followed by trypsin
I : 100 in PBS for a further 5 min, after
washing free of serum. All cell suspensions
were finally filtered (Simon Polyester Mesh,
aperture 30 ym) and a single-cell suspension
obtained in ice-cold Ham's medium and 15%
foetal calf serum. Viability was assessed by
dye exclusion using lissamine green. Dif¬
fusion chambers were then filled with the
required number of cells for assay, suspended
in Ham's medium, serum and 0-3% agar.
Filling and implantation of agar diffusion
chambers.—The preparation, filling and im¬
plantation of diffusion chambers for this
assay were identical to those previously
described for bone marrow cells (Gordon,
1974).
Pretreatment of mice before chamber im¬
plantation.—Pretreatment of C57BL mice
used in these experiments was required before
implantation for successful growth of colonies
in the diffusion chambers (see Results
section). Standard pretreatment was with
whole-body irradiation from a 60Co source,
3 h before chamber implantation. When
900 rad whole-body irradiation was used,
following the technique employed with bone
marrow (Gordon et al., 1975), transplantation
of the chambers to newly irradiated mice was
required every ninth day, since this dose of
irradiation was usually fatal to the mice
around this time. Smaller doses of whole-
body irradiation were not usually fatal and
therefore did not require transplantation of
chambers.
It has been found by Dr John Millar,
working in this laboratory, that death after
900 rad or even 1000 rad whole-body irradi¬
ation to C57BL mice can be prevented by
previous treatment with cytosine arabinoside
200 mg/kg i.p. between 1 and 3 days before
irradiation. Some chambers were therefore
implanted into C57BL mice treated with
cytosine arabinoside 200 mg/kg i.p. 48 h
before 1000 rad whole-body irradiation, and
in these animals transplantation was un¬
necessary. In other experiments, the mice
were pretreated with cyclophosphamide 200
mg/kg i.p. 24 h before implantation instead
of whole-body irradiation, and this was well
tolerated.
In 2 experiments, chambers were im¬
planted into thymectomized, whole-body
irradiated, marrow-reconstituted CBA/lac
mice (Pickard et al., 1975) or genetically
athymic nude mice, without irradiation or
other forms of pretreatment.
Colony counting.—Chamber-bearing mice
were killed by cervical dislocation, and the
Millipore filter of each chamber removed with
a scalpel blade. Colonies were then counted
in the chamber under a binocular microscope
at a magnification of X 50. Colonies were
defined as aggregates of at least 50 cells, and
clusters as aggregates of between 20 and 50
cells. The optimum incubation period for
colony formation was determined by colony
counting at various times after implantation
until there was no further increase in colony
numbers.
RESULTS
Cell suspensions of all 11 human
tumour xenografts so far studied repro-
ducibly grew agar colonies in diffusion
chambers, and details of the incubation
period, the mean plating efficiency (PE),
and the number of experiments performed
for each xenograft are shown in the Table.
The incubation periods ranged from 12 to
28 days, but were fairly constant for each
tumour, and in general colonies from the
less differentiated tumours grew more
rapidly than those from more differenti¬
ated ones. The mean PE of each tumour
was fairly constant, but the range between
tumours was from 0-3% to 16%.
There was variation in colony mor¬
phology between different tumours: some
tumours produced colonies composed of
fairly loosely clumped cells (Fig. la) while
others produced densely packed spherical
colonies (Fig. lb), which in one tumour
(colonic carcinoma HX18) appeared to
develop a mucinous capsule, demonstrated
by Giemsa staining of a colony removed
from agar (Fig. Ic). The morphology of
the colonies from each individual tumour
was the same on different occasions.
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Table.—Histology and Criteria for Colony Growth of Human Tumour Xenografts
Cell No. of Incubation
Code suspension experiments period
no. Tumour technique performed (days) Mean PE (%) Range (




26 18 11 9-14
HX 18 Colonic adenocarcinoma,
poorly differentiated Trypsin 8 21 1-9 0-9-2-4
XUR 5 Colonic carcimona,
anaplastic Trypsin 2 21 1-1 0-9-1-2
HXK 1 Colonic adenocarcinoma,
mod. differentiated (Met) Trypsin 2 28 0-5 0-4-0-5
HXK 9 Colonic adenocarcinoma,
poorly differentiated
(Met) Trypsin 1 21 3-5 —
HX 12 Rectal adenocarcinoma,
well differentiated Trypsin 1 28 1-1 —
HXK 4 Rectal adenocarcinoma,
poorly differentiated Trypsin 3 21 11-5 10-5-13
HX 29 Oat cell carcinoma of
lung (Met) PBSf 3 21 1-5 1-0-1-6
HX 33 Oat cell carcinoma of
lung (Met) PBS 3 18 0-3 0-25-0-4
HX 34 Melanoma (Met) PBS 0 12 16 15-18
HX 35 Uterine carcinoma,
anaplastic (Met) PBS 2 12 14 12-16
* Met—Metastasis biopsy,
f PBS—Phosphate buffered saline.
Fig. 1(a)
Fig. 1(c)
Fig. 1- -(a) Typical agar colony from cells of colonic adenocarcinoma xenograft HXK1. X 350.
(b) Typical agar colony from cells of colonic adenocarcinoma xenograft HX18. x 350. (c) Giemsa-
stained preparation of HX18 colony removed from agar, showing mucinous capsule "leaking"
cells at 2 sites, x 150.
33
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The PE of colonies from eacli tumour
cell suspension depended greatly on the
pretreatment of the diffusion chamber
host mice. Details of the effects of
different pretreatment regimes on PE for
2 human tumour xenografts are shown in
Fig. 2. Diffusion chamber colonies did
not grow in untreated mice. Whole-body
60Co y-irradiation to the mice promoted
colony growth, and the PE increased
with increasing doses of irradiation.
Colonies grew as well in chambers main¬
tained for 3 weeks in mice pretreated with
cytosine arabinoside 200 mg/kg and 1000
rad (preventing death of the mice) as in
chambers transplanted every ninth day
into mice pretreated with 900 rad alone.
Since the former technique saves mice
and labour, this has now been adopted as
standard pretreatment. Cyclophospha¬
mide 200 mg/kg i.p., which has been
shown to be many times more effective
than other pretreatment schedules in
allowing lung colony formation from
100—
HX 18 (Colonic)
C22LR mouse osteosarcoma (Smink and
van Dierendonck, personal communica¬
tion), was an ineffective pretreatment in
this system. PE was almost as high in
thymectomized, whole-body irradiated,
marrow-reconstituted CBA/lac mice as in
the 900-rad pretreated C57BL mice, while
chambers implanted into genetically athv-
mic " nude " mice produced the highest
PE of all. Practical factors prevented us
from using nude mice routinely for this
assay.
Chromosomal analyses of cell suspen¬
sions from 6 of the xenografts have so far
been carried out, and these were all of
human karyotype. Four tumours had a
normal diploid chromosomal complement,
one (colonic carcinoma HX18) had an
added large acrocentric marker chromo¬
some, and one (pancreatic carcinoma
HX32) showed aneuploidy, with a range
of 42 to 68 chromosomes and a mode of
62, with extra chromosomes coming from
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Fig. 2.—The influence of different types of pretreatment on PE for 2 xenografts. The results for
each pretreatment are expressed as a percentage of the yield achieved using host mice which had
received 900 rad whole-body irradiation (thymectomized and " nude " mice were not used for
HX18 xenograft). Each pretreatment result is the mean of at least 3 experiments, except for
" nude " mice, when only one experiment was performed.











Fig. 3.—The relationship between the number of colonies scored and the number of cells cultured
in agar diffusion chambers for 2 xenografts, (a) Pancreatic xenograft HX 32; (b) Colonic xeno¬
graft HX 18. Vertical bars represent ± s-e-
Giemsa-stained preparations of colo¬
nies grown from colonic carcinoma HX18
showed undifferentiated neoplastic cells
with high nuclear cytoplasmic ratio, all
basically of the same type; comparison
with histological sections of the original
tumour xenograft showed that the colony
cells were entirely compatible with an
origin from that tumour (Dr A. Mackay,
Consultant Pathologist, Royal Marsden
Hospital).
A linear relationship between the
yield of colonies and the number of cells
introduced into the chambers was demon¬
strated for the pancreatic tumour xeno¬
graft HX32 over a range from 1 X 102 to
1-75 X 103 cells per chamber, and for the
colonic tumour HX18 over a range from
5 x 102 to 3 x 103 cells per chamber
(Fig. 3a and b).
The ability of this system to measure
the effect of cytotoxic drugs on PE of
human colonic carcinoma xenograft HX18
is shown in Fig. 4. In this example, in
vivo cyclophosphamide i.p. produced a
dose survival curve with a small range of
cell kill; the surviving fraction at the
maximum tolerated dose to the mouse
(300 mg/kg) was about 0-2.
DISCUSSION
Agar colony assays of human bone
marrow progenitor cells (Pike and Robin¬
son, 1970; Gordon et al., 1975) and human
chronic granulocytic leukaemic cells
(Brown and Carbone, 1971; Chervenick
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Dose of cyclophosphamide (mg/kg)
Fig. 4.—The effect of in vivo cyclophosphamide on colony survival (colonic tumour HX18). Tumour
cell suspensions were made 18 h after i.p. injection. The surviving fraction was calculated as the
ratio of the PE of the treated cells to that of the controls. Each point represents the mean of at least
5 chambers. Vertical bars represent ± s.e.
et al., 1971) are well established, and some
childhood solid tumours including neuro¬
blastoma, hepatoblastoma, Wilms' tum¬
our and rhabdosarcoma have occasionally
been shown to form colonies in agar
(McAllister and Reed, 1968; Sandor, 1973;
Altman et al., 1975). However, a repro¬
ducible quantitative colony assay for
human solid tumours does not appear to
have been described. Practical diffi¬
culties present a major obstacle: prelimi¬
nary experiments suggest that cell suspen¬
sions direct from human tumour biopsies
sometimes grow colonies in this system,
but it is usually impossible to obtain
repeated biopsies of the same human
tumour over the prolonged period neces¬
sary to develop a reproducible assay.
This problem can to some extent be over¬
come by the use of human tumour xeno¬
grafts, which can provide a continuous
supply of tumour cells from which the
necessary criteria for colony growth can be
established. An important assumption
here is that biological characteristics
influencing xenograft response to therapy
do not alter with repeated passage: in this
laboratory no consistent major changes in
growth rate or histology of xenografts
have so far been demonstrated after the
initial passage from human to mouse
(Pickard et al., 1975) and reproducible dose
survival curves have been obtained using
the same treatment on different passages
of xenografts over a period of about 1 year.
All 11 xenografts so far studied grew
colonies using agar in diffusion chambers
and chromosomal analysis and colony
cell morphology demonstrated that the
colonies were derived from human rather
than murine cell lines. Colonies from
each tumour had their own individual
incubation period and PE in this system,
however, and these parameters must
therefore be established empirically on an
individual basis for each tumour under
study.
Whether the effect of cytotoxic agents
on human tumour colony-forming cells
in agar correlates with clinical tumour
response is a question that has yet to be
answered. But the dose response to
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cyclophosphamide of the colonic carcinoma
HX18 (Fig. 4) offers some encouragement:
the sensitivity of this tumour is much less
than that established for experimental
animal tumours to cyclophosphamide
(Bruce, Meeker and Yaleriote, 1966; Park
et al., 1971; Lin and Bruce, 1972; Ogawa,
Bergsagel and McCulloch 1973; Hill and
Stanley, 1975; Steel and Adams, 1975)
and this is consistent with the clinical
observation that human colonic carcino¬
mas do not usually show a marked
response to cyclophosphamide. An in
vitro agar assay using the same xenograft
material has also recently been developed
in this laboratory, producing dose survival
curves which correlate closely with those
obtained by the diffusion chamber method
(V. D. Courtenay, in preparation). These
human tumour colony-forming assays may
therefore prove to be more realistic than
assays based on experimental animal
tumours for extrapolating laboratory
tumour response data to clinical cancer
therapy.
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